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 Cannabinoid agonists, including delta-9-tetrahydrocannabinol (THC), are found 
rewarding by humans. In addition to human self-reports and experimental studies that show 
marijuana is rewarding, contributions from preclinical studies also have implicated cannabinoid 
receptors in reward-motivated behavior. One way to assess these preclinical effects of 
cannabinoids is intracranial self-stimulation (ICSS), where an animal performs a response to 
receive electrical stimulation of a specific brain area or circuit known to be involved in 
rewarding activities. Drugs of abuse, such as psychomotor stimulants, facilitate responding for 
ICSS. While a few studies have shown facilitating effects of cannabinoids in rats, several have 
shown the opposite effect, and no studies so far have evaluated cannabinoids in mouse ICSS. 
Furthermore there are no studies evaluating specific inhibitors of endocannabinoid catabolic 
enzymes in ICSS in any species. In these studies we assessed the cannabinoid agonist THC, as 
well as the fatty acid amide hydrolase (FAAH) inhibitor, PF-3845, the monoacylglycerol lipase 
(MAGL) inhibitor JZL184, and the combined FAAH/MAGL inhibitor SA-57 in ICSS of the 
medial forebrain bundle in C57BL/6 mice. Additionally, we assessed the psychomotor stimulant 
cocaine as a positive control to facilitate ICSS. These studies were complimented with 
spontaneous locomotor activity and food-maintained operant experiments to assess the 
sensitivity of ICSS to cannabinoids. Additionally, brain endocannabinoid levels were measured 
in brain regions associated with the mesolimbic system after enzyme inhibitor treatments. 
 THC, JZL184, and SA-57 all produced time-dependent reductions in ICSS that were 
mediated through CB1 receptors, as they were blocked by pre-treatment with the CB1 antagonist 
rimonabant, but not with the CB2 antagonist SR144528. PF-3845 also reduced ICSS, but did so 
independent of CB1 and CB2 receptors, and only with one dose (30.0 mg/kg) that has not been 
assessed previously in vivo. We showed that ICSS was more sensitive to the rate-reducing effects 
of cannabinoids than other measures of behavior with motor components including spontaneous 
locomotor activity and operant nose-poking for food, and that the reduction of ICSS produced by 
both JZL184 and SA-57 is accompanied by increases in 2-AG in mesolimbic brain areas. Thus, 
cannabinoids do not facilitate ICSS in C57BL/6 mice over a range of doses and pre-treatment 
times, similar to most studies with rats. These data suggest that cannabinoids may produce 
rewarding effects through non-mesolimbic areas of the brain.
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Cannabinoid Modulation of Reinforcement Maintained by Stimulation of the Medial Forebrain 
Bundle in C57Bl/6J Mice 
 
Endogenous Cannabinoid System 
 
The endocannabinoid system is composed of two known cannabinoid receptor types: 
cannabinoid receptor types 1 and 2 (CB1 and CB2) (Gerard, Mollereau, Vassart, & Parmentier, 
1991; Matsuda, Lolait, Brownstein, Young, & Bonner, 1990) as well as the endogenous ligands 
that bind to these receptors. Cannabinoid receptors are G-protein-coupled and activating them 
inhibits calcium influx into cells and reduces the accumulation of cyclic adenosine 
monophosphate (cAMP), ultimately producing an inhibitory effect  (Howlett et al., 1990; 
Pertwee et al., 2010). CB1 receptors are located on pre-synaptic terminals of several neuron types 
including GABAergic, glutamatergic, cholinergic, serotonergic, and noradrenergic neurons, and 
their stimulation inhibits the release of neurotransmitter into the synapse (Cadogan, Alexander, 
Boyd, & Kendall, 1997; Katona et al., 2000; Robbe, Alonso, Duchamp, Bockaert, & Manzoni, 
2001). Most behavioral effects produced by cannabinoids have been found to be mediated 
through CB1 receptors. For example the classical tetrad of behavioral effects (hypolocomotion, 
hypothermia, catalepsy, and antinociception) and discriminative stimulus effects have been 
shown to be mediated through CB1 receptors, as they were blocked by the CB1 receptor 
antagonist, rimonabant, in different species including mice, rats, and rhesus monkeys (Compton, 
Aceto, Lowe, & Martin, 1996; Rinaldi-Carmona et al., 1994; Wiley, Lowe, Balster, & Martin, 
1995).  
Some recent studies have demonstrated behavioral effects related to CB2 receptor 
activation. CB2 receptors have been thought to be predominantly located in the periphery and on 
immune cells during states of inflammation, but are also located on subpopulations of neurons 
and microglial cells (Ashton, Friberg, Darlington, & Smith, 2006; Baek, Zheng, Darlington, & 
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Smith, 2008; Gong et al., 2006; Onaivi, 2006; Onaivi et al., 2006; Stella, 2010; Van Sickle et al., 
2005). However, there is controversy over whether CB2 receptors are present on neurons, as the 
antibodies used to detect them are not highly selective. Recent studies have implicated CB2 
receptors as mediators of cocaine reinforcement and nicotine reward (Ignatowska-Jankowska, 
Muldoon, Lichtman, & Damaj, 2013; Xi et al., 2011). Xi and colleagues found that the CB2 
receptor agonist, JWH133, dose-dependently inhibited cocaine self-administration, cocaine-
induced activation of locomotor activity, and cocaine-induced increases in dopamine in the 
nucleus accumbens (Xi, et al., 2011). These effects were all prevented by treatment with the CB2 
antagonist, AM630, or when assessed in CB2 -/- mice (Xi, et al., 2011). Ignatowska-Jankowska 
and colleagues found that nicotine conditioned place preference (CPP) was blocked by pre-
treatment with the CB2 antagonist, SR144528; and the CB2 agonist 0-1966 enhanced nicotine 
CPP (Ignatowska-Jankowska, Muldoon, et al., 2013). These are some of the first studies 
implicating CB2 receptor activation in drug reward. Interestingly, CB2 receptor activity produces 
paradoxical effects on cocaine and nicotine behavior, as agonists block cocaine reward and 
enhance nicotine reward, and antagonists reverse blockade of cocaine self-administration and 
block nicotine reward. Taken together, these findings suggest that CB2 receptors may be involved 
in drug reward, and their effects seem to be specific to distinct drugs of abuse.  
Endocannabinoids 
The endogenous cannabinoids (endocannabinoids) include the lipid molecules N-
arachidonoylethanolamine (anandamide; AEA), 2-arachidonoylglycerol (2-AG) (Devane et al., 
1992; Mechoulam et al., 1995; Sugiura et al., 1995) as well as arachidonyl dopamine, nolandin 
ether, and virodhamine (Bisogno et al., 2000; Hanus et al., 2001; Porter et al., 2002). This 
dissertation focuses on 2-AG and AEA, as they are the predominant endocannabinoid ligands, 
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and pharmacological tools are available to evaluate them. AEA was discovered in 1992, and was 
the first endocannabinoid isolated, while screening endogenous ligands for CB1 receptor binding 
(Devane, et al., 1992). 2-AG was discovered simultaneously by two groups in 1995, when it was 
isolated from canine intestinal tissue (Mechoulam, et al., 1995) and rat brain tissue (Sugiura, et 
al., 1995), and found to bind to CB1 and CB2 receptors. AEA is thought to be primarily 
synthesized through phosphodiesterase activity or through cleavage of phospholipase C and a 
phosphatase (Liu et al., 2006). It was originally proposed that AEA is created primarily through 
the cleavage of N-arachidonylphosphatidylethanolamine (NAPE) by NAPE-phospholipase D 
(PLD), but a study by Leung and colleagues suggested that NAPE-PLD is not the major 
biosynthetic pathway for AEA, as NAPE-PLD knock-out mice were found to have similar 
amounts of AEA as wild-type controls (Leung, Saghatelian, Simon, & Cravatt, 2006). 2-AG is 
primarily synthesized through the cleavage of diacylglycerol (DAG) by the enzyme DAG lipase-
alpha (DAGLα) (Gao et al., 2010; Tanimura et al., 2010). This was confirmed by the observation 
that DAGLα knock-out mice have significantly lower levels of 2-AG in brain compared to wild-
type controls. 2-AG and AEA are primarily metabolized by the respective degradative enzymes 
monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH).  
As shown on Fig. 1, endocannabinoids are released from post-synaptic neuron terminals 
and move across the synapse and bind to CB1 receptors located on pre-synaptic neurons (Ahn, 
McKinney, & Cravatt, 2008). AEA and 2-AG are rapidly metabolized soon after they are 
released. FAAH is located within the post-synaptic terminal (Gulyas et al., 2004) and is 
primarily responsible for the degradation of AEA into arachidonic acid and ethanolamine.  
FAAH also metabolizes roughly thirteen other fatty acid amides including oleamide, 
oleylethanolamide (OEA) and palmitoylethanolamide (PEA) (Cravatt et al., 1995). Other 
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enzymes have the ability to metabolize AEA including FAAH-2 and N-acylethanolamine-
hydrolyzing acid amidase (NAAA), though the former is only found in human and primates. 
Both are found in higher relative abundance in peripheral tissues and are inferior to FAAH in 
their ability to metabolize AEA (Tsuboi et al., 2005; Ueda, Yamanaka, & Yamamoto, 2001; Wei, 
Mikkelsen, McKinney, Lander, & Cravatt, 2006). Similarly, 2-AG can be hydrolyzed by a 
number of different enzymes including FAAH, neuropathy target esterase (NTE), hormone 
sensitive lipase (HSL), alpha/beta hydrolase 6 and 12 (ABHD6, ABHD12), cyclooxygenase-2 
(COX2), or MAGL, but the majority of 2-AG (85%) is degraded by the enzyme MAGL located 
within the presynaptic terminal. Any remaining 2-AG is typically deactivated by enzymes 
alpha/beta ABHD6 or ABHD12 and converted to arachidonic acid (AA) and glycerol (Belfrage, 
Jergil, Stralfors, & Tornqvist, 1977; Blankman, Simon, & Cravatt, 2007; Dinh, Freund, & 
Piomelli, 2002; Goparaju, Ueda, Yamaguchi, & Yamamoto, 1998; Kim & Alger, 2004; van 
Tienhoven, Atkins, Li, & Glynn, 2002). In addition to being the main enzyme responsible for 
breaking down 2-AG, MAGL is also the major biosynthetic enzyme for arachidonic acid and its 
metabolites (Nomura et al., 2011). Hydrolysis of 2-AG produces arachidonic acid (AA) and 
glycerol; disruption of MAGL activity significantly decreases free AA, as well as the eicosanoids 
derived from it, including prostaglandins E2 (PGE2), PGD2, PGF2, and thromboxane B2 
(TXB2). This decrease in AA is associated with decreased inflammatory responses (Nomura, et 
al., 2011). 
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Figure 1. Depiction of a synapse with endocannabinoid system components including CB1 
receptors, ligands, and biosynthetic and degradative pathways. Figure adapted from (Ahn, et al., 
2008).    
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AEA and 2-AG: Distinct Endocannabinoids  
Although AEA and 2-AG are structurally similar and have been shown to bind to CB1 
and CB2 receptors, they are pharmacologically distinct ligands. There are a few important 
observed differences between these two endocannabinoids that set them apart from each other. 2-
AG is found at 170-1000 fold greater concentrations in the central nervous system than AEA 
(Sugiura et al., 2002). This relationship was confirmed at the synaptic level with a study that 
measured AEA and 2-AG in mouse and rat nucleus accumbens shell after FAAH and MAGL 
inhibitor administration using microdialysis (Wiskerke et al., 2012). Wiskerke and colleagues 
consistently observed basal levels of 2-AG at 9-16 fold those of AEA in the interstitial space in 
the nucleus accumbens shell of mice and 2-8 fold higher in rats (Wiskerke, et al., 2012), which 
suggests that 2-AG may be more relevant for CB1 receptor signaling. Although the ratio between 
the amounts of AEA and 2-AG in whole brain tissue is less than when measured in the interstitial 
space, 2-AG is still consistently found in greater quantities there also. 
AEA is a partial agonist at cannabinoid receptors in vitro, while 2-AG is a full agonist in 
stimulating GTPgammaS binding, as AEA reduced the functional activity of 2-AG, which 
suggests differential efficacy of the two endocannabinoids at cannabinoid receptors (Gonsiorek 
et al., 2000). Related to this fact 2-AG, but not AEA, has been shown to prolong depolarization-
induced suppression of inhibition/excitation (DSI, DSE). Suppression of inhibition/excitation 
refers to suppression of inhibitory or excitatory neuronal transmission via hyperpolarization of a 
depolarized neuron, which suppresses the release of a neurotransmitter. 2-AG can cause a 
suppression of stimulatory or excitatory neurotransmitters mediated by CB1 receptors, while 
AEA does not, indicating that 2-AG may be more relevant for neuronal retrograde signaling (Pan 
et al., 2009). Furthermore, in addition to binding to CB1 and CB2 receptors, AEA has also been 
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shown to activate the transient receptor potential cation channel subfamily V member 1 (TrpV1), 
and other substrates metabolized by FAAH including OEA and PEA have been shown to bind to 
peroxisome proliferator-activated alpha receptors (PPARα) receptors; while 2-AG and targets of 
MAGL inhibition lack affinity for those receptors (Jhaveri et al., 2008; Ross, 2003; Zygmunt et 
al., 1999). 
The availability of each endocannabinoid is regulated independently by distinct 
enzymatic pathways. As mentioned above, AEA is broken down by FAAH in the postsynaptic 
neuron, and other enzymes which do not affect 2-AG including FAAH-2 and NAAA, while 2-
AG primarily is broken down by MAGL in the presynaptic neuron, and also can be metabolized 
by ABHD6, ABHD12, HSL, NTE, or FAAH. Additionally, FAAH metabolism of AEA does not 
contribute substantially to available arachidonic acid pools in the brain, while disruption of 2-AG 
metabolism leads to significant reductions of available AA (Nomura, et al., 2011). In addition to 
differences in the metabolic inactivation of AEA and 2-AG, their biosynthetic precursors also 
vary, as AEA is synthesized primarily through phosphodiesterase activity or through cleavage of 
phospholipase C and a phosphatase, while 2-AG in the brain is synthesized primarily through the 
cleavage of diacylglycerol (DAG) by the enzyme DAG lipase-alpha (DAGLα) (Gao, et al., 2010; 
Tanimura, et al., 2010). These differences between biosynthetic and degradative pathways 
suggest AEA and 2-AG have distinct physiological functions.  
Tolerance to cannabinoid tetrad effects and regulation of cannabinoid receptors is 
differentially modulated when MAGL or FAAH are inhibited repeatedly. Previous studies have 
shown that potentially negative outcomes such as CB1 receptor down-regulation, desensitization, 
and cannabinoid somatic withdrawal symptoms occur after repeated administration with a high 
dose of the MAGL inhibitor JZL184 (40.0 mg/kg) and in MAGL knock-out mice. However, it 
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should be noted that follow-up studies to the initial reports have demonstrated that repeated 
partial inhibition of MAGL (low doses of JZL184; 4.0 mg/kg) does not affect CB1 receptor 
function, and can still produce therapeutic effects in preclinical assays (Kinsey et al., 2013). 
Repeated FAAH inhibition using genetic or pharmacological means fails to produce either of 
these undesirable effects (Falenski et al., 2010; Schlosburg et al., 2010). 
Endocannabinoids are synthesized locally and are produced “on-demand”, meaning that 
unlike many neurotransmitters, endocannabinoids are produced immediately before being 
released, rather than being stored in vesicles for later use. The heterogeneous distribution of 
AEA and 2-AG as well as the ability of endocannabinoids to be inactivated by rapid synthesis 
and degradation makes specific endocannabinoid enzymes intriguing targets for pharmaceutical 
development. For example, MAGL inhibition leads to increased 2-AG accumulation in brain, but 
only in a regionally dependent manner, and will presumably only activate a subset of CB1 
receptors near where it is produced and released. This is in contrast to exogenous administration 
of direct-acting cannabinoid receptor agonists, which activate cannabinoid receptors throughout 
the brain and periphery. In addition to the therapeutic potential of endocannabinoid deactivation 
inhibitors, they also represent an excellent tool to probe the cannabinoid system. The endogenous 
cannabinoid system is involved intricately in many distinct physiological and psychological 
processes including cognition, emotion, pain, and inflammation, and reward (Pertwee, 2012). 
FAAH and MAGL inhibitors are particularly useful tools for the investigation of 
endocannabinoid-mediated effects. 
Behavioral Effects of MAGL Inhibition 
MAGL inhibitors have been shown to produce a variety of behavioral effects. JZL184 
was the first marginally selective irreversible MAGL inhibitor developed, which produced up to 
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10-fold elevations of whole brain 2-AG compared to basal levels after acute administration of a 
high dose (40.0 mg/kg) (J. Z. Long, Li, et al., 2009) without affecting AEA levels. JZL184 has 
some activity at FAAH also, as repeated administration produces a small, but significant increase 
in brain AEA concentrations (Schlosburg, et al., 2010). Recently, novel MAGL inhibitors 
KML29 and MJN110 have been produced and have been reported to be more selective for 
MAGL over FAAH than JZL184, with observed efficacy in both rats and mice (Ignatowska-
Jankowska et al., 2013; Niphakis et al., 2013).  
JZL184 has been used as a pharmacological tool to investigate the role of 2-AG in 
treating several different conditions/symptoms including anxiety, pain, and ulcers. It has been 
demonstrated that JZL184 decreases anxiety-like behavior in both rats and mice in the elevated 
plus maze test (Aliczki, Balogh, Tulogdi, & Haller, 2012; Sciolino, Zhou, & Hohmann, 2011) 
and mice in the marble burying assay (Kinsey, O'Neal, Long, Cravatt, & Lichtman, 2011). 
JZL184 produces antinociception in a mouse model of neuropathic pain in the chronic 
constriction injury of the sciatic nerve (CCI) assay (Kinsey et al., 2009), a model of 
inflammatory pain using the carrageenan inflammatory assay (Ghosh et al., 2012), formalin-
induced pain (Guindon, Guijarro, Piomelli, & Hohmann, 2011) and a rat model of sodium mono-
iodoacetate induced osteoarthritis pain (Sagar et al., 2010). Further, JZL184 has been shown to 
decrease gastric hemorrhaging produced by gavage of the non-selective cyclooxygenase inhibitor 
diclofenac (Kinsey et al., 2011) as well as reduce alterations and inflammation of the colon 
induced by the trinitrobenzene sulfonic acid (TNBS) model of colitis in mice (Alhouayek, 
Lambert, Delzenne, Cani, & Muccioli, 2011). 
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Behavioral Effects of FAAH Inhibition 
Similar to MAGL inhibitors, there have been a few FAAH inhibitors developed over the 
past years, with selectivity for FAAH increasing over time. FAAH inhibitors, to name a few, 
include URB-597 (Kathuria et al., 2003; Piomelli et al., 2006) , OL-135 (Boger et al., 2005), PF-
622, PF-750 (Ahn et al., 2007), PF-3845 (Ahn et al., 2009) and more recently, JNJ5003 (Hill et 
al., 2012). FAAH inhibitors have been utilized to examine the effects of increased AEA in 
various models of behavior and disease states. Most notably, there has been interest in 
developing them for the treatment of pain. There has only been one clinical trial to date using a 
FAAH inhibitor, PF-04457845 (PF-7845), which is structurally similar to PF-3845, but 
optimized for human FAAH (Huggins, Smart, Langman, Taylor, & Young, 2012; Li et al., 
2012). PF-7845 did not show any analgesic efficacy in treating osteoarthritis; however it has not 
been tested to treat other types of pain or conditions in the clinic. In preclinical assays, FAAH 
inhibitors have been shown to be effective in collagen-induced models of arthritis (Kinsey, 
Naidu, Cravatt, Dudley, & Lichtman, 2011), LPS-induced allodynia (Booker et al., 2012), 
neuropathic pain (Caprioli et al., 2012), and multiple sclerosis pain models (Pryce et al., 2013), 
among others pain assays. In addition to antinociception, FAAH inhibitors have shown positive 
effects in various preclinical assays including enhancing active stress-coping strategies measured 
using the tail suspension test with URB597 (Gobbi et al., 2005; Naidu et al., 2007), tail pinch test 
(Haller, Goldberg, Pelczer, Aliczki, & Panlilio, 2013) and preventing restraint stress-induced 
biochemical markers in the amygdala with JNJ5003 (Hill, et al., 2012). Anxiolytic effects of 
FAAH inhibitors have been reported in studies evaluating animals using the elevated-zero maze 
(Kathuria, et al., 2003) and elevated-plus maze (Haller, et al., 2013; Patel & Hillard, 2006). 
FAAH inhibitors have also been shown to enhance both the acquisition (Varvel, Wise, Niyuhire, 
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Cravatt, & Lichtman, 2007; L. E. Wise, Harloe, & Lichtman, 2009) and extinction (Varvel, et al., 
2007) of aversive spatial memory tasks.   
Behavioral Effects of Combined FAAH and MAGL Inhibition 
FAAH or MAGL inhibition alone do not produce all of the disruptive effects commonly 
associated with cannabinoid agonists including catalepsy and THC-like discriminative stimulus 
effects (J. Z. Long, Nomura, et al., 2009). Combined inhibition of FAAH and MAGL, however, 
has been shown to produce more THC-like effects than either enzyme inhibited alone (J. Z. 
Long, Nomura, et al., 2009; Niphakis, Johnson, Ballard, Stiff, & Cravatt, 2012; L. E. Wise et al., 
2012). Dual FAAH/MAGL inhibition has also been shown to substitute for THC in drug 
discrimination studies, produce catalepsy in mice, as well as produce THC-like memory deficits 
in Morris water maze learning, all of which were shown to be mediated through CB1 receptors (J. 
Z. Long, Nomura, et al., 2009; L. E. Wise, et al., 2012). The effects produced by combined 
FAAH and MAGL inhibition are reflective of the fact that AEA and 2-AG have distinct 
signaling pathways. Specifically, it seems that 2-AG signaling produces more cannabimimetic 
effects than AEA (J. Z. Long, Nomura, et al., 2009).   
Although combined inhibition of FAAH and MAGL may produce undesirable effects, it 
has also shown some promising effects in some preclinical assays, as it has been shown to reduce 
somatic withdrawal signs in mice during spontaneous morphine withdrawal (Ramesh et al., 
2013); as well as produce enhanced reduction of inflammation and hypersensitivity to non-
noxious stimuli in the preclinical assay of carrageenan inflammation in mice (Ghosh and 
Lichtman, unpublished). 
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Cannabinoids and Reward  
 Abuse-related effects of cannabinoids have been demonstrated in humans through 
positive subjective effect ratings associated with marijuana use (Hart et al., 2010; Hart, van 
Gorp, Haney, Foltin, & Fischman, 2001), as well as through human brain imaging studies 
implicating reward-relevant brain responses in the bilateral amygdala and hippocampus during 
marijuana cue presentations and voluntary self-administration in marijuana-dependent 
individuals (Goldman et al., 2013). In recent years the use of synthetic cannabinoid agonists by 
humans has risen dramatically, as “herbal incense blend” products containing synthetic 
cannabinoids have become commercially available (Brents & Prather, 2013).  
Of particular importance, the majority of human reports of rewarding effects of 
cannabinoids refer to inhaled marijuana or synthetic cannabinoid blends (Calhoun, Galloway, & 
Smith, 1998). THC is not commonly used for recreational purposes by humans. In fact, 
dronabinol (Marinol), which is synthetic THC delivered in capsules with sesame oil, is classified 
as a schedule III compound by the FDA, while marijuana schedule I, meaning it has less abuse 
and dependence liability than marijuana and certain synthetic cannabinoid agonists. There has 
been no evidence of dronabinol prescriptions being diverted to non-medical use, and marijuana 
users have not reported any interest in the drug (Calhoun, et al., 1998). Furthermore, the effects 
of oral dronabinol have a slow onset, which reduces its potential for abuse, and the majority of 
people who try it for recreational purposes report it produces dysphoric effects (Calhoun, et al., 
1998), or at most modest reinforcing effects (Hart, Haney, Vosburg, Comer, & Foltin, 2005). 
Interestingly, dronabinol has been found to reduce symptoms of marijuana withdrawal without 
producing many negative side-effects, or affecting the subjective effects of smoked marijuana 
(Vandrey et al., 2013). Although THC is the main active constituent in marijuana, there are 
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hundreds of other chemicals present the plant material typically smoked by humans. Thus, 
preclinical research with THC may not be completely applicable to human use of marijuana. In 
addition to marijuana containing other chemicals, the route of administration also differs, as few 
preclinical studies have delivered cannabinoids via inhalation as they are typically consumed by 
humans (Niyuhire, Varvel, Martin, & Lichtman, 2007; Wiebelhaus et al., 2012). 
Preclinical Models of Reinforcement and Reward-Associated Behavior 
Reinforcing and rewarding properties of cocaine and other drugs of abuse are assessed in 
animals using various behavioral measures. Three of the most used preclinical assays to assess 
abuse liability of drugs are drug self-administration, conditioned place preference (CPP), and 
intracranial self-stimulation (ICSS). Descriptions of these assays and the respective effects of 
cannabinoids are detailed below. 
Self-Administration 
A preclinical measure of drug reinforcement that has high face validity is drug self-
administration. In this paradigm, subjects learn to perform a specific operant task, such as 
pressing a lever, spinning a wheel, or nose-poking, to obtain a specific drug reinforcer. Studies 
have shown that animals can learn to self-administer many substances that humans are known to 
abuse including cocaine (Panlilio & Goldberg, 2007), heroin (S. A. Chen et al., 2006), and 
ethanol (Mittleman, Van Brunt, & Matthews, 2003). While cannabinoids have been 
demonstrated to be self-administered by laboratory animals, historically researchers have had 
difficulty demonstrating consistent cannabinoid self-administration in any species of animals 
(Tanda & Goldberg, 2003). However, some studies have demonstrated self-administration of 
cannabinoid full agonists in mice and rats (Fattore, Cossu, Martellotta, & Fratta, 2001; Flores, 
Maldonado, & Berrendero, 2013; Martellotta, Cossu, Fattore, Gessa, & Fratta, 1998; Takahashi 
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& Singer, 1979, 1980). The rodent studies that have demonstrated self-administration of 
cannabinoids have employed specific methodological techniques that may have increased the 
likelihood to train self-administration of a cannabinoid agonist including food-deprivation, 
restraint-stress, short time-course of studies, and co-administration of food or water with 
cannabinoids, which can make interpretation of their results difficult. Squirrel monkeys have 
been demonstrated to self-administer cannabinoids (Justinova, Solinas, Tanda, Redhi, & 
Goldberg, 2005; Justinova, Tanda, Redhi, & Goldberg, 2003; Justinova, Yasar, Redhi, & 
Goldberg, 2011; Tanda, Munzar, & Goldberg, 2000). Initial studies utilized squirrel monkeys 
that had previously learned to self-administer cocaine, but follow-up studies demonstrated that 
naïve squirrel monkeys can also be trained to administer THC (Justinova, et al., 2003) as well as 
the endogenous cannabinoid AEA and the longer lived methanandamide (Justinova, et al., 2005) 
and 2-AG (Justinova, et al., 2011). Overall, cannabinoid self-administration is far less robust 
compared to other abused drugs and relies heavily upon non-traditional manipulations, making it 
difficult to interpret results.  
Conditioned Place Preference  
The conditioned place preference (CPP) model is based on the Pavlovian principle of 
classical conditioning. Presumed drugs of abuse are assessed by pairing a given drug to an 
experimental chamber with specific contextual cues, and then allowing an animal to choose 
whether or not to spend time in that environment while in a drug-free state. The drug serves as a 
unconditioned stimulus (US) and the specific environment it is paired to serves as a conditioned 
stimulus (CS). If the subjects choose to spend more time in the drug-paired environment than a 
similar, but distinct environment, it is inferred that there is a positive association between the 
drug and the context in which it was administered (Tanda & Goldberg, 2003). 
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While most drugs of abuse including psychomotor stimulants and opiates produce CPP, 
cannabinoids often fail to do so, or only do so within an extremely limited range of doses, with a 
large degree of inconsistency between studies (Cheer, Kendall, & Marsden, 2000; McGregor, 
Issakidis, & Prior, 1996; Sanudo-Pena et al., 1997). Even when cannabinoids are found to 
produce CPP, this effect can be dependent on timing of injections, and other procedural 
manipulations. Additionally, conditioned place aversion is often observed with higher doses 
(Braida, Pozzi, Cavallini, & Sala, 2001; Ghozland et al., 2002; Lepore, Vorel, Lowinson, & 
Gardner, 1995). 
Intracranial Self-Stimulation 
Intracranial self-stimulation (ICSS) is a methodology in which a subject performs an 
operant response in order to receive electrical stimulation of a brain region implicated in reward 
function. ICSS has most commonly been used to assess the motivational effects and abuse 
liability of drugs (Carlezon & Chartoff, 2007), but has also been used to assess affective signs of 
drug withdrawal and other aversive states (Cryan, Hoyer, & Markou, 2003; Markou & Koob, 
1991; Schulteis, Markou, Cole, & Koob, 1995). ICSS was first discovered serendipitously by 
Olds and Milner in 1954 while attempting to stimulate the reticular formation (Milner, 1989; 
Olds & Milner, 1954). James Olds noticed that a particular rat in which he had implanted an 
electrode seemed to “seek out” the electrical stimulation that he applied, and he confirmed that 
the stimulation served as a reinforcer after constructing a crude operant chamber and allowing 
the rat to lever press for stimulation. He later realized that the electrode was bent when it was 
inserted into the brain, and had actually terminated in the septum, and concluded that this brain 
area was involved in reward (Milner, 1989). Gradually, various methodologies for studying 
reward substrates and effects of drugs grew out of his early research. Today, these methodologies 
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are referred to collectively as ICSS or brain stimulation reward. ICSS is one of the most salient 
forms of reinforcement, and it is based on electrical activation of the mesolimbic dopamine 
system (Kornetsky, 2004; Roy A. Wise, 2002). A stimulating electrode is implanted into one of 
several possible sites including the various parts of the hypothalamus including the medial 
forebrain bundle, or other areas including the septum, which have projections to the ventral 
tegmental area (VTA). A large group of dopaminergic neurons in the VTA known as A10 
neurons project to forebrain areas including the nucleus accumbens and prefrontal cortex. ICSS 
is mediated mainly through activation of glutamatergic projections to dopaminergic neurons in 
the VTA, which stimulates dopamine release originating from the VTA to the nucleus 
accumbens (Shizgal, Schindler, & Rompre, 1989), where it activates GABAergic medium spiny 
neurons in the nucleus accumbens. Dopamine release in the nucleus accumbens is associated 
with natural rewards, including palatable feeding and increases in spontaneous locomotor 
activity, as well as drug reward (Cheer, Aragona, et al., 2007; Neill, Fenton, & Justice, 2002; R. 
A. Wise, 2005). This indirect stimulation of dopamine neurons in the nucleus accumbens is 
thought to maintain ICSS behavior.  
There are several different methodologies of ICSS, including discrete trial, auto-titration, 
rate-based studies, and rate-frequency. All of the models except rate-based vary the electrical 
current during session, which allows for analysis of drug effects across a range of response rates, 
and reinforcer values. This dissertation will mainly focus on rate-frequency procedures. During 
baseline conditions subjects typically respond at low rates for lower frequencies of stimulation, 
and at increasingly higher rates as frequency is increased. Many drugs of abuse, and specifically 
psychomotor stimulants such as cocaine, produce an increase in total responses, and manifests as 
a leftward shift from baseline on the rate-frequency response curve (Corbett, 1991; Fish et al., 
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2012; Robinson, Agoglia, Fish, Krouse, & Malanga, 2012). This profile of effects also is referred 
to as a decrease in the reward threshold because the frequency, or number of pulses per train in 
the medial forebrain bundle necessary to maintain responding is reduced. ICSS is also used to 
assess affective signs of drug withdrawal and other aversive states (Cryan, et al., 2003; Markou 
& Koob, 1991; Schulteis, et al., 1995), as these manipulations can produce a reduction of ICSS, 
or an increase in reward threshold, reflected by a rightward shift of the rate-frequency curve. 
Many animal species will respond for brain stimulation including mice, rats, monkeys, and 
humans (Bewernick, Kayser, Sturm, & Schlaepfer, 2012; Olds & Milner, 1954; Randt & 
Quartermain, 1972; Rolls, Burton, & Mora, 1980). The first procedure in mice was established 
by Randt and Quartermain in 1972 (Randt & Quartermain, 1972) and was followed by several 
studies in mice by Cazala and Cardo (Cazala & Cardo, 1972).   
Cannabinoid facilitation of ICSS has been difficult to observe and studies have resulted 
in inconsistent observations similar to the effects of cannabinoids on reward or reinforcement in 
other preclinical models. Some studies have shown that THC reduces reward thresholds of ICSS 
in rats (Gardner et al., 1988; Katsidoni, Kastellakis, & Panagis, 2013; Lepore, Liu, Savage, 
Matalon, & Gardner, 1996), while others have demonstrated that THC (Fokos & Panagis, 2010; 
Stark & Dews, 1980) and synthetic full agonists WIN 55,212-2 (Vlachou, Nomikos, & Panagis, 
2003) and CP 55,940 (Arnold, Hunt, & McGregor, 2001) fail to affect ICSS responding. The 
majority of studies with cannabinoids and ICSS have found threshold increasing, or response-
attenuating effects of various cannabinoid drugs including THC (Kwilasz & Negus, 2012; 
Vlachou, Nomikos, Stephens, & Panagis, 2007), synthetic agonists WIN 55,212-2 (Mavrikaki, 
Markaki, Nomikos, & Panagis, 2010; Vlachou, Nomikos, & Panagis, 2005), levonantradol 
(Kucharski, Williams, & Kornetsky, 1983), nabilone and canbisol (Stark & Dews, 1980), CP 
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55,940 (Kwilasz & Negus, 2012; Vlachou, et al., 2005), AMG-3 (Antoniou et al., 2005), and 
HU-210 (Vlachou, et al., 2005), and endocannabinoid enhancing (and purportedly enhancing) 
drugs URB-597, PMSF, and OMDM-2 (Vlachou, Nomikos, & Panagis, 2006) and the supposed 
AEA transport inhibitor AM-404 (Vlachou, Stamatopoulou, Nomikos, & Panagis, 2008). For a 
complete summary of cannabinoid agonist and endocannabinoid modulator effects on ICSS, see 
Table 1. A common trend among ICSS studies with THC was that low doses produced 
facilitation, or leftward shifts of the rate-frequency curves, or did not affect responding, and 
higher doses reduced responding, or produced a rightward shift in the curve (Katsidoni, et al., 
2013; Lepore, et al., 1996). Furthermore, three of the four studies that found a 
facilitating/threshold decreasing effect of THC utilized Lewis rats (Gardner, et al., 1988; Lepore, 
et al., 1996); evidence that THC-induced facilitation of ICSS is a strain-dependent effect. Of 
particular importance to the present studies is that no cannabinoid compounds have been 
assessed in mouse ICSS.      
The effects of CB1 receptor antagonists on ICSS are also somewhat inconsistent between 
studies. The CB1 antagonist, rimonabant, has been shown to attenuate ICSS responding or reduce 
reinforcement in some studies, usually at higher doses (De Vry, Schreiber, Eckel, & Jentzsch, 
2004; Deroche-Gamonet, Le Moal, Piazza, & Soubrie, 2001; Trujillo-Pisanty et al., 2011; Xi, et 
al., 2011), while it produces no change on ICSS responding in others (Antoniou, et al., 2005; 
Arnold, et al., 2001; Kwilasz & Negus, 2012; Vlachou, et al., 2003; Vlachou, et al., 2005, 2006; 
Vlachou, et al., 2007; Vlachou, et al., 2008). For a complete summary of cannabinoid antagonist 
effects in ICSS, see Table 1 on pages 18 - 21. Certainly dose is a factor, as higher doses tend to 
disrupt responding, and lower doses tend to have no effect on ICSS. As shown in Table 1, doses 
of 3.0 mg/kg rimonabant or higher tend to produce rightward shifts in ICSS, or attenuate 
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responding. These discrepancies may also be due to differences in endocannabinoid tone 
produced by distinct experimental procedures. For example, procedural variations that produce 
more stress than others may alter the endocannabinoid tone. The differences in amount of AEA 
or 2-AG available to bind to CB1 receptors may alter the way that CB1 antagonists affect ICSS 
behavior. If there is an abundance of endocannabinoids available and binding to CB1 receptors, 
CB1 antagonists could conceivably produce more aversive effects than when an antagonist is 
administered under less stressful conditions. Also, similar to results with agonists, all 
assessments of CB1 antagonists have been conducted in rats. Certainly, there may be a species 
difference in response to CB1 antagonists, as the facilitation caused by agonists seems to be 
strain-dependent in rats. For a summary of all cannabinoid ICSS studies ICSS, see Table 1.  
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Table 1  
 
Summary of Cannabinoids Agonist, Antagonist, and Endocannabinoid Modulating Drug Effects in ICSS 
Cannabinoid Agonists 
                Rat ICSS 
Drug Dose/R.O.A.            Strain  Test Effect       Reference    
 
THC 0.1 & 1.0 mg/kg i.p.  S-D R-F 
*
decreased thresholds w/0.1 mg/kg (n=8)  (Katsidoni, et al., 2013) 
       
*
increased thresholds w/1.0 mg/kg (n=8) 
 
THC 0.1 – 10.0 mg/kg i.p.  S-D R-F *attenuated responding w/3.2 & 10 mg/kg (n=6) (Kwilasz & Negus, 2012) 
CP 10.0 - 320 μg/kg i.p.    attenuated responding w/100 & 320 μg/kg (n=5) 
 
THC 0.5 & 1.0 mg/kg i.p.  S-D R-F n.s. trend of increased thresholds w/1 mg/kg (note: (Fokos & Panagis, 2010) 
       showed same trend in rats exposed to chronic 
       unpredictable stress as control rats) (n=7) 
 
THC 0.5 – 2.0 mg/kg i.p.  S-D R-F *increased thresholds w/1.0 & 2.0 mg/kg (n=6-9) (Vlachou, et al., 2007) 
 
THC 1.0 mg/kg i.p.   Lewis R-F decreased thresholds     (Lepore, et al., 1996) 
THC 1.0 mg/kg i.p.   S-D  no change in thresholds 
THC 1.0 mg/kg i.p.   Fischer-  no change in thresholds (n=9? not reported, but 
     344  Determined from degrees of freedom reported) 
 
THC 1.0 & 1.5 mg/kg i.p.  Lewis ??? decreased thresholds (n not reported)   (Gardner et al., 1989) 
 
THC 1.5 mg/kg i.p.   Lewis A-T decreased thresholds (n=10? not reported, but  (Gardner, et al., 1988)  
       determined from degrees of freedom reported) 
 
THC 10.0 mg/kg; oral  L-E Rate n.s. decreased response rates by 50% (n=3)  (Stark & Dews, 1980) 
nabilone  0.12 - 4.0 mg/kg; oral   decreased response rates w/1 & 4 mg/kg (n=6) 
canbisol 0.25 & 0.32 mg/kg; oral   decreased response rates w/0.32 mg/kg (n=6) 
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           Rat ICSS 
Drug Dose/R.O.A.           Strain  Test Effect       Reference    
 
WIN  0.1 – 3.0 mg/kg i.p.  S-D R-F increased thresholds w/1 mg/kg (n=5-6)  (Mavrikaki, et al., 2010) 
                       
WIN 0.1 – 3.0 mg/kg i.p.  S-D R-F *increased thresholds w/3 mg/kg (n=7)  (Vlachou, et al., 2005) 
CP 10.0 – 100.0 μg/kg i.p.   *increased thresholds w/100 μg/kg (n=8) 
HU-210  10.0 – 100.0 μg/kg i.p.   *increased thresholds w/30 & 100 μg/kg (n=7) 
 
WIN  0.1 – 1.0 mg/kg i.p.  S-D R-F no change in thresholds (n=4-9)   (Vlachou, et al., 2003) 
 
CP 10.0 – 50.0 μg/kg i.p.  Lewis R-F no change in thresholds (n=7)   (Arnold, et al., 2001) 
 
 
^
AMG-3  1.0 – 8.0 mg/kg i.p.  S-D R-F *increased thresholds w/8.0 mg/kg (n=14)  (Antoniou, et al., 2005) 
 
levonantradol               CDF D-T increased thresholds w/0.2 & 0.3 mg/kg (n=4) (Kucharski, et al., 1983) 
(0.0125 - 0.3 mg/kg; s.c.) 
 
Endocannabinoid Enzyme/Transport Inhibitors             
 
#
AM-404  1.0 – 30.0 mg/kg i.p.    S-D R-F *increased thresholds w/30 mg/kg (n=11)  (Vlachou, et al., 2008) 
 
$
URB-597   0.3 – 3.0 mg/kg i.p.   S-D R-F *increased thresholds w/1 and 3 mg/kg (n=7) (Vlachou, et al., 2006) 
%
PMSF    15.0 – 60.0 mg/kg i.p.   increased thresholds w/15, 30, & 60 mg/kg (n=7) 
#
OMDM-2  3.0 – 30.0 mg/kg i.p.   *increased thresholds w/30 mg/kg (n=5) 
 
Cannabinoid Antagonists                
 
RIM     0.02 mg/kg   S-D R-F no change in responding; 0.02 mg/kg blocked (Katsidoni, et al., 2013) 
     facilitation produced by 0.1 mg/kg and attenuation 
     by 1.0 mg/kg THC (listed above) 
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                          Rat ICSS 
Drug Dose/R.O.A.           Strain  Test Effect       Reference  
 
RIM     1.0 mg/kg i.p.   S-D R-F no change in responding; 1 mg/kg blocked (n=5-6) (Kwilasz & Negus, 2012) 
     attenuated responding by 3.2 mg/kg THC (listed above 
 
RIM     0.1 – 10.0 mg/kg i.p.  L-E R-F !increased thresholds w/10 mg/kg (n=6-7)  (Xi et al., 2008) 
AM-251    0.1 – 10.0 mg/kg i.p.   !no change in thresholds (n=7-9) 
 
RIM 0.02 mg/kg i.p.  S-D R-F no change in thresholds (n=6), blocked threshold (Vlachou, et al., 2008) 
       increase by 30 mg/kg AM-404 (n=6) (listed above) 
 
RIM     0.02 mg/kg i.p.  S-D R-F no change in thresholds, blocked threshold increase (Vlachou, et al., 2007) 
by 2 mg/kg THC (n=6) (listed above) 
 
RIM 0.02 – 1.0 mg/kg i.p.  S-D R-F no change in thresholds; 0.02 mg/kg blocked (Vlachou, et al., 2006) 
     threshold increase by URB-597 and OMDM-2 
       (n=5-7) (listed above) 
 
RIM 0.02 – 3.0 mg/kg i.p.  S-D R-F no change in thresholds (n=9), blocked threshold (Vlachou, et al., 2005) 
increase by 100 μg/kg CP (n=9) and 3 mg/kg WIN  
(n=11) with 0.02 mg/kg SR 
 
AM-251  1.0 & 3.0 mg/kg i.p.  S-D R-F no change in thresholds (n=6), blocked threshold 
       increase by 100 μg/kg HU-210 (n=6) with 1 & 3 
       mg/kg AM251 (listed above) 
 
RIM 1.0 – 10.0 mg/kg i.p.  W-f R-F decreased responses on FR10 schedule of ICSS (De Vry, et al., 2004) 
       w/3 & 10 mg/kg SR (n=3-12) (note: also reduced 
       operant responding for food in female and male rats 
       w/1, 3, & 10 SR) 
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           Rat ICSS 
Drug Dose/R.O.A.           Strain  Test Effect       Reference    
 
RIM 0.02 & 0.3 mg/kg i.p.  S-D R-F no change in thresholds (n=9) (note: reversed the (Vlachou, et al., 2003) 
       effects of WIN, which blocked cocaine-induced 
       threshold decreases) (listed above) 
 
RIM  1.0 – 20.0 mg/kg i.p.  S-D R-F increased thresholds w/20 mg/kg SR (n=6)  (Arnold, et al., 2001) 
       (listed above) 
 
RIM 0.3 – 10.0 mg/kg i.p.  S-D R-F increased thresholds w/1, 3, and 10 mg/kg (n=8) (Deroche-Gamonet, et al., 
2001) 
 
AM-251    3.0 mg/kg i.p.  L-E MT decreased the price (lever press duration) able to (Trujillo-Pisanty, et al., 2011) 
       sustain ICSS responding without significantly 
       affecting frequency threshold (n=8) 
 
AM-251   1.0 mg/kg i.p.  S-D R-F no change in thresholds (n=14), blocked threshold (Antoniou, et al., 2005) 
       increase by 8 mg/kg 
^
AMG-3 (n=14) (listed above) 
 
                   
Table 1 was adapted from (Panagis, Vlachou, & Nomikos, 2008) and expanded upon.  
 
Symbol definitions: 
*
effect was also blocked by a CB1 antagonist, 
^∆(8)-THC analogue with cannabimimetic properties, $FAAH 
inhibitor, 
#
purported AEA uptake/transport inhibitor, 
%
nonselective serine protease inhibitor (non-selectively inhibits FAAH), 
!
produced a reduction in cocaine-facilitated ICSS. 
 
Abbreviations: R.O.A. = route of administration, S-D = Sprague-Dawley, L-E = Long-Evans, CDF = albino CDF, W-f = Wister 
(female), R-F = rate frequency, A-T = auto-titration, Rate = stimulation parameters were not varied and rate was measured, DT = 
discrete trials, MT = reinforcement mountain, THC = tetrahydrocannabinol, RIM = rimonabant, WIN = WIN 55212-2 a synthetic full 
agonist at the CB1 receptor, AEA = anandamide, CP = CP 55,940 a synthetic full agonist at the CB1 receptor, n.s. = not statistically 
significant, levonantradol = CP 50,556-1
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The results with CB1 antagonists in ICSS provide evidence that the endocannabinoid 
system is involved in mesolimbic reward. Since high doses of CB1 antagonists can reduce ICSS, 
it may indicate that endocannabinoid tone is necessary to produce normal mesolimbic reward 
functioning. If blockade of endocannabinoid tone reduces responding for mesolimbic activation, 
2-AG and/or AEA may be necessary for normal functioning in that system. It is important to 
note however, that rimonabant has also been shown to disrupt other behaviors, including operant 
responding for food, so the effect may not be specific to brain stimulation reward (De Vry, et al., 
2004; Marusich & Wiley, 2012).   
Cannabinoid Activity in the Mesolimbic System 
As briefly discussed earlier, the mesolimbic system is a dopaminergic signaling pathway 
that contains projections and interconnections to and from the ventral tegmental area (VTA), 
amygdala, hippocampus, and prefrontal cortex, and to the nucleus accumbens. It is largely 
comprised of dopaminergic projections from the VTA, and is innervated by many excitatory and 
inhibitory inputs including glutamatergic and GABAergic inputs (Bielajew & Shizgal, 1986). 
This system has been studied exhaustively as a potential common pathway of drug and non-drug 
reward and reward-motivated behavior, and it has been reported that ICSS activates this system 
and increases dopamine in this system (Cheer, Wassum, et al., 2007; Neill, et al., 2002; R. A. 
Wise, 2005). Many psychomotor stimulants including cocaine and amphetamine interact with 
this pathway due to their direct activity at dopaminergic neurons. 
Cannabinoid receptors and endocannabinoids are located within the mesolimbic system. 
CB1 receptors are located in the nucleus accumbens, VTA, PFC, as well as the amygdala and 
many other regions (Hrabovszky et al., 2012; Yoshida et al., 2006). Additionally, AEA and 2-
AG and their precursors have been found throughout these regions (Matyas et al., 2008; Melis et 
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al., 2006; Yoshida, et al., 2006). Also, of interest to this study, the biosynthetic enzyme of 2-AG, 
diacylglycerol lipase (DAGL) is found in the membranes of dopaminergic neurons in the VTA 
(Matyas, et al., 2008; Yoshida, et al., 2006), though CB1 receptors are not present on those 
neurons. Specifically, CB1 receptors have been found within GABAergic and glutamatergic 
terminals in the VTA and nucleus accumbens (Kortleven, Fasano, Thibault, Lacaille, & Trudeau, 
2011; Matyas, et al., 2008). The presence of cannabinoid receptors and endocannabinoids in 
these regions suggests a role for cannabinoid modulation of dopamine release.  
Interestingly, rat studies with exogenous cannabinoids have been shown to increase 
dopamine release in brain regions in the mesolimbic system including the nucleus accumbens 
(NAc) and prefrontal cortex. For example, i.v. administration of the CB1 agonist WIN55,212-2 
increases dopamine release in the NAc core and shell (Cheer, Wassum, Heien, Phillips, & 
Wightman, 2004; Tanda, Pontieri, & Di Chiara, 1997), i.v. THC mimics those effects (Tanda, et 
al., 1997) Conversely, i.v. administration of the CB1 antagonist, RIM, blocks enhanced dopamine 
release in the NAc shell produced by drugs of abuse such as cocaine, ethanol, nicotine, and THC 
measured with in vivo voltammetry (Cheer, Wassum, et al., 2007) and microdialysis (Tanda, et 
al., 1997).  Furthermore, THC has been shown to strain-dependently enhance dopamine release 
in the nucleus accumbens and medial prefrontal cortex (J. Chen, Paredes, Lowinson, & Gardner, 
1990; J. P. Chen et al., 1990; J. P. Chen, Paredes, Lowinson, & Gardner, 1991). In another study, 
i.v. administration of THC was shown to produce increases in striatal dopamine release 
measured with microdialysis (Malone & Taylor, 1999). Further evidence of cannabinoid 
involvement in the mesolimbic system shows that micro-injection of THC into the VTA also 
enhances dopamine release (J. Chen, Marmur, Pulles, Paredes, & Gardner, 1993). In addition to 
these data, cannabinoid agonists have been shown to increase dopaminergic neuron firing in the 
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rat VTA, which has projections to the nucleus accumbens. This effect has been shown with i.v. 
administration of the cannabinoid agonists THC, WIN 55,212-2, and CP 55,940 measured by 
whole cell electrophysiology (French, 1997; French, Dillon, & Wu, 1997; Gessa, Melis, 
Muntoni, & Diana, 1998). These studies suggest that cannabinoids may produce rewarding 
effects through a similar mechanism to other drugs of abuse including psychomotor stimulants 
and opiates.  
A generally accepted theory of how cannabinoids may modulate activity in the 
mesolimbic system was proposed by Carl Lupica’s group in 2005. As mentioned earlier, CB1 
receptors are generally located on pre-synaptic neuron terminals where their activation reduces 
the release of a specific neurotransmitter from that terminal (Cadogan, et al., 1997; Katona, et al., 
2000; Robbe, et al., 2001). Additionally, GABAergic projections are responsible for tonic 
inhibition of spontaneous dopamine firing in the VTA, while glutamatergic projections excite 
dopaminergic neurons, as depicted on Fig. 2. Lupica and colleagues propose that CB1 stimulated 
dopamine release is maintained through CB1 receptors on GABAergic primary and interneurons 
projecting onto dopaminergic neurons in the VTA (Lupica & Riegel, 2005). By reducing 
GABAergic signaling, which normally inhibits dopaminergic activity, it could result in a 
functional increase in dopamine. It is important to note though, that CB1 receptors are located on 
GABAergic neuron terminals, (Fernandez-Ruiz, Hernandez, & Ramos, 2010; Katona, et al., 
2000; Ong & Mackie, 1999) as well as on glutamatergic and cholinergic neuron terminals 
(Fernandez-Ruiz, et al., 2010; Lu, Ong, & Mackie, 1999; Ong & Mackie, 1999). In contrast to 
GABAergic CB1 receptor activation, CB1 receptors on glutamate neurons can reduce 
spontaneous dopaminergic neuron firing (Fig. 2). There is evidence however, that CB1 receptors 
are found in higher levels in GABAergic interneurons than on cholinergic or glutamatergic 
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projecting neurons, which indicates they may be more sensitive to cannabinoid activation 
(Marsicano & Lutz, 1999). Additionally, electrophysiology data shows that the cannabinoid 
agonist, WIN55,212-2 is more potent at reducing neuronal transmission in GABAergic neurons 
than glutamatergic neurons (Hajos & Freund, 2002a, 2002b; Ohno-Shosaku et al., 2002).   
This evidence supports observations that cannabinoids can produce biphasic effects in 
some behavioral tests measuring reward or reinforcement, and may only do so within a limited 
dose-range. High doses of CB1 agonists produce different effects than low doses, which may 
indicate the balance of CB1 receptor activation shifts from GABAergic to 
glutamatergic/cholinergic in the VTA.  
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Figure 2. A depiction of cannabinoid receptors and endocannabinoid activity on GABAergic and 
glutamatergic axons projecting to dopaminergic neurons in the ventral tegmental area (VTA). 
Cannabinoid receptor activation on GABAergic neurons increases dopaminergic firing, while 
activation of cannabinoid receptors on glutamatergic neurons produces the opposite effect. 
Figure adapted from (Lupica & Riegel, 2005). 
 
Rationale 
Although reward-associated effects of cannabinoids are difficult to assess using 
preclinical measures, there is much evidence that marijuana produces positive subjective effects 
in humans, including positive subjective effect ratings associated with marijuana use (Hart, et al., 
2010; Hart, et al., 2001), and brain imaging studies implicating reward-relevant brain areas 
during marijuana cue presentations in marijuana-dependent individuals (Goldman, et al., 2013). 
Several studies have demonstrated that THC facilitates ICSS (Gardner, et al., 1988; Lepore, et 
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al., 1996), which suggests that ICSS may allow for evaluation of reinforcement-potentiating 
effects associated with cannabinoids. Additionally, blockade of CB1 receptors has been shown to 
reduce ICSS behavior, which provides further evidence that the endocannabinoids and 
cannabinoid receptors are involved in mesolimbic brain functioning.   
Neurochemical correlates associated with other drugs of abuse in the mesolimbic system 
are also observed during cannabinoid administration. For example, exogenous cannabinoids 
increase dopamine release in brain areas including the nucleus accumbens and prefrontal cortex 
as measured with in vivo microdialysis or voltammetry (Cheer, et al., 2004; Cheer, Wassum, et 
al., 2007; J. Chen, et al., 1993; J. Chen, et al., 1990; J. P. Chen, et al., 1991; Malone & Taylor, 
1999; Ng Cheong Ton et al., 1988; Tanda, et al., 1997). Additionally, cannabinoid agonists have 
been shown to increase dopaminergic neuron firing in the rat VTA (French, 1997; French, et al., 
1997; Gessa, et al., 1998), suggesting they activate the mesolimbic system, and may in fact 
potentiate reinforcement produced by stimulation of the medial forebrain bundle. 
Almost all of the findings with THC and reward-related behaviors discussed above have 
been demonstrated in rats. However, there are far fewer studies investigating these effects in 
mice. As shown on table 1, there have been no studies involving cannabinoid agonists or 
antagonists with ICSS in mice. C57BL/6 mice are known to engage in certain drug-taking 
behaviors that other strains and species do not, such as freely drinking unsweetened ethanol 
diluted with water (Elmer, Meisch, & George, 1987). Furthermore, alcohol has been shown to 
facilitate ICSS in mice (Fish et al., 2010), while producing mixed effects in rats depending on 
strain and ICSS assay used (Carlson & Lydic, 1976; Schaefer & Michael, 1992; Schaefer, 
Richardson, Bonsall, & Michael, 1988). Additionally, there have been three studies 
demonstrating self-administration of i.v. WIN55,212-2 in mice (Flores, et al., 2013; Martellotta, 
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et al., 1998; Mendizabal, Zimmer, & Maldonado, 2006), and reports of increases in dopamine in 
the nucleus accumbens with systemic administration of the synthetic cannabinoid agonist 
WIN55,212-2, which suggests that this strain may be a good candidate to observe ICSS 
facilitation with cannabinoids, and demonstrate cannabinoid rewarding effects in a preclinical 
mouse model (Robledo, Trigo, Panayi, de la Torre, & Maldonado, 2007).   
 The effects of THC and selective FAAH, MAGL and combined FAAH/MAGL 
inhibitors have not been investigated in mouse ICSS assays. Furthermore, no published studies to 
date have evaluated MAGL inhibitors, or the FAAH inhibitor PF-3845 in any species with ICSS. 
In this study, we assessed THC and selective inhibitors of FAAH, MAGL, and a novel dual 
FAAH/MAGL using ICSS to infer the consequences of increased endocannabinoid levels on 
operant responding for electrical stimulation of the medial forebrain bundle. Mechanism of 
action for any observed effects were evaluated with CB1 and CB2 antagonism tests. We also 
investigated spontaneous locomotor behavior and operant responding for food pellets in order to 
ascertain whether these pharmacological treatments affected other behavioral measures in a 
similar fashion as ICSS. Additionally, we measured brain endocannabinoid levels in regions 
associated with the mesolimbic system including the prefrontal cortex, ventral mid-brain 
(approximation of VTA), nucleus accumbens and amygdala after specific enzyme inhibitor 
treatments to determine changes after drug treatment. The cerebellum was assessed as a non-
mesolimbic region.   
Overall Hypothesis 
Cannabinoid agonists and endocannabinoid enzyme inhibitors will potentiate 
reinforcement maintained by self-stimulation of the medial forebrain bundle in C57BL/6 mice. 
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Selection of Pharmacological Agents  
The CB1 agonist THC was assessed in ICSS to determine the effect of the primary active 
constituent in marijuana. The MAGL inhibitor JZL184 was used to assess elevation of 2-AG and 
other effects attributable to MAGL inhibition. JZL184 is a selective and readily available MAGL 
inhibitor that is irreversible, and has been shown to produce 10-fold elevations in whole mouse 
brain 2-AG that persist over 12 hours after administration (J. Z. Long, Li, et al., 2009). JZL184 
also produces increases of interstitial 2-AG in the mouse nucleus accumbens, and although it has 
been shown to inhibit FAAH when given repeatedly, it does not affect interstitial AEA levels 
when give acutely (Wiskerke, et al., 2012). The FAAH inhibitor PF-3845 was used to assess 
consequences of preventing AEA degradation, and other effects attributable to FAAH inhibition. 
PF-3845 is highly selective for FAAH inhibition and also produces up to 10-fold increases of 
AEA that persist over a similar time-course as JZL184 increasing levels of 2-AG (Ahn, et al., 
2009). The dual (FAAH/MAGL) inhibitor SA-57 was used to assess the effects of combined 
inhibition of both endocannabinoid degrading enzymes on ICSS responding. SA-57 produces 
dose-related elevations in AEA and 2-AG, and has a higher affinity for FAAH than MAGL 
(Niphakis, et al., 2012). Cocaine HCl was used as a positive control, as it reliably facilitates 
ICSS in a robust fashion (Corbett, 1991; Fish, et al., 2012; Robinson, et al., 2012). 
Methods 
Subjects 
A total of 245 male C57Bl/6 mice aged 8 – 10 weeks (22-30g), obtained from Jackson 
Laboratories (Bar Harbor, Maine) were used for the experiments described (78 for ICSS studies, 
13 for operant studies, 90 for endocannabinoid measurement, and 64 for locomotor activity 
studies). Mice were between 8 and 12 weeks of age at the time of either surgery, brain dissection 
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for endocannabinoid quantification, operant training, or locomotor activity testing. Mice were 
maintained on a 12:12 hour light/dark cycle beginning at 6:00 AM, individually housed, and 
given free access to food and water. All experiments were conducted in accordance with the NIH 
Guide for the Care and Use of Laboratory Animals, and have been approved by the Virginia 
Commonwealth University Institutional Animal Care and Use Committee (IACUC). 
Drugs 
Cocaine HCl (obtained from NIDA drug supply) was dissolved in 0.9% saline. JZL184, 
rimonabant, SR144528, and THC (obtained from NIDA drug supply) SA-57 (obtained from 
Micah Niphakis, TSRT, La Jolle, CA), and PF-3845 (obtained from Organix, Woburn, MA) was 
dissolved in a vehicle solution (VEH) of 1 part ethanol, 1 part Emulphor-620 (Rhone-Poulenc, 
Princeton, NJ), and 18 parts 0.9% saline (1:1:18). 
Apparatus 
ICSS testing was conducted using eight standard (18 X 18 X 18 cm) mouse operant 
conditioning chambers (Med Associates Inc., St. Albans, VT, USA). Each chamber was 
equipped with a retractable lever located in the right-hand position on the front chamber wall, 2 
LED stimulus lights, a chamber house-light, and a tone-generator. The outside of each chamber 
was equipped with a suspended electrical commutator connected to a shock generator, as well as 
to a tether that is fed through a hole in the top of the chamber, in order to be connected to the 
electrode attached to a mouse. Chambers were enclosed within sound and light attenuating 
chambers equipped with exhaust fans. MED Associates Inc. software was used to control 
manipulations in the operant chambers and record data during training and testing sessions. 
Operant responding for food tests were conducted in mouse operant conditioning chambers (Med 
Associates Inc.) similar to those described above. Each chamber was equipped with two nose 
 
 
33 
 
poke apertures (instead of levers), a food hopper to deliver sweetened food pellets (Bio-Serv) to 
a recessed well within the chamber. All other aspects of the chamber were identical to those used 
for ICSS testing, except they lack tone generators, and all equipment related to electrical 
stimulation, including commuators, tethers, etc. Locomotor activity testing was conducted in 
Plexiglas boxes (17.5 X 8.5 X 8 in) with plastic floor inserts, capped with clear Plexiglas lids, 
and enclosed within light and sound attenuating chambers. Locomotor activity was recorded 
during the tests, using Unibrain Fire-I digital cameras and analyzed using ANY-maze software 
(Stoelting, Kiel, WI) track and quantify movements.  
Stereotaxic Surgery 
Surgical procedures for implanting electrodes in mice for ICSS studies were similar to 
those previously reported (Carlezon & Chartoff, 2007). Mice were anesthetized with isoflurane 
and received constant delivery during surgical procedures. Bipolar twisted stainless steel 
electrodes (0.125 mm single wire diameter without insulation; Plastics One, Roanoke, VA) were 
implanted into the right medial forebrain bundle of the mice using coordinates similar to those 
reported by Straub and colleagues: 2.0 mm posterior of bregma, 0.8 mm lateral from midline, 
and 4.8 mm below dura (Straub, Carlezon, & Rudolph, 2010). After the hole for the electrode 
was drilled, three holes were bored into the skull surrounding the area the electrode would be 
placed, anchoring screws were secured in those holes. Finally, an electrode was inserted and 
fixed to the skull using dental cement. Mice were given post-operative care for five days 
following surgery including treatment with bacitracin and acetaminophen, and were introduced 
to operant chambers one week after surgery. 
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Behavioral Procedures 
Locomotor activity. Mice were acclimated to testing room 24 hours before testing 
began. After mice were given selected drugs/doses, they were returned to their home cages for 
two hours. Following the two hour pre-treatment time mice were immediately placed in the 
Plexiglas activity observation boxes and recording using Any-maze software (Stoelting, Kiel, 
WI) began. Activity was assessed for 25 minutes and mice were returned to home cages at the 
conclusion of the test. All tests were recorded, and distance travelled, time-immobile, and 
adjusted speed (distance/time – time immobile) was calculated. Box assignment and time-of test 
were counter-balanced between the different drug/dose conditions. Separate groups of mice were 
used for each treatment condition. Mice were exposed to the Plexiglas observation boxes once 
under a single experimental condition to prevent habituation from altering results. 
Operant responding for food. Mice were initially food deprived to 85% of their free 
feeding weight, before being exposed to operant chambers. During 15 minute operant sessions, 
mice were assigned one nose-poke aperture, while the aperture on the opposite side of the 
chamber was blocked with a rubber stopper to prevent spontaneous responding. Responding in 
the aperture under a fixed ratio 1 (FR-1) schedule of reinforcement resulted in delivery of 1 food 
pellet reinforcers (Bio-Serv), and FR value was gradually increased to a FR-10 schedule of 
reinforcement.  A computer with logic interface and MED-PC software (Med Associates) was 
used to manipulate rate of reinforcement and record data from training and test sessions. Mice 
began testing when they maintained at least 20 responses per minute, and total responses 
remained within 10% of the prior 2 training days for at least 3 consecutive training days. These 
criteria were evaluated before every operant test was conducted, also ensuring that mice had a 
minimum of 96 hours between testing conditions. Subjects were given a minimum 1 week wash-
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out period before beginning testing a new compound. On test days, mice were injected in the 
testing room, and allowed to remain in home cages during the given pre-treatment time. Vehicle 
(VEH) solution tests were conducted at the beginning and end of every dose-effect curve to 
assess response rate stability over time. Dose conditions were tested using a quasi-randomized 
design to control for order effects. 
ICSS. Seventy-eight mice were implanted with electrodes, twenty-one mice were able to 
complete at least one experiment, while fifty-seven mice either didn’t reach testing criteria, or 
lost electrode viability before completing a single test series. After recovery, mice began lever-
press training. Mice were trained to lever press on a fixed-ratio 1 (FR1) schedule of 
reinforcement, where each lever press delivered a 0.5-s train of square-wave cathodal pulses 
(0.1-ms pulse duration) at a frequency of 141 Hz, and was accompanied by a stimulus light, 
house light, and tone cue presentation. Amplitudes of stimulation were adjusted for each mouse 
on an individual basis to produce maximal responding at this stage. Mice were exposed to daily 
30 - 60 min FR1 training sessions until they maintained stable responding at a reasonable 
response rate (i.e. ≥ 35 responses per minute). Stimulation amplitudes were adjusted individually 
between 20 and 300 μA in order to maintain maximal rates before testing began.  
After stable responding was maintained, mice were moved to rate-frequency training. 
During rate-frequency training mice were presented with and allowed to respond for a series of 
10 descending stimulation frequencies at 0.05 log unit increments (56-158 Hz), in contrast to 
only being exposed to one frequency (141 Hz) during FR training. During each frequency 
presentation within each series, mice were first given a 5 s time-out in which levers were not 
present in the boxes, followed by 5 s during which the lever was extended and 5 non-contingent 
stimulations at a given frequency were delivered, followed by a 60 s period when they were 
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allowed to respond for stimulations at that specific frequency. The lever was then retracted, the 
stimulation frequency decreases by 0.05 log units, and the next frequency presentation begins. 
For example the first frequency presentation is 158 Hz, after the 60 s response period has 
concluded, and mice were allowed to respond for 141 Hz for the next 60 s, followed by 126, and 
so on until they are presented with the tenth and last frequency (56 Hz), which concluded the 
series.  These frequency presentation series’ were repeated between 3 and 5 times per training 
session. Current amplitudes were further individually adjusted if needed for each subject to 
maintain ≥ 50% baseline maximal responding in at least three and fewer than eight frequencies. 
The first series of frequency presentations each day was considered a daily “warm-up” period 
and data is excluded from all analyses. The next two series were averaged together to create the 
baseline response curve for that day. Following a given treatment, mice were again allowed to 
respond for two series of frequencies, which were averaged together for analysis. When the total 
responses during baseline varied by less than 20% within each mouse for 3 consecutive days of 
assessment, and VEH/saline tests produced between 80 and 120% of baseline responding for at 
least two consecutive assessments, and visual analysis of rate-frequency curves confirmed they 
were curvilinear, mice were deemed able to begin testing.  
On test days, mice were placed in the chambers and allowed to respond during the 
“warm-up” and baseline phases. Immediately after baseline responding, mice were removed 
from operant chambers, placed in their home cages, injected with drug, saline, or VEH, and 
returned to home cages for pre-treatment time before beginning testing. Mice were then returned 
to the operant chambers to respond during two additional series of frequency presentations, 
which were considered the test series. Mice first received injections of vehicle (VEH) and/or 
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saline to ensure that neither solution affected the frequency response curves before beginning 
dose response curves.  
Drugs were tested with a minimum of 72 hours between tests, and at least 1 week 
between drugs, to ensure drug clearance and baseline assessments were made before all tests, to 
ensure the subjects were responding normally before drugs are administered. VEH or saline tests 
were conducted before and after determining dose-effect curves to ensure that conditioned 
effects did not develop over time, and that baselines remained stable throughout the course of the 
experiment. Mice were exposed to doses in ascending or descending order in a counter-balanced 
design. Antagonist test conditions were tested in a quasi-randomized order. This study used a 
mixed design wherein some subjects completed only one drug curve, and other subjects 
completed all drug tests. All drugs tested included some drug-naïve subjects. Cannabinoid effects 
on ICSS were reproducible over time during time-course and antagonist testing.  
Analytical Procedures 
Tissue extraction and quantification of AEA, 2-AG and AA. Drug naïve subjects were 
injected with VEH, JZL184 (4.0 and 40.0 mg/kg) or SA-57 (1.0 or 10.0 mg/kg) i.p. two hours 
prior to sacrificing. Immediately following cervical dislocation and decapitation, brains of C57 
male mice were removed, dissected, and the prefrontal cortex, nucleus accumbens, ventral mid-
brain, amygdala, and cerebellum were removed. The selected brain regions of interest were 
dissected from whole fresh brains. The prefrontal cortex was dissected by making a cut at the 
posterior extent of the anterior olfactory nucleus after which the olfactory nuclei were removed.  
This sample included frontal association, primary and secondary motor, anterior cingulate, 
prelimbic and orbital frontal cortices. The next cut was made anterior to the optic chiasm to 
produce a thick coronal section. The nucleus accumbens was dissected by removing the cortex 
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ventrally and the septum and nucleus of the horizontal limb of the diagonal band medially and 
then collecting the tissue surrounding the anterior commissure. The amygdala (including the 
central nucleus, basolateral and basomedial nuclei) dissection was made by first cutting caudal to 
the optic chiasm, and then making a second cut directly caudal to the median eminence. The 
amygdala was isolated by removing piriform cortex lateral of the amygdala and taking the region 
included in the bifurcated corpus collosum and all regions ventral to that. The ventral midbrain 
dissection was made by making a cut rostral to the cerebellar peduncles, then removing the 
remaining hypothalamic subregions ventrally and substantia nigra laterally. Isolation of ventral 
midbrain was made by removing the remaining regions below the red nucleus and includes the 
ventral tegmental area and interfascicular nucleus. The cerebellum was then removed from the 
brain stem. 
On the day of processing, the pre-weighed tissues were homogenized with 1.4 ml 
chloroform: methanol (2:1 v/v containing 0.0348g PMFS/ml) after the addition of internal 
standards to each sample (2 pmole AEA –d8, 1 nmole 2-AG-d8 and 1 nmole AA-d8). 
Homogenates were then mixed with 0.3 ml of 0.73% w/v NaCl, vortexed and then centrifuged 
for 10 min at 2054g (4 C). The aqueous phase plus debris were collected and extracted again 
twice with 0.8 ml chloroform. The organic phases from the three extractions were pooled and the 
organic solvents were evaporated under nitrogen gas. Dried samples were reconstituted with 0.1 
ml chloroform and mixed with 1 ml cold acetone. The mixtures were then centrifuged for 5 min 
at 2054g and 4 C to precipitate the proteins. The upper layer of each sample was collected and 
evaporated under nitrogen. Dried samples were reconstituted with 0.1 ml methanol and placed in 
autosample vials for analysis. 
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LC/MS/MS was used to quantify AEA, 2-AG and AA. The mobile phase consisted of 
(10:90) water: methanol with 0.1% ammonium acetate and 0.1% formic acid. The column used 
was a Discovery  HS C18, 2.1* 150 mm, 3 micron (Supelco, USA). Ions were analyzed in 
multiple reaction monitoring mode and the following transitions were monitored in positive 
mode: (348>62) and (348>91) for AEA; (356>62) for AEA-d8; (379>287) and(379>269) for 2-
AG ;  (387>96) for 2AG-d8; (300>62) and  in negative mode : (303>259) and  (303>59) for AA 
and (311>267) for AA-d8. A calibration curve was constructed for each assay based on linear 
regression using the peak area ratios of the calibrators. The extracted standard curves ranged 
from 0.039 pm to 40 pm for AEA, from 0.0625nm to 64 nm for 2-AG and from 1 nm to 32 nm 
for AA.  
Data Analysis 
The independent variable measured in the ICSS studies was stimulations per min during 
each frequency trial. ICSS response data were evaluated using two separate methods. In the first 
method, data were normalized to the highest response rate recorded during the baseline rate-
frequency curve generated for each individual mouse. This transformation allowed us to display 
the data as the percent maximum control rate (% MCR) and normalized individual response rates 
between subjects. These data were used to generate the rate-frequency curves which were 
assessed using repeated-measures, two-way ANOVAs (treatment x frequency) between baseline 
and treatment curves for each drug/dose tested. Holm-Sidak tests were used for post-hoc 
analyses of rate-frequency results which allowed multiple comparisons at all frequencies.  
A second method to analyze the data was also used in order to perform between-dose 
comparisons, and provide summary data. The total number of stimulations during the test series 
was divided by the total number of responses during the baseline series and multiplied by 100 to 
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produce percent baseline stimulations (% Baseline Stimulations) (Negus, Morrissey, Rosenberg, 
Cheng, & Rice, 2010). This effectively collapsed all the separate frequency stimulation rates into 
an overall stimulation count and allowed for comparison of data between days/treatments. This 
calculation was performed for all doses of each drug and VEH/saline and those values were 
analyzed using repeated-measures one-way ANOVAs. Dunnett’s post-hoc test were used 
following significant ANOVAs to compare treatment groups to VEH controls. 
Distance travelled, time-immobile, and adjusted mean speed (distance/(time – time 
immobile)) were observed during locomotor activity studies and analyzed using independent 
sample 1-way analysis of variance (ANOVA), and followed up with Dunnett’s post-hoc tests. In 
the operant responding for food studies response rate was the independent variable of interest, 
and was analyzed using repeated-measures 1-way ANOVAs, post-hoc analyses were conducted 
using Dunnett’s post-hoc test. Brain endocannabinoid and AA levels (pm/g or nm/g) were 
analyzed using individual one-way ANOVA for each brain region and substrate measured. 
Significant ANOVAs were assessed using Dunnett’s post-hoc analysis.  
Results 
Cocaine ICSS Dose-Response Assessment 
 This study evaluated the ability of cocaine to facilitate ICSS in C57Bl/6 mice. Seven 
mice were assessed with ICSS after saline and cocaine (1.0, 5.0 and 10.0 mg/kg), and data were 
analyzed using repeated-measures two-way ANOVAs (treatment x frequency) for each test 
conducted. Saline and 1.0 mg/kg cocaine did not affect ICSS responding, while 5.0 and 10.0 
mg/kg cocaine significantly facilitated self-stimulations. Saline produced a main effect of 
frequency (F 9, 54 = 47.16, p < 0.0001), but no main effect of treatment (F 1, 6 = 0.005, p > 0.05), 
and no interaction (F 9, 54 = 1.83, p > 0.05) (Fig. 3a); similarly, 1.0 mg/kg cocaine showed a main 
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effect of frequency (F 9, 36 = 48.23, p < 0.0001), but no main effect of treatment (F 1, 4 = 0.09, p > 
0.05), and no interaction (F 9, 36 = 1.83, p > 0.05) (Fig. 3b). Higher doses of cocaine (5.0 and 10.0 
mg/kg) significantly and robustly facilitated ICSS. Cocaine (5.0 mg/kg) had a main effect of 
frequency (F 9, 54 = 33.27, p < 0.0001), treatment (F 1, 6 = 76.72, p < 0.001) and an interaction (F 
9, 54 = 11.52, p < 0.0001) (Fig. 3c); 10.0 mg/kg cocaine also produced a main effect of frequency 
(F 9, 54 = 63.04, p < 0.0001), treatment (F 1, 6 = 37.69, p < 0.001) and an interaction between 
frequency and treatment (F 9, 54 = 4.15, p < 0.001) (Fig. 3d), indicating that 5.0 and 10.0 mg/kg 
cocaine facilitated ICSS responding. Post-hoc analysis revealed increases at five and seven 
frequencies respectively as shown on Fig. 3c and d. Baseline rate-frequency stimulation rates did 
not differ over the course of testing; there was a main effect of frequency (F 9, 36 = 81.22, p < 
0.0001), but no main effect of baseline day (F 3, 12 = 0.95, p > 0.05), and no interaction (F 27, 108 = 
0.82, p > 0.05) (Fig. 3e).  
 The percent baseline stimulations data were analyzed using a repeated-measures one-way 
ANOVA. Cocaine facilitated ICSS (F 4, 12 = 18.56, p < 0.001) (Fig. 3f); post-hoc analysis showed 
that 5.0 and 10.0 mg/kg cocaine produced significant facilitation of ICSS, while 1.0 mg/kg did 
not differ from saline treatment. These results are in accordance with the rate-frequency analysis. 
Cocaine produced a dose-related facilitation of ICSS, as has been shown in the literature.  
 
 
42 
 
S a lin e
L o g  F re q u e n c y
%
 M
C
R
1 .7 1 .8 1 .9 2 .0 2 .1 2 .2
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
S a lin e
B a s e lin e
1 .75 1 .85 1 .95 2 .05 2 .15 2 .25
a 1 .0  C o c a in e
L o g  F re q u e n c y
%
 M
C
R
1 .7 1 .8 1 .9 2 .0 2 .1 2 .2
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
B a s e lin e
1 .0  c o c a in e
1 .75 1 .85 1 .95 2 .05 2 .15 2 .25
b
5 .0  C o c a in e
L o g  F re q u e n c y
%
 M
C
R
1 .7 1 .8 1 .9 2 .0 2 .1 2 .2
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
* * * *
*
*
* * * *
* * *
5 .0  c o c a in e
B a s e lin e
1 .75 1 .85 1 .95 2 .05 2 .15 2 .25
c 1 0 .0  C o c a in e
L o g  F re q u e n c y
%
 M
C
R
1 .7 1 .8 1 .9 2 .0 2 .1 2 .2
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
1 0 .0  c o c a in e
B a s e lin e
*
* * * *
* * * *
* * * *
* * * ** * * *
* * * *
1 .75 1 .85 1 .95 2 .05 2 .15 2 .25
d
B a s e lin e s
L o g  F re q u e n c y
%
 M
C
R
1 .7 1 .8 1 .9 2 .0 2 .1 2 .2
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
B a s e lin e  1 .0
1 .75 1 .85 1 .95 2 .05 2 .15 2 .25
B a s e lin e  s a lin e
B a s e lin e  5 .0
B a s e lin e  1 0 .0
e
%
 B
a
s
e
li
n
e
 S
ti
m
u
la
ti
o
n
s
s a lin e 1 .0 5 .0 1 0 .0
0
4 0
8 0
1 2 0
1 6 0
2 0 0
* *
c o c a in e  (m g /k g )
* * *
f
 
Figure Continues 
 
 
43 
 
Figure Continued 
Figure 3. Cocaine ICSS assessment. Panels a – e show rate-frequency stimulation values (± 
SEM) after saline or cocaine (1.0, 5.0, and 10.0 mg/kg); percent maximum control rate is 
displayed on the Y-axis, log-frequency values are shown on the x-axis. Panel e shows all 
baselines during testing. Panel f shows percent baseline stimulations (± SEM) from all tests. 
With rate-frequency tests, interactions that achieved significance and were accompanied by 
significant post-hoc analyses are denoted by asterisks at values that are significantly different 
from baseline, ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05. Raw overall response rates 
(stimulations/min; mean ± SEM) during baseline (B) and test (T) sessions were as follows: (a) 
saline: B (31.98 ± 3.14) T (32.09 ± 3.06); (b) 1.0 mg/kg cocaine: B (27.83 ± 2.76) T (29.61 ± 
5.40); (c) 5.0 mg/kg cocaine: B (31.25 ± 2.10) T (47.51 ± 2.75); (d) 10.0 mg/kg cocaine: B 
(36.26 ± 4.40) T (61.44 ± 2.66).     
THC ICSS Experiments 
THC dose-response assessment. These experiments were conducted to determine the 
effect of THC on brain-stimulation reinforcement. ICSS was assessed in seven mice after 
treatment of vehicle (VEH) and THC (0.3, 1.0, 3.0, 5.6, and 10.0 mg/kg). Data were analyzed 
using two-way repeated-measures ANOVAs (treatment x frequency) for each condition. 
Analysis of rate frequency data showed that VEH, 0.3 and 1.0 mg/kg THC did not alter 
responding from baseline while 3.0, 5.6, and 10.0 mg/kg THC reduced ICSS. With VEH, there 
was a main effect of frequency (F 9, 54 = 52.09, p < 0.0001), but no main effect of treatment (F 1, 6 
= 1.21, p > 0.05) and no interaction (F 9, 54 = 1.03, p > 0.05) (Fig. 4a). THC (0.3 mg/kg) produced 
a main effect of frequency (F 9, 54 = 71.93, p < 0.0001), but no main effect of treatment (F 1, 6 = 
4.28, p > 0.05) and no interaction (F 9, 54 = 1.13, p > 0.05) (Fig. 4b). Similarly, 1.0 mg/kg THC 
produced a main effect of frequency (F 9, 54 = 60.20, p < 0.0001), but no main effect of treatment 
(F 1, 6 = 3.16, p > 0.05) and no interaction (F 9, 54 = 0.67, p > 0.05) (Fig. 4c). As mentioned above, 
3.0 mg/kg THC led to a significant reduction of ICSS; there were significant main effects of 
frequency (F 9, 54 = 53.27, p < 0.0001) and drug treatment (F 1, 6 = 8.15, p < 0.05).  However, the 
interaction between treatment and frequency did not achieve significance (F 9, 54 = 1.83, p > 0.05) 
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(Fig. 4d). Higher doses of THC (i.e., 5.6 and 10 mg/kg) also produced significant decreases in 
ICSS. THC (5.6 mg/kg) produced main effects of frequency (F 9, 54 = 44.15, p < 0.0001) and 
treatment (F 1, 6 = 13.54, p < 0.05), but no interaction (F 9, 54 = 1.05, p > 0.05) (Fig. 4e). THC 
(10.0 mg/kg) produced main effects of frequency (F 9, 54 = 46.58, p < 0.0001) and treatment (F 1, 
6 = 60.55, p < 0.001) as well as an interaction (F 9, 54 = 5.83, p < 0.0001) (Fig. 4f). Post-hoc 
analysis showed that stimulations were significantly reduced at eight frequencies, which are 
denoted on Fig. 4f. These findings indicated that THC (3.0, 5.6, and 10.0 mg/kg) reduced ICSS. 
All baseline rate-frequency curves were analyzed after all doses were assessed in order to 
ascertain if ICSS behavior differed over time (Fig. 5a). Two-way ANOVA revealed a main effect 
of frequency (F 9, 54 = 46.58, p < 0.0001), but no main effect of baseline day (F 6, 36 = 0.70, p > 
0.05) and no interaction between treatment and baseline day (F 54, 324 = 1.2, p > 0.05). 
Additionally, a second VEH test was conducted and compared to the initial VEH assessment and 
showed VEH tests did not differ (Fig. 5b). There was a main effect of frequency (F 9, 54 = 68.82, 
p < 0.0001), but no main effect of treatment (F 1, 6 = 0.24, p > 0.05) and no interaction (F 9, 54 = 
0.91, p > 0.05). These findings indicate that ICSS remained stable throughout the course of this 
experiment.  
Percent baseline stimulations were calculated and evaluated using one-way repeated 
measures ANOVA. VEH percent baseline stimulations were used for comparison. THC reduced 
percent baseline stimulations (F 6, 30 = 24.14, p < 0.0001). The three lowest doses of THC (0.3, 
1.0, and 3.0 mg/kg) did not differ from VEH (Fig. 6). In contrast, the higher doses of THC (i.e., 
5.6 and 10.0 mg/kg) did significantly reduce percent baseline stimulations. Post-hoc analysis 
showed that the respective doses of THC produced 73.56 % and 30.71% baseline stimulations 
and were significantly lower (p < 0.05; p < 0.01) than VEH percent baseline stimulations (Fig. 
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6). These results confirm rate-frequency analysis that 5.6 and 10.0 mg/kg THC produced a 
significant reduction of ICSS. Interestingly, rate-frequency analysis showed 3.0 mg/kg THC 
produced a small reduction in ICSS, but that effect was not detected when analyzing percent 
baseline stimulations.    
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Figure Continued 
Figure 4. THC ICSS dose-response assessment. Panels a – f show rate-frequency stimulation 
values (± SEM) after VEH or THC (0.3, 1.0, 3.0, 5.6, and 10.0 mg/kg); percent maximum 
control rate is displayed on the Y-axis, log-frequency values are shown on the x-axis. Significant 
main effects of treatment are denoted by asterisks by the figure legend; interactions that achieved 
significance and were accompanied by significant post-hoc results and are denoted by asterisks 
at values that are significantly different from baseline. ****p < 0.0001, ***p < 0.001, **p < 
0.01, *p < 0.05. Raw overall response rates (stimulations/min; mean ± SEM) during baseline (B) 
and test (T) sessions were as follows: (a) VEH: B (27.67 ± 2.98) T (27.25 ± 3.23); (b) 0.3 mg/kg 
THC: B (30.94 ± 3.72) T (28.93 ± 4.15); (c) 1.0 mg/kg THC: B (29.49 ± 3.52) T (27.16 ± 3.85); 
(d) 3.0 mg/kg THC: B (30.61 ± 5.21) T (26.72 ± 4.39); (e) 5.6 mg/kg THC: B (35.06 ± 4.84) T 
(25.22 ± 4.17); (f) 10.0 mg/kg THC: B (33.47 ± 4.60) T (10.85 ± 2.77). 
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Figure 4. Baseline ICSS tests. Mean rate-frequency stimulation values (± SEM) during (a) 
baselines of THC tests and (b) comparing initial VEH tests to VEH tests after THC testing was 
completed.  Percent maximum control rate is displayed on the Y-axis, log-frequency values are 
shown on the x-axis. Raw overall response rate (stimulations/min; mean ± SEM) during VEH 1 
was (27.25 ± 3.23) and VEH 2 was (28.81 ± 3.53) (Panel b).  
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Figure. 6. THC ICSS percent baseline stimulations. Fig. 6 shows percent baseline stimulations 
(± SEM) from all THC tests. The one-way ANOVA was significant and post-hoc analysis 
showed significant differences from VEH, which are denoted with asterisks. ****p < 0.0001, 
***p < 0.001, **p < 0.01, *p < 0.05 
THC time-course assessment. This study was conducted to assess the time-course of the 
ICSS rate-reduction produced by 10.0 mg/kg THC. Seven mice completed THC time-course 
testing, in which ICSS was assessed at 5 min, as well as 0.5, 2, 4, 8, 24, and 48 h after 
administration of VEH or 10.0 mg/kg THC. Two-way repeated measures ANOVAs (Treatment x 
Frequency) were used to compare rate-frequency curves of VEH and THC at each time-point. 
Stimulations after 10.0 mg/kg THC were significantly reduced compared with VEH at 5 min, 
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0.5, 2, 4, and 8 h after injection. Baseline rate-frequency curves between the two conditions did 
not differ from each other, as indicated by a main effect of frequency (F 9, 54 = 42.73, p < 
0.0001), but no main effect of treatment (F 1, 6 = 0.12, p > 0.05) and no interaction (F 9, 54 = 0.41, 
p > 0.05) (Fig. 7a). At the five minute time-point, there was a main effect of frequency (F 9, 54 = 
69.58, p < 0.0001) and treatment (F 1, 6 = 6.84, p < 0.05), but no interaction (F 9, 54 = 0.71, p > 
0.05) (Fig. 7b). At the 30 minute time-point there was a main effect of frequency (F 9, 54 = 52.82, 
p < 0.0001), treatment (F 1, 6 = 202.20, p < 0.0001) and an interaction (F 9, 54 = 9.05, p < 0.0001) 
(Fig. 7c). Post-hoc analysis showed reductions at six specific frequencies which are denoted on 
Fig. 7c. At the two hour time-point there was a main effect of frequency (F 9, 54 = 39.26, p < 
0.0001), treatment (F 1, 6 = 82.48, p < 0.001), and an interaction (F 9, 54 = 12.44, p < 0.0001) (Fig. 
7d). Post-hoc analysis showed reductions at six specific frequencies which are denoted on Fig. 
7d. At the four hour time-point there was a main effect of frequency (F 9, 54 = 25.96, p < 0.0001), 
treatment (F 1, 6 = 79.54, p < 0.001) and an interaction (F 9, 54 = 10.15, p < 0.0001) (Fig. 7e). Post-
hoc analysis revealed reductions at five specific frequencies which are denoted on Fig. 7e. Eight 
hours after injection, there was a main effect of frequency (F 9, 54 = 27.45, p < 0.0001), treatment 
(F 1, 6 = 50.42, p < 0.001) and an interaction (F 9, 54 = 4.22, p < 0.001) (Fig. 7f). Post-hoc analysis 
showed reductions at six frequencies which are denoted on Fig. 7f. ICSS returned to VEH levels 
at 24 and 48 h after administration; at 24 hours, there was a main effect of frequency (F 9, 54 = 
39.08, p < 0.0001), but no main effect of treatment (F 1, 6 = 0.55, p > 0.05) and no interaction (F 
9, 54 = 0.87, p > 0.05) (Fig. 7g). Similarly, at 48 hours after injection, there was a main effect of 
frequency (F 9, 54 = 37.13, p < 0.0001), but no main effect of treatment (F 1, 6 = 0.35, p > 0.05) 
and no interaction (F 9, 54 = 1.41, p > 0.05) (Fig. 7h). The reduction of ICSS produced by THC 
occurs as early as five minutes after administration and returned to baseline within 24 h.  
 
 
51 
 
A two-way repeated-measures ANOVA (Time-point x Treatment) was used to compare 
the percent baseline stimulations of VEH and 10.0 mg/kg THC across all time-points (Fig. 8). 
10.0 mg/kg THC produced a reduction from VEH percent baseline stimulations, as there was a 
main effect of time-point (F 6, 36 = 44.14, p < 0.0001), treatment (F 1, 6 = 128.5, p < 0.0001) and 
an interaction between time-point and treatment (F 6, 36 = 17.09, p < 0.0001). Post-hoc analysis 
revealed THC reduced ICSS at 0.5, 2, 4, and 8 h, while it did not differ from VEH at 5 min, 24 
and 48 h as denoted on Fig. 8. The reduction of ICSS produced by 10.0 mg/kg began 30 min 
after administration, and returned to baseline levels within 24 h, which is similar to rate-
frequency analysis results.  
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Figure Continued 
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Figure 7. THC ICSS time-course evaluation. Panels a – h show rate-frequency stimulation 
values (± SEM) after VEH or THC (10.0 mg/kg) at each time-point (5 min, 0.5, 2, 4, 8, 24 and 
48 h); percent maximum control rate is displayed on the Y-axis, log-frequency values are shown 
on the x-axis. Significant main effect of treatment is denoted by asterisks by the figure legend. 
Interactions that achieved significance and were accompanied by significant post-hoc analyses 
are denoted by asterisks at values that are significantly different from VEH. ****p < 0.0001, 
***p < 0.001, **p < 0.01, *p < 0.05. Raw overall response rates (stimulations/min; mean ± 
SEM) during VEH (V) and 10.0 mg/kg THC (T) conditions were as follows: (a) Baseline: V 
(31.2 ± 3.90) T (30.99 ± 4.36); (b) 5 min: V (28.12 ± 4.16) T (23.24 ± 3.74); (c) 30 min: V 
(25.34 ± 3.36) T (7.24 ± 1.90); (d) 2 h: V (26.21 ± 3.61) T (4.51 ± 1.92); (e) 4 h: V (24.13 ± 
3.57) T (6.89 ± 2.77); (f) 8 h: V (28.10 ± 3.53) T (13.61 ± 4.69); (g) 24 h: V (27.83 ± 3.50) T 
(25.79 ± 4.54); (h) 48 h: V (29.14 ± 4.17) T (28.34 ± 4.43).   
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Figure 8. THC ICSS percent baseline stimulations time-course evaluation. Percent baseline 
stimulations (± SEM) between VEH and THC (10.0 mg/kg) tests were compared across time-
points. The two-way ANOVA was significant and post-hoc analysis showed significant 
differences from VEH, which are denoted with asterisks. ****p < 0.0001 
THC: Evaluation of CB1 receptors. In this study, we tested whether the CB1 
antagonist/inverse agonist rimonabant (RIM) would block the rate-decreasing effects of THC 
(10.0 mg/kg) on ICSS. Six mice completed testing and the data were analyzed using a within-
subjects two-way ANOVA (treatment x frequency) for each dose combination tested. 
Administration of VEH with VEH did not produce a change from baseline; there was a main 
effect of frequency (F 9, 54 = 69.10, p < 0.0001), but no main effect of treatment (F 1, 6 = 0.001, p 
 
 
55 
 
> 0.05) and no interaction (F 9, 54 = 1.21, p > 0.05) (Fig. 9a). Combined treatment of VEH and 
10.0 mg/kg THC reduced stimulations from baseline similar to THC alone; there was a main 
effect of frequency (F 9, 54 = 58.59, p < 0.0001), treatment (F 1, 6 = 251.8, p < 0.0001) and an 
interaction (F 9, 54 = 6.97, p < 0.0001) (Fig. 9b); post-hoc analysis showed reductions at seven 
frequencies which are denoted on Fig. 9b. RIM (3.0 mg/kg) and VEH administration did not 
produce a change from baseline, indicating that CB1 antagonism does not affect ICSS; there was 
a main effect of frequency (F 9, 54 = 44.65, p < 0.0001), but no main effect of treatment (F 1, 6 = 
0.32, p > 0.05) and no interaction (F 9, 54 = 0.92, p > 0.05) (Fig. 9c). RIM (3.0 mg/kg) blocked the 
reduction of ICSS produced by THC (10.0 mg/kg), as stimulations did not differ from baseline, 
indicated by a main effect of frequency (F 9, 54 = 34.02, p < 0.0001), but no main effect of 
treatment (F 1, 6 = 0.79, p > 0.05), and no interaction (F 9, 54 = 1.78, p > 0.05) (Fig. 9d). Baseline 
rate-frequency curves did not differ under any condition tested (Fig. 9e). There was a main effect 
of frequency (F 9, 54 = 46.98, p < 0.0001), but no main effect of baseline day (F 3, 18 = 0.98, p > 
0.05), and no interaction between baseline day and frequency (F 27, 162 = 1.10, p > 0.05). 
A two-way ANOVA (3.0 mg/kg rimonabant vs. vehicle x 10.0 mg/kg THC vs. vehicle) 
was conducted using the percent baseline stimulation data. The reduction produced by 10.0 
mg/kg THC was blocked by administration of 3.0 mg/kg RIM. There was a main effect of first 
treatment (VEH vs. RIM) (F 1, 6 = 54.41, p < 0.001), a main effect of the second treatment (VEH 
vs. THC) (F 1, 6 = 54.41, p < 0.001) and an interaction between first and second treatment (F 1, 6 = 
90.81, p < 0.0001) (Fig. 9f). Post-hoc analysis revealed that percent baseline stimulations were 
reduced (p < 0.0001) in mice treated with 10.0 mg/kg THC, but only when first treated with 
VEH. RIM (3.0 mg/kg) pre-treatment blocked the reduction in stimulations produced by 10.0 
mg/kg THC. These results indicate that CB1 receptors mediate the rate-decreasing effects of 10.0 
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mg/kg THC on ICSS. Furthermore, the CB1 antagonist, RIM (3.0 mg/kg) did not produce any 
effect on ICSS alone. 
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Figure Continued 
 
Figure. 9. THC CB1 antagonism assessment. Panel a – d shows rate-frequency data during RIM 
antagonism tests. Panel e shows all baselines rate-frequency curves during CB1 testing. Percent 
maximum control rate is displayed on the Y-axis, log-frequency values are shown on the x-axis. 
Panel f shows percent baseline stimulations (± SEM) for all treatments. There was a significant 
interaction with the two-way ANOVA for percent baseline stimulations. Significant interactions 
were followed up by post-hoc analysis, and differences are denoted by asterisks at values that are 
significantly different from baseline (a – e), or other treatment conditions (f). ****p < 0.0001, 
**p < 0.01. Raw overall response rates (stimulations/min; mean ± SEM) during baseline (B) and 
test (T) sessions were as follows: (a) VEH + VEH: B (27.67 ± 3.51) T (28.36 ± 3.48); (b) VEH + 
10.0 mg/kg THC: B (29.80 ± 3.86) T (6.85 ± 2.45); (c) 3.0 mg/kg RIM + VEH: B (31.01 ± 4.96) 
T (29.67 ± 4.01); (d) 3.0 mg/kg RIM + 10.0 mg/kg THC: B (28.49 ± 3.97) T (26.48 ± 3.81). 
 
THC: Evaluation of CB2 Receptors. For this experiment, we evaluated whether the CB2 
antagonist/inverse agonist SR2 would block the reduction of ICSS produced by 10.0 mg/kg 
THC. Five mice completed testing and the data were analyzed using a within-subjects two-way 
ANOVA (treatment x frequency) for each dose combination. Similar to CB1 testing, 
administration of VEH and VEH did not produce a change from baseline ICSS; there was a main 
effect of frequency (F 9, 36 = 60.04, p < 0.0001), but no main effect of treatment (F 1, 4 = 5.34, p > 
0.05) and no interaction (F 9, 36 = 60.04, p > 0.05) (Fig. 10a). Similar to previous tests with 10.0 
mg/kg THC, stimulations with VEH and 10.0 mg/kg THC were reduced; there was a main effect 
of frequency (F 9, 36 = 28.93, p < 0.0001), treatment (F 1, 4 = 240.6, p < 0.001) and an interaction 
(F 9, 36 = 4.14, p < 0.01) (Fig. 10b). Post-hoc analysis showed reductions at seven frequencies 
which are denoted on Fig. 10b. SR2 (3.0 mg/kg) given with VEH did not affect baseline ICSS; 
there was a main effect of frequency (F 9, 36 = 28.79, p < 0.0001), but no main effect of treatment 
(F 1, 4 = 5.49, p > 0.05) and no interaction (F 9, 36 = 0.88, p > 0.05) (Fig. 10c). SR2 (3.0 mg/kg) 
was not able to block the reduction in ICSS produced by 10.0 mg/kg THC; there was a main 
effect of frequency (F 9, 36 = 35.66, p < 0.0001), treatment (F 1, 4 = 39.96, p < 0.01) and an 
interaction (F 9, 36 = 6.13, p < 0.0001) (Fig. 10d). Post-hoc analysis showed decreases at five 
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frequencies which are denoted on Fig. 10d. Baseline rate-frequency curves did not differ under 
any condition tested (Fig. 10e); there was a main effect of frequency (F 9, 36 = 36.48, p < 0.0001), 
but no main effect of baseline day (F 3, 12 = 0.91, p > 0.05), and no interaction between baseline 
day and frequency (F 27, 108 = 1.15, p > 0.05). 
A two-way ANOVA (3.0 mg/kg SR2 vs. VEH x 10.0 mg/kg THC vs. VEH) was 
conducted using the percent baseline stimulations data. The reduction of ICSS produced by 10.0 
mg/kg THC was not blocked by 3.0 mg/kg SR2 (Fig. 10f). There was no main effect of first 
treatment (VEH vs. SR2) (F 1, 4 = 2.19, p > 0.05), but there was a main effect of second treatment 
(VEH vs. THC) (F 1, 4 = 43.66, p < 0.01), as 10.0 mg/kg THC reduced ICSS. There was no 
interaction between first treatment and second treatment (F 1, 4 = 2.32, p > 0.05). The reduction in 
stimulations produced by 10.0 mg/kg THC was not blocked by SR2 (3.0 mg/kg), which suggests 
that the attenuation of ICSS responding is not mediated through CB2 receptors, which is in 
agreement with the rate-frequency findings.  
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Figure Continued 
 
Figure. 10. THC CB2 antagonism assessment. Panels a – d shows rate-frequency data during 
SR2 antagonism tests. Panel e shows all baselines rate-frequency curves during CB2 testing. 
Percent maximum control rate is displayed on the Y-axis, log-frequency values are shown on the 
x-axis. Panel f shows percent baseline stimulations (± SEM) for all treatments. Significant main 
effects of treatment are denoted by asterisks by the figure legend. Significant interactions were 
investigated with post-hoc analysis, and differences from baseline are denoted by asterisks. 
****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05. Raw overall response rates 
(stimulations/min; mean ± SEM) during baseline (B) and test (T) sessions were as follows: (a) 
VEH + VEH: B (29.99 ± 3.54) T (26.13 ± 2.67); (b) VEH + 10.0 mg/kg THC: B (28.11 ± 4.52) 
T (6.72 ± 3.12); (c) 3.0 mg/kg SR2 + VEH: B (28.80 ± 4.58) T (24.11 ± 3.09); (d) 3.0 mg/kg 
SR2 + 10.0 mg/kg THC: B (26.73 ± 3.83) T (8.91 ± 3.71). 
THC Operant Responding for Food Assessment 
In this experiment the effects of THC (5.0, 7.5, 10.0 and 20.0 mg/kg) on operant 
responding for food pellets were assessed; thirteen mice were evaluated and response rates were 
analyzed using a one-way repeated measures ANOVA. THC reduced operant response rates (F 4, 
59 = 15.46, p < 0.0001) (Fig. 11). Post-hoc analysis showed that THC (10.0 and 20.0 mg/kg) 
produced a reduction (p < 0.01; p < 0.0001 respectively) in operant response rates compared to 
VEH, while 5.0 and 7.5 mg/kg THC group were not affected, though there was a trend toward 
7.5 being significantly reduced (p = 0.06) (Fig. 11). The reduction of response rates produced by 
THC was not specific to brain stimulation reinforcement, as it occurred in both ICSS and operant 
responding for food. 
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Figure. 11. THC operant responding for food. Figure showing response rate (± SEM) on the y-
axis, and dose of THC or VEH on the x-axis. A significant one-way ANOVA was investigated 
with post-hoc analysis, and differences from VEH are denoted by asterisks. ****p < 0.0001, **p 
< 0.01 
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JZL184 ICSS Experiments 
JZL184 dose-response assessment. ICSS was assessed after administration of JZL184 
(1.0, 4.0, 16.0 and 40.0 mg/kg) and VEH. Seven mice completed testing, and the rate-frequency 
stimulation data were analyzed using a two-way, repeated-measures ANOVA (frequency x drug 
treatment). When analyzing rate-frequency data VEH, 1.0, and 4.0 mg/kg JZL184 did not affect 
baseline ICSS, while 16.0 and 40.0 mg/kg significantly attenuated stimulations. VEH produced a 
main effect of frequency (F 9, 54 = 39.11, p < 0.0001), but no main effect of treatment (F 1, 6 = 
0.23, p > 0.05) and no interaction (F 9, 54 = 0.92, p > 0.05) (Fig. 12a). JZL184 (1.0 mg/kg) 
produced a main effect of frequency (F 9, 54 = 87.40, p < 0.0001), but no main effect of treatment 
(F 1, 6 = 2.80, p > 0.05) and no interaction (F 9, 54 = 0.40, p > 0.05) (Fig. 12b). Similarly, 4.0 
mg/kg JZL184 produced a main effect of frequency (F 9, 54 = 64.98, p < 0.0001), but no main 
effect of treatment (F 1, 6 = 2.71, p > 0.05) and no interaction (F 9, 54 = 0.47, p > 0.05) (Fig. 12c). 
Higher doses of JZL184 (16.0 and 40.0 mg/kg) attenuated ICSS; after 16.0 mg/kg JZL184 
produced a main effect of frequency (F 9, 54 = 52.11, p < 0.0001), treatment (F 1, 6 = 14.68, p < 
0.001) and an interaction (F 9, 54 = 2.18, p < 0.05) (Fig. 12d). Post-hoc analysis revealed 
significant reductions at two frequencies which are denoted on Fig. 12d. JZL184 (40.0 mg/kg) 
produced a main effect of frequency (F 9, 54 = 39.9, p < 0.0001), no main effect of treatment (F 1, 
6 = 5.78, p = 0.05), but an interaction between treatment and frequency (F 9, 54 = 2.43, p < 0.05) 
(Fig. 12e); post-hoc analysis showed significant reductions at four frequencies which are denoted 
on Fig. 12e.  
All baseline rate-frequency curves were analyzed after all tests were completed to 
determine if baseline responding differed over time (Fig. 12f). Baseline stimulations slightly 
differed between test days; there was a main effect of frequency (F 9, 54 = 100.90, p < 0.0001) and 
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baseline day (F 4, 24 = 3.19, p < 0.05), but no interaction between treatment and baseline day (F 36, 
216 = 0.97, p > 0.05). Additionally, a second VEH test was conducted and compared to the initial 
VEH assessment (data not shown); tests did not differ. There was a main effect of frequency (F 9, 
54 = 55.33, p < 0.0001), but no main effect of treatment (F 1, 6 = 0.36, p > 0.05) and no interaction 
(F 9, 54 = 1.61, p > 0.05). Baselines varied slightly over time, but analysis from daily baseline 
allows for minimal baseline drift. Data are always assessed in terms of change from that day’s 
baseline to minimize experimental error due to baseline drift.  
Percent baseline stimulations were calculated for each test and evaluated using one-way 
repeated measures ANOVA. VEH was calculated to serve as a comparison to JZL184. JZL184 
reduced ICSS percent baseline stimulations (F 4, 24 = 4.48, p < 0.01) (Fig. 13); post-hoc analysis 
showed lower doses of JZL184 (1.0 and 4.0 mg/kg) did not affect percent baseline stimulations, 
while higher doses of JZL184 (16.0 and 40.0 mg/kg) reduced (p < 0.05; p < 0.01) percent 
baseline stimulations (76.28 % and 70.99 %) compared to VEH. These results agreed with the 
rate-frequency analysis, as the same doses of JZL184 (16.0 and 40.0 mg/kg) produced significant 
attenuation using both measure of ICSS. 
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Figure Continued 
 
Figure 12. JZL184 ICSS dose-response assessment. Panels a – e show rate-frequency stimulation 
values (± SEM) after VEH or JZL184 (1.0, 4.0, 16.0 and 40.0 mg/kg). Panel f shows all baseline 
rate-frequency curves during testing. Percent maximum control rate is displayed on the Y-axis, 
log-frequency values are shown on the x-axis. Significant main effects of treatment are denoted 
by asterisks by the figure legend. Interactions that achieved significance were investigated with 
post-hoc analyses, and differences from baseline are denoted by asterisks. ****p < 0.0001, ***p 
< 0.001, **p < 0.01, *p < 0.05. Raw overall response rates (stimulations/min; mean ± SEM) 
during baseline (B) and test (T) sessions were as follows: (a) VEH: B (33.99 ± 2.05) T (33.51 ± 
2.31); (b) 1.0 mg/kg JZL184: B (28.98 ± 2.53) T (27.55 ± 2.72); (c) 4.0 mg/kg JZL184: B (28.60 
± 3.90) T (26.08 ± 2.66); (d) 16.0 mg/kg JZL184: B (30.76 ± 3.76) T (23.08 ± 2.62); (e) 40.0 
mg/kg JZL184: B (34.00 ± 2.28) T (23.91 ± 3.95). 
 
 
 
 
 
 
 
67 
 
%
 B
a
s
e
li
n
e
 S
ti
m
u
la
ti
o
n
s
V E H 1 .0 4 .0 1 6 .0 4 0 .0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
*
J Z L  1 8 4  (m g /k g )
* *
*
 
Figure. 13. JZL184 ICSS percent baseline stimulations. Fig. 13 shows percent baseline 
stimulations (± SEM) from JZL184 dose-response tests. The one-way ANOVA was significant 
and post-hoc analysis revealed significant differences from VEH, which are denoted with 
asterisks. **p < 0.01, *p < 0.05 
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JZL184 Time-course Assessment. The purpose of this study was to assess the time-
course of JZL184-induced suppression of ICSS. Self-stimulations were assessed at 1, 2, 4, 8, 24, 
and 48 h after administration of VEH or 40.0 mg/kg JZL184. Six mice completed JZL184 time-
course testing, and two-way repeated-measures ANOVAs (Treatment x Frequency) were 
conducted to compare rate-frequency curves between VEH and JZL184 treatment at each time-
point. JZL184 (40.0 mg/kg) significantly reduced stimulations compared to VEH at 1, 2, 4, 8 and 
24 h after injection. Baselines between the two conditions did not differ from each other; there 
was a main effect of frequency (F 9, 45 = 83.39, p < 0.0001), but no main effect of treatment (F 1, 6 
= 0.38, p > 0.05) and no interaction (F 9, 45 = 0.63, p > 0.05) (Fig. 14a). At the one hour time-
point there was a main effect of frequency (F 9, 45 = 31.91, p < 0.0001), treatment (F 1, 5 = 7.01, p 
< 0.05) and an interaction (F 9, 45 = 2.18, p < 0.05) (Fig. 14b); post-hoc analysis showed 
reductions at two frequencies which are denoted on Fig. 14b. Similarly, at the two hour time-
point there was a main effect of frequency (F 9, 45 = 33.43, p < 0.0001), treatment (F 1, 5 = 7.80, p 
< 0.05) and an interaction (F 9, 45 = 2.11, p < 0.05) (Fig. 14c). Post-hoc analysis showed 
reductions at two frequencies which are denoted on Fig. 14c. Four hours after administration, 
there was a main effect of frequency (F 9, 45 = 19.01, p < 0.0001), treatment (F 1, 5 = 11.81, p < 
0.05), and an interaction (F 9, 45 = 2.71, p < 0.05) (Fig. 14d). Post-hoc analysis showed reductions 
at two frequencies are denoted on Fig. 14d. At the eight hour time-point there was a main effect 
of frequency (F 9, 45 = 28.31, p < 0.0001) and treatment (F 1, 5 = 61.41, p < 0.001), but no 
interaction (F 9, 45 = 2.07, p = 0.05) (Fig. 14e). At 24 hours after administrations, JZL184 
responding was still attenuated; there was a main effect of frequency (F 9, 45 = 63.87, p < 0.0001), 
treatment (F 1, 5 = 14.21, p < 0.001) and an interaction (F 9, 45 = 2.82, p < 0.001) (Fig. 14f); post-
hoc analysis showed reductions at four frequencies which are denoted on Fig. 14f. 48 hours after 
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administration, JZL184 stimulation rates returned to normal, as they did not differ from VEH; 
there was a main effect of frequency (F 9, 45 = 48.10, p < 0.0001), but no main effect of treatment 
(F 1, 5 = 0.66, p > 0.05) and no interaction (F 9, 45 = 1.41, p > 0.05) (Fig. 14g).  
A two-way repeated-measures ANOVA (Time-point x Treatment) was conducted to 
compare the percent baseline stimulations of VEH and 40.0 mg/kg JZL184 across all time-points 
(Fig. 14h). JZL184 (40.0 mg/kg) reduced percent baseline stimulations from VEH at several 
time-points after administration; there was a main effect of time-point (F 5, 25 = 12.48, p < 
0.0001), treatment (F 1, 5 = 11.54, p < 0.05), and an interaction between time-point and treatment 
(F 5, 25 = 2.61, p < 0.05). Post-hoc tests showed that 40.0 mg/kg JZL184 reduced percent baseline 
stimulations compared to VEH treatment at 2, 4, 8 and 24 hours after treatment as denoted on 
Fig. 14h. The attenuation of ICSS produced by JZL184 is apparent 2 hours after administration, 
and returns to baseline within 48 hours after administration according to percent baseline 
stimulations data. Similarly, the rate-frequency analysis shows reductions at 1 hour after 
administration, which persist between 24 and 48 h. 
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Figure Continued 
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Figure 14. JZL184 ICSS time-course evaluation. Panels a – g show rate-frequency stimulation 
values (± SEM) after VEH or JZL184 (40.0 mg/kg) at each time-point (1, 2, 4, 8, 24 and 48 h); 
percent maximum control rate is displayed on the Y-axis, log-frequency values are shown on the 
x-axis. Panel h shows percent baseline stimulations data over time. Significant main effects of 
treatment are denoted by asterisks by the figure legend. Interactions that achieved significance 
and were accompanied by significant post-hoc analyses are denoted by asterisks at values that 
are significantly different from baseline VEH. ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 
0.05. Raw overall response rates (stimulations/min; mean ± SEM) during VEH (V) and 40.0 
mg/kg JZL184 (J) conditions were as follows: (a) Baseline: V (26.78 ± 3.41) J (28.68 ± 2.27); 
(b) 1 h: V (23.11 ± 3.70) J (19.48 ± 4.38); (c) 2 h: V (22.73 ± 2.19) J (14.81 ± 4.01); (d) 4 h: V 
(20.28 ± 3.27) J (11.31 ± 3.78); (e) 8 h: V (23.83 ± 4.99) J (12.93 ± 3.18); (f) 24 h: V (29.33 ± 
3.00) J (19.78 ± 3.56); (g) 48 h: V (26.90 ± 4.55) J (25.01 ± 2.88). 
JZL184: Evaluation of CB1 receptors. In these experiments the CB1 antagonist/inverse 
agonist RIM (3.0 mg/kg) was administered with JZL184 (40.0 mg/kg) to determine if it would 
block the JZL184-induced attenuation of ICSS. Eight mice completed testing and the data were 
analyzed using two-way  
 (treatment x frequency) repeated-measures ANOVAs. Administration of VEH and VEH did not 
affect ICSS; there was a main effect of frequency (F 9, 63 = 39.01, p < 0.0001), but no main effect 
of treatment (F 1, 7 = 2.42, p > 0.05) and no interaction (F 9, 63 = 0.42, p > 0.05) (Fig. 15a). 
Administration of VEH and 40.0 mg/kg JZL184 reduced stimulations from baseline; there was a 
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main effect of frequency (F 9, 63 = 34.95, p < 0.0001), treatment (F 1, 7 = 29.94, p < 0.001) and an 
interaction (F 9, 63 = 6.97, p < 0.05) (Fig. 15b). Post-hoc analysis revealed reductions at six 
frequencies which are denoted on Fig. 15b. RIM (3.0 mg/kg) and VEH did not produce a change 
from baseline responding; there was a main effect of frequency (F 9, 63 = 52.30, p < 0.0001), but 
no main effect of treatment (F 1, 7 = 1.71, p > 0.05) and no interaction (F 9, 63 = 1.42, p > 0.05) 
(Fig. 15c). The attenuation of ICSS produced by 40.0 mg/kg JZL184 was blocked by treatment 
with 3.0 mg/kg RIM, as stimulations did not differ from baseline; there was a main effect of 
frequency (F 9, 63 = 66.55, p < 0.0001), but no main effect of treatment (F 1, 7 = 0.13, p > 0.05), 
and no interaction (F 9, 63 = 0.49, p > 0.05) (Fig. 15d). Baseline rate-frequency curves did not 
differ during any condition tested (Fig. 15e); there was a main effect of frequency (F 9, 63 = 66.23, 
p < 0.0001), but no main effect of baseline day (F 3, 21 = 2.78, p > 0.05) and no interaction 
between baseline day and frequency (F 27, 189 = 1.49, p > 0.05). 
A two-way, repeated-measures ANOVA (3.0 mg/kg RIM vs. VEH x 40.0 mg/kg JZL184 
vs. VEH) was conducted using the percent baseline stimulations data. RIM (3.0 mg/kg) blocked 
the attenuation of ICSS produced by 40.0 mg/kg JZL184 (Fig. 15f). There was no main effect of 
first treatment (RIM vs. VEH) (F 1, 7 = 3.20, p > 0.05), but there was a main effect of second 
treatment (JZL184 vs. VEH) (F 1, 7 = 6.10, p < 0.05) and an interaction between first and second 
treatment (F 1, 7 = 7.66, p < 0.05). Post-hoc analysis revealed that percent baseline stimulations 
were reduced (p < 0.001) in mice treated with 40.0 mg/kg JZL184, but only when first treated 
with VEH (Fig. 15f). Administration of 3.0 mg/kg RIM blocked the ICSS reduction produced by 
40.0 mg/kg JZL184, demonstrating that the attenuation of stimulations produced by 40.0 mg/kg 
JZL184 was CB1 receptor dependent. Rate-frequency findings were consistent with percent 
 
 
73 
 
baseline stimulations, as that also showed a blockade of JZL184-induced attenuation of ICSS by 
RIM. Similar to THC, the attenuation of ICSS was mediated through CB1 receptors. 
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Figure Continued 
 
Figure 15. JZL184 CB1 antagonism assessment. Panel a – d shows rate-frequency data during 
RIM antagonism tests. Panel e shows all baselines rate-frequency curves during CB1 testing. 
Percent maximum control rate is displayed on the Y-axis, log-frequency values are shown on the 
x-axis. Panel f shows percent baseline stimulations (± SEM) for all treatments. Significant 
interactions were followed up by post-hoc analysis, and differences are denoted by asterisks at 
values that are significantly different from baseline (a – e), or other treatment conditions (f). 
****p < 0.0001, ***p < 0.001, **p < 0.01. Raw overall response rates (stimulations/min; mean ± 
SEM) during baseline (B) and test (T) sessions were as follows: (a) VEH + VEH: B (31.20 ± 
3.46) T (29.14 ± 3.96); (b) VEH + 40.0 mg/kg JZL184: B (31.22 ± 3.18) T (19.31 ± 4.23); (c) 
3.0 mg/kg RIM + VEH: B (29.18 ± 2.94) T (26.94 ± 2.88); (d) 3.0 mg/kg RIM + 40.0 mg/kg 
JZL184: B (31.53 ± 3.22) T (28.41 ± 3.52).   
 
JZL184: Evaluation of CB2 receptors. The purpose of this study was to evaluate 
whether CB2 receptor played a necessary role in the suppressive ICSS effects produced by 
JZL184 (40.0 mg/kg). The CB2 receptor antagonist/inverse agonist SR2 (10.0 mg/kg) was co-
administered to determine if it would block the reduction in stimulation rate produced by 
JZL184. Eight mice were used for testing and data were analyzed using two-way (treatment x 
frequency) repeated-measures ANOVAs to compare each drug combination to baseline. Similar 
to previous tests administration of VEH and VEH did not affect baseline responding; there was a 
main effect of frequency (F 9, 63 = 46.89, p < 0.0001), but no main effect of treatment (F 1, 7 = 
1.50, p > 0.05), and no interaction (F 9, 63 = 1.00, p > 0.05) (Fig. 16a). Administration of VEH 
and 40.0 mg/kg attenuated ICSS from baseline, similar to results of CB1 tests; there was a main 
effect of frequency (F 9, 63 = 43.63, p < 0.0001), treatment (F 1, 7 = 92.02, p < 0.0001) and an 
interaction (F 9, 63 = 2.06, p < 0.05) (Fig. 16b). Post-hoc analysis showed reductions at six 
frequencies which are denoted on Fig. 16b. SR2 (10.0 mg/kg) co-administered with VEH did not 
affect baseline ICSS; there was a main effect of frequency (F 9, 63 = 35.02, p < 0.0001), but no 
main effect of drug treatment (F 1, 7 = 1.78, p > 0.05) and no interaction (F 9, 63 = 0.79, p > 0.05) 
(Fig. 16c). SR2 (10.0 mg/kg) was not able to block the effects of JZL184, as it still produced a 
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main effect of frequency (F 9, 63 = 33.23, p < 0.0001), treatment (F 1, 7 = 5.87, p < 0.05) and an 
interaction (F 9, 63 = 2.053, p < 0.05) (Fig. 16d). Post-hoc analysis revealed reductions at 2 
frequencies which are denoted on Fig. 16d. Baseline rate-frequency curves did not differ during 
any condition tested (Fig. 16e); there was a main effect of frequency (F 9, 63 = 62.05, p < 0.0001), 
but no main effect of baseline day (F 3, 21 = 3.00, p > 0.05) and no interaction between baseline 
day and frequency (F 27, 189 = 1.43, p > 0.05). 
Percent baseline stimulations data were analyzed using a two-way, repeated-measures 
ANOVA (10.0 mg/kg SR2 vs. VEH x 40.0 mg/kg JZL184 vs. VEH). The attenuation of ICSS 
produced by 40.0 mg/kg JZL184 was not blocked by co-administration with SR2 (10.0 mg/kg) 
(Fig. 16f). There was no main effect of first treatment (SR2 vs. VEH) (F 1, 7 = 0.56, p > 0.05), but 
there was a main effect of second treatment (JZL184 vs. VEH) (F 1, 7 = 34.59, p < 0.001) and an 
interaction between first treatment and second treatment (F 1, 7 = 7.17, p < 0.05). Post-hoc 
analysis revealed that JZL184 significantly reduced percent baseline stimulations when co-
administered with SR2 or VEH, indicating that JZL184 induced attenuation of ICSS was CB2 
receptor independent. These results completely agreed with rate-frequency analysis. These 
results were also similar to findings with THC which produced attenuation mediated through 
CB1 receptors, and not affected by CB2 receptor antagonism.  
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Figure Continued 
 
Figure 16. JZL184 CB2 antagonism assessment. Panels a – d shows rate-frequency data during 
SR2 antagonism tests. Panel e shows all baselines rate-frequency curves during CB2 testing. 
Percent maximum control rate is displayed on the Y-axis, log-frequency values are shown on the 
x-axis. Panel f shows percent baseline stimulations (± SEM) for all treatments. Significant 
interactions with were investigated with post-hoc analysis, and differences are denoted by 
asterisks at values that are significantly different from baseline (a – e), or other treatment 
conditions (f). ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05. Raw overall response rates 
(stimulations/min; mean ± SEM) during baseline (B) and test (T) sessions were as follows: (a) 
VEH + VEH: B (34.04 ± 3.06) T (33.88 ± 3.54); (b) VEH + 40.0 mg/kg JZL184: B (36.02 ± 
3.38) T (26.98 ± 3.40); (c) 10.0 mg/kg SR2 + VEH: B (30.98 ± 4.31) T (29.47 ± 4.31); (d) 10.0 
mg/kg SR2 + 40.0 mg/kg JZL184: B (30.81 ± 3.44) T (25.09 ± 3.47). 
 
JZL184 Operant Responding for Food Assessment 
In this study, operant responding for food pellets was assessed after VEH and JZL184 
(1.0, 4.0, 16.0 and 40.0 mg/kg). A one-way repeated-measures ANOVA was used to analyze 
response rates. JZL184 reduced operant response rates (F 4, 32 = 9.89, p < 0.0001) (Fig. 17). Post-
hoc analysis showed that 40.0 mg/kg JZL184 significantly attenuated (p < 0.0001) response 
rates, while 1.0, 4.0, and 16.0 mg/kg JZL184 did not differ from VEH as denoted on Fig. 17. 
These findings with high dose JZL184 (40.0 mg/kg) support ICSS findings, in which both 16.0 
and 40.0 mg/kg JZL184 attenuated responding. This was also similar to THC, as THC (10.0 
mg/kg) reduced operant response rates for both food and brain stimulation. 
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Figure 17. JZL184 effects on operant responding for food. Mean response rates (± SEM) are 
displayed on the y-axis, and dose of JZL184 or VEH is on the x-axis. A significant one-way 
ANOVA was investigated with post-hoc analysis, and significant differences from VEH are 
denoted by asterisks. ****p < 0.0001 
 
JZL184 Spontaneous Locomotor Activity Assessment 
Spontaneous locomotor activity was assessed after administration of JZL184 (4.0, 16.0 
and 40.0 mg/kg) or VEH. Distance travelled (m), mean speed (m/s) and time immobile (s) were 
recorded and are displayed on Fig. 18. A significant main effect of JZL184 treatment on distance 
travelled was observed (F 3, 31 = 8.91, p < 0.001) (Fig. 18a). Post-hoc analysis showed that 40.0 
mg/kg JZL184 reduced (p < 0.001) distance travelled, while 4.0 and 16.0 mg/kg did not differ 
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from VEH. JZL184 also increased time-immobile (F 3, 31 = 30.60, p < 0.0001). Post-hoc analysis 
showed that 40.0 and 16.0 mg/kg JZL184 increased (p < 0.0001; p < 0.01) time-immobile 
compared to VEH, while 4.0 mg/kg did not differ from VEH (Fig. 18b). JZL184 also 
significantly reduced speed of locomotion (F 3, 31 = 3.07, p < 0.05) (Fig. 18c). Post-hoc analysis 
showed that 40.0 mg/kg JZL184 decreased (p < 0.05) mean adjusted speed from VEH, while 4.0 
and 16.0 mg/kg did not differ from VEH. These results support ICSS and operant responding 
data, as distance travelled, operant responding, and ICSS were all reduced with high dose 
JZL184 (40.0 mg/kg), while time-immobile and ICSS were also affected by 16.0 mg/kg JZL184.  
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Figure Continued 
 
Figure 18. JZL184 effects on spontaneous locomotor activity. All panels show dose of JZL184 
and VEH on the x-axis. Panel a shows distance travelled on the y-axis, panel b shows time-
immobile, and panel c shows adjusted speed. Significant one-way ANOVAs were investigated 
with post-hoc analysis, and significant differences from VEH are denoted by asterisks. ****p < 
0.0001, ***p < 0.001, **p < 0.01, *p < 0.05 
 
JZL184 Endocannabinoid Quantification 
 Concentrations of 2-AG, AEA, and AA were determined from tissue samples from PFC, 
NAc, VMB, amygdala, and cerebellum after treatment with VEH, or JZL184 (4.0 or 40.0 
mg/kg). Separate one-way ANOVAs were conducted within each brain region to analyze 
concentration changes from VEH treatment. JZL184 dose-dependently increased 2-AG 
concentrations in the PFC (F 2, 12 = 124.2, p < 0.0001); post-hoc analysis showed that 40.0 mg/kg 
JZL184 produced a 7-fold increase (p < 0.0001) of 2-AG from VEH, while treatment 4.0 mg/kg 
JZL184 did not differ from VEH (Fig. 19a). JZL184 decreased AEA in the PFC by JZL184 (F 2, 
12 = 4.45, p < 0.05); post-hoc analysis showed that 40.0 mg/kg JZL184 reduced (p < 0.05) AEA 
concentrations to 49 % of VEH, while 4.0 mg/kg JZL184 AEA concentrations did not differ 
from VEH (Fig. 19b). JZL184 decreased concentrations of AA in the PFC (F 2, 12 = 12.32, p < 
0.01); post-hoc analysis showed that 40.0 mg/kg JZL184 reduced AA concentrations to 78 % of 
VEH, while 4.0 mg/kg JZL184 did not affect AA (Fig. 19c). 
 JZL184 increased 2-AG concentrations in the NAc (F 2, 11 = 130.9, p < 0.0001); post-hoc 
analysis showed that 4.0 and 40.0 mg/kg JZL184 increased (p < 0.001; p < 0.0001) 2-AG levels 
over 4-fold and 10-fold respectively from VEH (Fig. 19a). JZL184 decreased AEA in the NAc 
(F 2, 11 = 4.92, p < 0.05); post-hoc analysis showed that 40.0 mg/kg JZL184 reduced (p < 0.05) 
AEA concentrations to 46 % of VEH levels, while 4.0 mg/kg JZL184 did not affect AEA levels 
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(Fig. 19b). JZL184 did not affect AA concentrations in the NAc (F 2, 11 = 3.88, p = 0.05); 
however, there was a trend toward reduction of AA (Fig. 19c).  
Administration of JZL184 increased 2-AG concentrations in the VMB (F 2, 12 = 33.41, p < 
0.0001); post-hoc analysis showed that 4.0 and 40.0 mg/kg JZL184 increased (p < 0.01; p < 
0.0001) 2-AG over 7-fold and 13-fold VEH levels (Fig. 19a). JZL184 did not affect AEA in the 
VMB (F 2, 12 = 0.42, p > 0.05), as concentrations did not differ from VEH (Fig. 19b). JZL184 
reduced AA concentrations in the VMB (F 2, 12 = 4.35, p < 0.05); post-hoc analysis showed that 
40.0 mg/kg JZL184 decreased (p < 0.05) AA concentrations (p < 0.05) to 61 % of VEH AA, 
while 4.0 mg/kg JZL184 AA levels did not differ from VEH (Fig. 19c). 
JZL184 increased 2-AG levels in the amygdala (F 2, 12 = 87.70, p < 0.0001); post-hoc 
analysis showed that both 4.0 and 40.0 mg/kg JZL184 increased (p < 0.05; p < 0.0001) 2-AG 
over 2-fold and 8-fold of VEH levels respectively (Fig. 19a). JZL184 did not affect AEA levels 
in the amygdala (F 2, 12 = 3.69, p > 0.05) (Fig. 19b). JZL184 reduced AA concentrations in the 
amygdala (F 2, 12 = 10.12, p < 0.01). Post-hoc analysis showed that 40.0 mg/kg JZL184 reduced 
(p < 0.01) AA levels to 65 % of VEH concentrations, while 4.0 mg/kg JZL184 AA levels did not 
differ from VEH (Fig. 19c). 
Administration of JZL184 increased 2-AG in the cerebellum after (F 2, 12 = 75.91, p < 
0.0001); post-hoc analysis showed that 4.0 and 40.0 mg/kg JZL184 increased (p < 0.001; p < 
0.0001) 2-AG concentrations by over 2-fold and nearly 4-fold of VEH levels respectively (Fig. 
19a). JZL184 did not affect AEA concentrations in the cerebellum (F 2, 12 = 1.09, p > 0.05); (Fig. 
19b). JZL184 lowered AA concentrations in the cerebellum (F 2, 12 = 30.192, p < 0.0001). Post-
hoc analysis showed that 40.0 mg/kg JZL184 decreased AA to 69 % of VEH levels, while 4.0 
mg/kg JZL184 AA concentrations did not differ from VEH (Fig. 19c).  
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Figure Continued 
Figure 19. JZL184 effects on endocannabinoid and AA concentrations. All panels show brain 
region on the x-axis (AMYG = amygdala, CEREB = cerebellum). Panel a shows 2-AG levels on 
the y-axis, panel b shows AEA, and panel c displays AA. One-way ANOVAs were calculated 
within each brain region and substrate measured. Significant one-way ANOVAs were 
investigated with post-hoc analyses, and significant differences from corresponding VEH 
treatment are denoted by symbols. 
+
 p < 0.0001, 
#
p < 0.001, 
!
p < 0.01, *p < 0.05 
 
PF-3845 ICSS Experiments 
PF-3845 dose-response assessment. This study examined the effects of FAAH 
inhibition on ICSS. ICSS was assessed after administration of VEH and PF-3845 (1.0, 3.0, 10.0, 
and 30.0 mg/kg). ICSS was not affected by VEH, 1.0, 3.0, or 10.0 mg/kg PF-3845, but it was 
significantly attenuated by 30.0 mg/kg PF-3845. It is important to note that no other behavioral 
studies have assessed doses over 10.0 mg/kg, which we will discuss further in the discussion. 
VEH produced a main effect of frequency (F 9, 72 = 103.2, p < 0.0001), but no main effect of 
treatment (F 1, 8 = 0.09, p > 0.05) and no interaction (F 9, 72 = 0.30, p > 0.05) (Fig. 20a). As 
mentioned above, PF-3845 (1.0, 3.0 and 10.0 mg/kg) did not affect ICSS; with 1.0 mg/kg there 
was a main effect of frequency (F 9, 72 = 63.36, p < 0.0001), but there was no main effect of 
treatment (F 1, 8 = 5.17, p = 0.05) and no interaction (F 9, 72 = 0.72, p > 0.05) (Fig. 20b). PF-3845 
(3.0 mg/kg) produced a main effect of frequency (F 9, 72 = 64.84, p < 0.0001), but no main effect 
of treatment (F 1, 8 = 2.60, p > 0.05) and no interaction (F 9, 72 = 0.82, p > 0.05) (Fig. 20c). PF-
3845 (10.0 mg/kg) produced a main effect of frequency (F 9, 72 = 63.50, p < 0.0001), but no main 
effect of treatment (F 1, 8 = 2.07, p > 0.05) and no interaction (F 9, 72 = 0.61, p > 0.05) (Fig. 20d). 
The highest dose of PF-3845 (30.0 mg/kg) reduced ICSS rate; there was a main effect of 
frequency (F 9, 72 = 61.19, p < 0.0001), treatment (F 1, 8 = 8.32, p < 0.05) and an interaction (F 9, 72 
= 3.72, p < 0.001) (Fig. 20e). Post-hoc analysis showed reductions at four frequencies which are 
denoted on Fig. 20e. All baseline rate-frequency stimulation rates were analyzed after testing to 
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determine if there were any differences (Fig. 20f). There was a main effect of frequency (F 9, 72 = 
110.10, p < 0.0001), but no main effect of baseline day (F 4, 32 = 0.24, p > 0.05) and no 
interaction between treatment and baseline day (F 36, 288 = 0.64, p > 0.05), indicating that 
baselines did not differ over time. Additionally, a second VEH test was conducted and compared 
to the initial VEH assessment; VEH tests did not differ from each other (data not shown), as 
there was a main effect of frequency (F 9, 72 = 79.31, p < 0.0001), but there was no main effect of 
treatment (F 1, 8 = 2.39, p > 0.05) and no interaction (F 9, 72 = 0.99, p > 0.05). Similar to JZL184 
treatment, the high dose of PF-3845 produced a significant reduction of ICSS. 
Percent baseline stimulations were calculated for each condition and evaluated using one-
way repeated measures ANOVA. PF-3845 reduced percent baseline stimulations (F 4, 24 = 4.48, p 
< 0.01) (Fig. 21). Post-hoc analysis showed that 30.0 mg/kg (79.10 %) produced significant 
attenuation (p < 0.05) of percent baseline stimulations from VEH. While other doses of PF-3845 
(1.0, 3.0 and 10.0 mg/kg) did not affect percent baseline stimulations. These results are in 
agreement with the rate-frequency data analysis, as only the high dose of PF-3845 (30.0 mg/kg) 
produced a reduction of ICSS.  
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Figure Continued 
Figure 20. PF-3845 ICSS dose-response assessment. Panels a – e show rate-frequency 
stimulation values (± SEM) after VEH or PF-3845 (1.0, 3.0, 10.0 and 30.0 mg/kg). Panel f shows 
all baseline rate-frequency curves during testing. Percent maximum control rate is displayed on 
the Y-axis, log-frequency values are shown on the x-axis. Interactions that achieved significance 
were investigated with post-hoc analyses, and significant differences from baseline are denoted 
by asterisks. ***p < 0.001, **p < 0.01, *p < 0.05. Raw overall response rates (stimulations/min; 
mean ± SEM) during baseline (B) and test (T) sessions were as follows: (a) VEH: B (32.81 ± 
2.19) T (32.13 ± 1.94); (b) 1.0 mg/kg PF-3845: B (32.82 ± 2.90) T (30.73 ± 2.83); (c) 3.0 mg/kg 
PF-3845: B (32.59 ± 2.58) T (31.28 ± 2.91); (d) 10.0 mg/kg PF-3845: B (34.08 ± 2.40) T (32.10 
± 2.72); (e) 30.0 mg/kg PF-3845: B (32.96 ± 2.55) T (27.08 ± 3.68).  
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Figure 21. PF-3845 ICSS percent baseline stimulations. Fig. 21 shows percent baseline 
stimulations (± SEM) after PF-3845 or VEH. The one-way ANOVA was significant and post-
hoc analysis revealed a significant difference from VEH, which is denoted with an asterisk. *p < 
0.05 
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PF-3845 time-course assessment. The purpose of this experiment was to assess the 
time-course of PF-3845 induced attenuation of ICSS. Self-stimulations were assessed at 1, 2, 4, 
8, 24, and 48 h after administration of 30.0 mg/kg PF-3845 or VEH. Eight mice completed 
testing, and two-way repeated-measures ANOVAs (Treatment x Frequency) were conducted to 
compare rate-frequency curves between VEH and PF-3845 treatment at each time-point. Rate-
frequency data shows that PF-3845 (30.0 mg/kg) attenuated stimulations compared to VEH at 1, 
2, 4, 8 and 24 h after injection, but did not differ from each other 48 h after administration. 
Baseline rate-frequency curves between the two conditions did not differ from each other, as 
there was a main effect of frequency (F 9, 63 = 71.80, p < 0.0001), but no main effect of treatment 
(F 1, 7 = 1.1, p > 0.05) and no interaction (F 9, 63 = 0.90, p > 0.05) (Fig. 22a). One hour after 
administration there was a main effect of frequency (F 9, 63 = 46.84, p < 0.0001), treatment (F 1, 7 
= 7.99, p < 0.05) and an interaction (F 9, 63 = 2.12, p > 0.05), indicating a significant reduction of 
ICSS (Fig. 22b). Post-hoc analysis showed a difference at one frequency which is denoted on 
Fig. 22b. Two hours after injection, there was a main effect of frequency (F 9, 63 = 55.03, p < 
0.0001) and a main effect of treatment (F 1, 7 = 3.66, p < 0.05), but no interaction (F 9, 63 = 1.36, p 
> 0.05) (Fig. 22c). At the four hour time-point there was a main effect of frequency (F 9, 63 = 
64.03, p < 0.0001) and treatment (F 1, 7 = 6.80, p < 0.05), but no interaction (F 9, 63 = 0.82, p > 
0.05) (Fig. 22d). Eight hours after injection, there was a main effect of frequency (F 9, 63 = 51.67, 
p < 0.0001) and treatment (F 1, 7 = 6.56, p < 0.05), but there was no interaction (F 9, 63 = 1.09, p > 
0.05) (Fig. 22e). At the 24 h time-point, there was a main effect of frequency (F 9, 63 = 62.67, p < 
0.0001), treatment (F 1, 7 = 6.47, p < 0.05) and an interaction (F 9, 63 = 3.33, p < 0.01) (Fig. 22f). 
Post-hoc analysis showed differences at two frequencies which are denoted on Fig. 22f. After 48 
hours, stimulations with VEH and 30.0 mg/kg PF-3845 did not differ; there was a main effect of 
 
 
91 
 
frequency (F 9, 63 = 86.94, p < 0.0001), but no main effect of treatment (F 1, 7 = 3.13, p > 0.05) 
and no interaction (F 9, 63 = 0.86, p > 0.05) (Fig. 22g). The reduction of ICSS produced by PF-
3845 (30.0 mg/kg) persisted between 24 and 48 hours after treatment, similar to the reduction 
produced by the MAGL inhibitor JZL184.  
Percent baseline stimulations data were analyzed using a two-way repeated-measures 
ANOVA (Time-point x Treatment) to assess changes in ICSS across all time-points (Fig. 22h). 
PF-3845 (30.0 mg/kg) reduced percent baseline stimulations compared to VEH, as there was a 
main effect of time-point (F 5, 35 = 4.66, p < 0.01), treatment (F 1, 7 = 14.32, p < 0.01) and an 
interaction between time-point and treatment (F 5, 35 = 3.75, p < 0.01). Post-hoc analysis shows 
that 30.0 mg/kg PF-3845 attenuated percent baseline stimulations compared to VEH treatment at 
1, 2, 4, 8 and 24 hours after treatment as denoted on Fig. 22h. These results are in agreement 
with the rate-frequency analysis, as nearly all time-points were shown to be significantly reduced 
with both measures. Percent baseline stimulations analysis showed that PF-3845 (30.0 mg/kg) 
also reduced responding 2 h after administration, in agreement with our initial findings.   
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Figure Continued 
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Figure 22. PF-3845 ICSS time-course evaluation. Panels a – g show rate-frequency stimulation 
values (± SEM) after VEH or PF-3845 (30.0 mg/kg) at each time-point (1, 2, 4, 8, 24 and 48 h); 
percent maximum control rate is displayed on the y-axis, log-frequency values are shown on the 
x-axis. Panel h shows percent baseline stimulations data over time. Significant main effects of 
treatment are denoted by asterisks on the figure legend. Interactions that achieved significance 
and were accompanied by significant post-hoc analyses are denoted by asterisks at values that 
are significantly different from VEH. ***p < 0.001, **p < 0.01, *p < 0.05. Raw overall response 
rates (stimulations/min; mean ± SEM) during VEH (V) and 30.0 mg/kg PF-3845 (P) conditions 
were as follows: (a) Baseline: V (35.24 ± 2.05) P (34.84 ± 2.48); (b) 1 h: V (33.54 ± 2.26) P 
(26.86 ± 2.87); (c) 2 h: V (33.69 ± 2.75) P (25.18 ± 2.67); (d) 4 h: V (33.01 ± 2.19) P (27.53 ± 
2.20); (e) 8 h: V (32.37 ± 2.27) P (27.26 ± 2.32); (f) 24 h: V (33.29 ± 1.96) P (28.29 ± 1.97); (g) 
48 h: V (33.94 ± 1.90) P (34.88 ± 2.69). 
PF-3845: Evaluation of CB1 receptors. The purpose of this study was to examine 
whether the reduction of ICSS produced by PF-3845 was CB1 dependent. Similar to JZL184 
antagonist experiments, we tested whether rimonabant was able to block PF-3845 induced 
attenuation of ICSS. Six mice completed testing and data were analyzed using two-way repeated-
measures ANOVAs (treatment x frequency) for each dose combination tested. Administration of 
VEH and VEH did not produce a change from baseline; there was a main effect of frequency (F 
9, 45 = 56.60, p < 0.0001), but no main effect of treatment (F 1, 5 = 2.36, p > 0.05) and no 
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interaction (F 9, 45 = 0.94, p > 0.05) (Fig. 23a). PF-3845 (30.0 mg/kg) given in combination with 
VEH attenuated stimulations from baseline as expected; there was a main effect of frequency (F 
9, 45 = 51.72, p < 0.0001), treatment (F 1, 5 = 43.55, p < 0.01) and an interaction (F 9, 45 = 2.72, p < 
0.05) (Fig. 23b). Post-hoc analysis showed reductions at four frequencies which are denoted on 
Fig. 23b. RIM (3.0 mg/kg) and VEH did not affect baseline ICSS; there was a main effect of 
frequency (F 9, 45 = 94.34, p < 0.0001), but no main effect of treatment (F 1, 5 = 3.73, p > 0.05) 
and no interaction (F 9, 45 = 1.04, p > 0.05) (Fig. 23c). RIM (3.0 mg/kg) did not block the 
attenuation of ICSS produced by 30.0 mg/kg PF-3845, as the combination reduced responding 
compared to baseline ICSS; there was a main effect of frequency (F 9, 45 = 47.41, p < 0.0001), 
treatment (F 1, 5 = 20.23, p < 0.01), and an interaction (F 9, 45 = 3.51, p < 0.01) (Fig. 23d). Post-
hoc analysis showed reductions at six frequencies which are denoted on Fig. 23d. Next, we 
assessed a higher dose (10.0 mg/kg) of RIM with VEH and PF-3845. ICSS after administration 
of 10.0 mg/kg RIM and VEH did not differ from baseline; there was a main effect of frequency 
(F 9, 45 = 31.09, p < 0.0001), but no main effect of treatment (F 1, 5 = 202, p > 0.05) and no 
interaction (F 9, 45 = 0.36, p > 0.05) (Fig. 23e). However, RIM (10.0 mg/kg) was also not able to 
block the PF-3845-induced attenuation of ICSS, as there was a main effect of frequency (F 9, 45 = 
22.09, p < 0.0001), treatment (F 1, 5 = 41.64, p < 0.01), and an interaction (F 9, 45 = 3.48, p < 0.01) 
(Fig. 23f). Post-hoc analysis revealed reductions at five frequencies which are denoted on Fig. 
23f. Baseline rate-frequency responses slightly differed during the course of these experiments 
(Fig. 23g); there was a main effect of frequency (F 9, 45 = 62.28, p < 0.0001) and baseline day (F 
5, 25 = 3.23, p > 0.05), but there was no interaction between baseline day and frequency (F 45, 225 = 
1.26, p > 0.05). Baseline rate-frequency curves during 10.0 mg/kg RIM antagonism tests did not 
differ; there was a main effect of frequency (F 9, 45 = 48.20, p < 0.0001), but no main effect of 
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baseline day (F 3, 15 = 0.63, p > 0.05) and no interaction between baseline day and frequency (F 
27, 135 = 0.94, p > 0.05).  
A two-way ANOVA (RIM vs. VEH x 30.0 mg/kg PF-3845 vs. VEH) was conducted with 
the percent baseline stimulations data. RIM (3.0 and 10.0 mg/kg) was not able to block the 
reduction in ICSS produced by 30.0 mg/kg PF-3845 (Fig. 23h); there was no main effect of first 
treatment (VEH, 3.0 vs. 10.0 mg/kg RIM) (F 2, 10 = 0.34, p > 0.05), but there was a main effect of 
second treatment (VEH vs. PF-3845) (F 2, 10 = 6.10, p < 0.0001); however there was no 
interaction between first treatment and second treatment (F 2, 10 = 0.46, p > 0.05) (Fig. 23h). PF-
3845 (30.0 mg/kg) reduced ICSS regardless of pre-treatment. The percent baseline stimulations 
assessment confirmed the rate-frequency analysis. In contrast to the effects observed with THC 
and JZL184, the attenuation of stimulations after administration of 30.0 mg/kg PF-3845 was not 
mediated through CB1 receptors.  
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Figure 23. PF-3845 CB1 antagonism assessment. Panels a – f shows rate-frequency data during 
RIM antagonism tests with 30.0 mg/kg PF-3845. Panel g shows all baselines rate-frequency 
curves during CB1 testing. Percent maximum control rate is displayed on the Y-axis, log-
frequency values are shown on the x-axis. Panel h shows percent baseline stimulations (± SEM) 
for all treatments. Significant main effects are denoted by asterisks by the figure legend. 
Significant interactions were followed up by post-hoc analysis, and differences are denoted by 
asterisks at values that are significantly different from baseline (a – e). ****p < 0.0001, ***p < 
0.001, **p < 0.01. Raw overall response rates (stimulations/min; mean ± SEM) during baseline 
(B) and test (T) sessions were as follows: (a) VEH + VEH: B (31.53 ± 3.11) T (29.56 ± 2.23); (b) 
VEH + 30.0 mg/kg PF-3845: B (33.49 ± 2.96) T (19.70 ± 2.99); (c) 3.0 mg/kg RIM + VEH: B 
(32.86 ± 2.87) T (29.37 ± 3.27); (d) 3.0 mg/kg RIM + 30.0 mg/kg PF-3845: B (26.87 ± 3.61) T 
(16.47 ± 2.58); (e) 10.0 mg/kg RIM + VEH: B (30.97 ± 4.24) T (28.84 ± 4.51); (f) 10.0 mg/kg 
RIM + 30.0 mg/kg PF-3845: B (31.32 ± 4.50) T (22.03 ± 4.52). 
 
PF-3845: Evaluation of CB2 receptors. These experiments were conducted to determine 
if the PF-3845 induced attenuation of ICSS was mediated through CB2 receptors. ICSS was 
assessed after SR2 (10.0 mg/kg) co-administered with PF-3845 (30.0 mg/kg) to determine if the 
CB2 antagonist/inverse agonist SR2 could block the reduction produced by 30.0 mg/kg PF-3845. 
Six mice completed testing, and data were analyzed using two-way repeated measure ANOVAs 
(treatment x frequency) for each dose-combination tested, similar to JZL184 antagonist testing. 
Administration of VEH and VEH did not affect ICSS rates (Fig. 24a); there was a main effect of 
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frequency (F 9, 45 = 43.20, p < 0.0001), but no main effect of treatment (F 1, 5 = 2.13, p > 0.05) 
and no interaction (F 9, 45 = 1.003, p > 0.05). VEH co-administered with 30.0 mg/kg PF-3845 
attenuated ICSS from baseline (Fig. 24b), as there was a main effect of frequency (F 9, 45 = 27.15, 
p < 0.0001), treatment (F 1, 5 = 15.10, p < 0.05) and an interaction (F 9, 45 = 2.41, p < 0.05). Post-
hoc analysis revealed reductions at two frequencies which are denoted on Fig. 24b. Similar to 
VEH, SR2 (10.0 mg/kg) and VEH treatment did not affect self-stimulation rate (Fig. 24c); there 
was a main effect of frequency (F 9, 45 = 30.18, p < 0.0001), but no main effect of treatment (F 1, 5 
= 1.52, p > 0.05) and no interaction (F 9, 45 = 0.48, p > 0.05). Administration of SR2 (10.0 mg/kg) 
did not block the attenuation produced by 30.0 mg/kg PF-3845, as there was a main effect of 
frequency (F 9, 45 = 22.91, p < 0.0001), no main effect of treatment (F 1, 5 = 6.05, p = 0.05), but a 
significant interaction between treatment and frequency (F 9, 45 = 2.11, p < 0.05) (Fig. 24d); post-
hoc analysis showed reductions at three frequencies which are denoted on Fig. 24d. Baseline 
rate-frequency response rates did not differ across conditions tested (Fig. 24e); there was a main 
effect of frequency (F 9, 45 = 33.86, p < 0.0001), but no main effect of baseline day (F 3, 15 = 1.14, 
p > 0.05), and no interaction between baseline day and frequency (F 27, 135 = 1.51, p > 0.05). 
Percent baseline stimulations data were analyzed with a repeated-measures two-way 
ANOVA (SR2 vs. VEH x PF-3845 vs. VEH). SR2 (10.0 mg/kg) did not block the attenuation of 
stimulations produced by 30.0 mg/kg PF-3845 (Fig. 24f). There was no main effect of first 
treatment (VEH vs. SR2) (F 1, 5 = 4.87, p > 0.05), but there was a main effect of second treatment 
(VEH vs. PF-3845) (F 1, 5 = 7.96, p < 0.05) and an interaction between first treatment and second 
treatment (F 1, 5 = 8.46, p < 0.05). Post-hoc analysis revealed that PF-3845-induced attenuation of 
ICSS was not blocked by the CB2 antagonist SR2, as ICSS was reduced (p < 0.01; p < 0.001) 
regardless of co-administration with either VEH or SR2 (Fig. 24f). These results confirm the 
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findings from rate-frequency analysis, that the attenuation of ICSS is not mediated through CB2 
receptors. Interestingly, the attenuation of ICSS produced by PF-3845 (30.0 mg/kg) was not 
mediated through CB1 or CB2 receptors. 
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Figure Continued 
Figure 24. PF-3845 CB2 antagonism assessment. Panels a – d shows rate-frequency data during 
SR2 antagonism tests with 30.0 mg/kg PF-3845. Panel e shows all baselines rate-frequency 
curves during CB2 testing. Percent maximum control rate is displayed on the Y-axis, log-
frequency values are shown on the x-axis. Panel f shows percent baseline stimulations (± SEM) 
for all treatments. Significant interactions with were investigated with post-hoc analyses, and 
differences from baseline (a – e) or other conditions (f) are denoted by asterisks. ***p < 0.001, 
**p < 0.01, *p < 0.05. Raw overall response rates (stimulations/min; mean ± SEM) during 
baseline (B) and test (T) sessions were as follows: (a) VEH + VEH: B (37.10 ± 2.66) T (35.20 ± 
2.92); (b) VEH + 30.0 mg/kg PF-3845: B (35.12 ± 3.24) T (27.06 ± 3.57); (c) 10.0 mg/kg SR2 + 
VEH: B (34.10 ± 2.39) T (36.31 ± 2.92); (d) 10.0 mg/kg SR2 + 30.0 mg/kg PF-3845: B (37.02 ± 
3.05) T (27.71 ± 4.33). 
 
SA-57 ICSS Experiments 
SA-57 dose-response assessment. This study evaluated the effect of combined inhibition 
of FAAH and MAGL on ICSS. ICSS was examined after administration of the dual 
FAAH/MAGL inhibitor SA-57 (1.0, 3.0, 10.0, and 17.8 mg/kg) or VEH. Seven mice completed 
the study; the rate-frequency response data was analyzed using two-way repeated measures 
ANOVAs (treatment x frequency) for each dose. Low dose SA-57 (1.0 mg/kg) did not affect 
self-stimulation rate, while 3.0, 10.0, and 17.8 mg/kg SA-57 significantly attenuated ICSS 
responding. VEH produced a main effect of frequency (F 9, 54 = 4.9, p < 0.0001), but no main 
effect of treatment (F 1, 6 = 0.05, p > 0.05) and no interaction (F 9, 54 = 1.12, p > 0.05) (Fig. 25a). 
Similarly, SA-57 (1.0 mg/kg) produced a main effect of frequency (F 9, 54 = 48.64, p < 0.0001), 
but no main effect of treatment (F 1, 6 = 0.81, p > 0.05) and no interaction (F 9, 54 = 0.39, p > 0.05) 
(Fig. 25b). As mentioned above, higher doses of SA-57 (3.0, 10.0, and 17.8 mg/kg) reduced 
ICSS; 3.0 mg/kg produced a main effect of frequency (F 9, 54 = 29.95, p < 0.0001), treatment (F 1, 
6 = 40.88, p < 0.001) and an interaction (F 9, 54 = 2.62, p < 0.05) (Fig. 25c). Post-hoc analysis 
showed reduced stimulations at five frequencies which are denoted on Fig. 25c. SA-57 (10.0 
mg/kg) produced a main effect of frequency (F 9, 54 = 34.51, p < 0.0001), treatment (F 1, 6 = 
55.49, p < 0.001) and an interaction (F 9, 54 = 8.17, p < 0.0001) (Fig. 25d); post-hoc analysis 
 
 
102 
 
showed significant attenuation of ICSS at five frequencies which are denoted on Fig. 25d. SA-57 
(17.8 mg/kg) also produced a main effect of frequency (F 9, 54 = 40.05, p < 0.0001), treatment (F 
1, 6 = 170.8, p < 0.0001) and an interaction (F 9, 54 = 6.06, p < 0.0001) (Fig. 25e). Post-hoc 
analysis revealed significant reductions at seven frequencies which are denoted on Fig. 25e.  
Baseline rate-frequency curves were analyzed after tests were completed to determine if 
there were any differences in basal responding; they did not differ as there was a main effect of 
frequency (F 9, 54 = 61.21, p < 0.0001), but no main effect of baseline day (F 4, 24 = 0.47, p > 
0.05), and no interaction between treatment and baseline day (F 36, 216 = 0.81, p > 0.05) (Fig. 25f). 
The effect of VEH on ICSS was re-assessed after testing and compared to the initial VEH 
assessment; they did not differ as there was a main effect of frequency (F 9, 54 = 56.79, p < 
0.0001), but no main effect of treatment (F 1, 6 = 0.56, p > 0.05) and no interaction (F 9, 54 = 0.84, 
p > 0.05). 
A one-way repeated measures ANOVA was used to analyze percent baseline stimulations 
data that were calculated for each condition. SA-57 attenuated percent baseline stimulations (F 4, 
24 = 49.25, p < 0.0001) (Fig. 26); post-hoc analysis revealed that SA-57 (3.0, 10.0, and 17.8 
mg/kg) (67.80 %, 35.06 % and 27.61 %) significantly reduced (p <0.001; p < 0.0001; p < 
0.0001) percent baseline stimulations compared to VEH, while low dose SA-57 (1.0 mg/kg) did 
not affect percent baseline stimulations. The results of the percent baseline stimulations analysis 
agrees with rate-frequency data, as the same doses of SA-57 (3.0, 10.0, and 17.8 mg/kg) 
produced attenuation with both measures. 
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Figure Continued 
Figure 25. SA-57 ICSS dose-response assessment. Panels a – e show rate-frequency stimulation 
values (± SEM) after VEH or JZL184 (1.0, 4.0, 16.0 and 40.0 mg/kg). Panel f shows all baseline 
rate-frequency curves during testing. Percent maximum control rate is displayed on the Y-axis, 
log-frequency values are shown on the x-axis. Interactions that achieved significance were 
investigated with post-hoc analyses, and differences from baseline are denoted by asterisks. 
****p < 0.0001, ***p < 0.001, **p < 0.01. Raw overall response rates (stimulations/min; mean ± 
SEM) during baseline (B) and test (T) sessions were as follows: (a) VEH: B (32.21 ± 3.47) T 
(32.44 ± 3.89); (b) 1.0 mg/kg SA-57: B (33.21 ± 2.85) T (31.98 ± 3.80); (c) 3.0 mg/kg SA-57: B 
(33.45 ± 3.41) T (23.56 ± 3.81); (d) 10.0 mg/kg SA-57: B (32.83 ± 4.02) T (12.19 ± 3.80); (e) 
17.8 mg/kg SA-57: B (33.98 ± 2.98) T (9.89 ± 2.20).  
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Figure 26. SA-57 ICSS percent baseline stimulations. Values represent mean percent baseline 
stimulations (± SEM) after VEH or SA-57. The one-way ANOVA was significant and post-hoc 
analysis revealed significant differences from VEH, which are denoted with asterisks. ****p < 
0.0001, ***p < 0.001 
SA-57 time-course assessment. This study assessed the attenuation of ICSS produced by 
10.0 mg/kg SA-57 over time. ICSS was assessed after VEH and 10.0 mg/kg SA-57 at 1, 2, 4, 8, 
24 and 48 h after injection. Similar to PF-3845 time-course tests, data were analyzed using two-
way repeated measures ANOVAs (Treatment x Frequency) to compare rate-frequency 
responding between VEH and SA-57 at each time-point. SA-57 (10.0 mg/kg) attenuated ICSS at 
1, 2, 4 and 8 h after injection and returned to baseline 24 hours after injection. Baseline rate-
frequency responding for VEH and SA-57 tests did not differ from each other; there was a main 
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effect of frequency (F 9, 45 = 28.10, p < 0.0001), but no main effect of treatment (F 1, 6 = 0.12, p > 
0.05) and no interaction (F 9, 45 = 0.28, p > 0.05) (Fig. 27a). At the one hour time-point there was 
a main effect of frequency (F 9, 45 = 22.06, p < 0.0001), treatment (F 1, 5 = 56.31, p < 0.001) and 
an interaction (F 9, 45 = 4.73, p < 0.001) (Fig. 27b); post-hoc analysis revealed reductions at six 
frequencies which are denoted on Fig. 27b. Two hours after administration there was a main 
effect of frequency (F 9, 45 = 22.63, p < 0.0001), treatment (F 1, 5 = 64.32, p < 0.001) and an 
interaction (F 9, 45 = 7.21, p < 0.0001) (Fig. 27c); post-hoc analysis showed reductions at six 
frequencies which are denoted on Fig. 27c. Four hours after injection there was a main effect of 
frequency (F 9, 45 = 47.54, p < 0.0001), treatment (F 1, 5 = 109.9, p < 0.001) and an interaction (F 
9, 45 = 3.09, p < 0.01) (Fig. 27d); post-hoc analysis revealed reductions at five frequencies which 
are denoted on Fig. 27d. Eight hours after administration, there was a main effect of frequency 
(F 9, 45 = 38.47, p < 0.0001) and treatment (F 1, 5 = 17.35, p < 0.01), but no interaction (F 9, 45 = 
1.50, p > 0.05) (Fig. 27e). At the 24 hour time-point 10.0 mg/kg SA-57 stimulations did not 
differ from VEH; there was a main effect of frequency (F 9, 45 = 34.50, p < 0.0001), but no main 
effect of treatment (F 1, 5 = 0.72, p > 0.05) and no interaction (F 9, 45 = 0.34, p > 0.05) (Fig. 27f). 
Similarly, at the 48 hour time-point, there was a main effect of frequency (F 9, 45 = 34.69, p < 
0.0001), but no main effect of treatment (F 1, 5 = 0.003, p > 0.05) and no interaction (F 9, 45 = 
0.80, p > 0.05) (Fig. 27g).  
A repeated-measures two-way ANOVA (Time-point x Treatment) was used to analyze 
percent baseline stimulations of VEH and 10.0 mg/kg SA-57 across all time-points (Fig. 27h). 
SA-57 decreased ICSS at several time-points, as there was a main effect of time-point (F 5, 25 = 
34.73, p < 0.0001), treatment (F 1, 5 = 22.06, p < 0.01), and an interaction between time-point and 
treatment (F 5, 25 = 33.30, p < 0.0001). Post-hoc analysis revealed significant attenuation of ICSS 
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1, 2, 4 and 8 hours after treatment. These data are concordant with results of rate-frequency 
analysis; the attenuation of ICSS produced by SA-57 (10.0 mg/kg) was apparent 1 h after 
administration and returned to normal responding within 24 h.  
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Figure 27. SA-57 ICSS time-course evaluation. Panels a – g show rate-frequency stimulation 
values (± SEM) after VEH and SA-57 (10.0 mg/kg) at each time-point (1, 2, 4, 8, 24 and 48 h); 
percent maximum control rate is displayed on the y-axis, log-frequency values are shown on the 
x-axis. Panel h shows percent baseline stimulations data over time. Significant main effects of 
treatment are denoted by asterisks next on the figure legend. Significant interactions were 
investigated with post-hoc analyses, and differences from VEH are denoted by asterisks. ****p < 
0.0001, ***p < 0.001, **p < 0.01, *p < 0.05. Raw overall response rates (stimulations/min; mean 
± SEM) during VEH (V) and 10.0 mg/kg SA-57 (S) conditions were as follows: (a) Baseline: V 
(34.53 ± 4.98) S (35.09 ± 3.93); (b) 1 h: V (32.78 ± 3.76) S (11.13 ± 4.10); (c) 2 h: V (30.93 ± 
4.16) S (8.58 ± 3.11); (d) 4 h: V (30.68 ± 3.70) S (13.85 ± 3.51); (e) 8 h: V (31.50 ± 4.20) S 
(21.78 ± 2.77); (f) 24 h: V (31.76 ± 3.73) S (33.77 ± 4.65); (g) 48 h: V (33.14 ± 4.96) S (32.72 ± 
3.52). 
 
SA-57: Evaluation of CB1 receptors. This experiment was conducted to determine if 
SA-57 induced attenuation of ICSS can be blocked by the CB1 antagonist/inverse agonist RIM. 
Six mice completed the experiments, and data were analyzed using a two-way repeated measures 
ANOVA (treatment x frequency) for each dose combination tested. Administration of VEH and 
VEH did not differ from baseline, as there was a main effect of frequency (F 9, 63 = 35.71, p < 
0.0001), but no main effect of treatment (F 1, 5 = 0.01, p > 0.05), and no interaction (F 9, 45 = 0.19, 
p > 0.05) (Fig. 28a). VEH and 10.0 mg/kg SA-57 administration reduced ICSS rates; there was a 
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main effect of frequency (F 9, 45 = 30.82, p < 0.0001), treatment (F 1, 5 = 116.60, p < 0.001) and an 
interaction (F 9, 45 = 5.55, p < 0.0001) (Fig. 28b). Post-hoc analysis revealed reductions at six 
frequencies which are denoted on Fig. 28b. Treatment with 3.0 mg/kg RIM and VEH did not 
affect baseline ICSS; there was a main effect of frequency (F 9, 45 = 28.08, p < 0.0001), but no 
main effect of treatment (F 1, 5 = 0.38, p > 0.05). There was an interaction (F 9, 45 = 2.36, p < 
0.05), but post-hoc analysis revealed that there were no differences at any frequency (Fig. 28c). 
RIM (3.0 mg/kg) was not able to block SA-57 induced attenuation of ICSS, as co-administration 
with 10.0 mg/kg SA-57 reduced ICSS from baseline; there was a main effect of frequency (F 9, 45 
= 27.37, p < 0.0001), but no main effect of treatment (F 1, 5 = 5.01, p > 0.05). However, there was 
an interaction (F 9, 45 = 2.41, p < 0.05) (Fig. 28d); post-hoc analysis showed a reduction at one 
frequency which is denoted on Fig. 28d. RIM (10.0 mg/kg) co-administered with VEH did not 
affect baseline ICSS, as there was a main effect of frequency (F 9, 45 = 28.04, p < 0.0001), but no 
main effect of treatment (F 1, 5 = 0.37, p > 0.05) and no interaction (F 9, 45 = 1.92, p > 0.05) (Fig. 
28e). Administration of RIM (10.0 mg/kg) blocked the rate-reducing effects produced by SA-57, 
as stimulations after co-administration with 10.0 mg/kg SA-57 did not differ from baseline. 
There was a main effect of frequency (F 9, 45 = 21.27, p < 0.0001), but no main effect of 
treatment (F 1, 5 = 0.11, p > 0.05), and no interaction (F 9, 45 = 1.76, p > 0.05) (Fig. 28f). Baselines 
did not differ during any condition tested (Fig. 28g), as there was a main effect of frequency (F 9, 
45 = 39.17, p < 0.0001), but no main effect of baseline day (F 5, 25 = 2.01, p > 0.05) and no 
interaction between baseline day and frequency (F 45, 225 = 1.07, p > 0.05). 
A repeated-measures two-way ANOVA (RIM vs. VEH x 10.0 mg/kg SA-57 vs. VEH) 
was conducted to analyze the percent baseline stimulations data. RIM blocked the attenuation of 
percent baseline stimulations produced by 10.0 mg/kg SA-57 (Fig. 28h). There was a main effect 
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of first treatment (VEH vs. RIM) (F 2, 10 = 11.40, p < 0.01), second treatment (VEH vs. SA-57) 
(F 1, 5 = 43.68, p < 0.01) and an interaction between first treatment and second treatment (F 2, 10 = 
25.90, p < 0.05). Post-hoc analysis revealed reductions in percent baseline stimulations after 10.0 
mg/kg SA-57, but only when first treated with VEH or 3.0 mg/kg RIM.  The reduction in 
stimulations produced by 10.0 mg/kg SA-57 was blocked by pre-treatment with 10.0 mg/kg 
RIM, and therefore was mediated through CB1 receptors. These data confirm the results of rate-
frequency analysis, and also coincide with results of JZL184 and THC studies, which were also 
found to produce effects mediated through CB1 receptors. Though, they were blocked with 3.0 
mg/kg RIM, while the antagonism of SA-57s attenuation required 10.0 mg/kg RIM. It is also 
noteworthy that high dose RIM (10.0 mg/kg) did not affect basal ICSS.  
 
 
112 
 
V E H  +  V E H
L o g  F re q u e n c y
%
 M
C
R
1 .7 1 .8 1 .9 2 .0 2 .1 2 .2
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
V E H  +  V E H
B a s e lin e
1 .75 1 .85 1 .95 2 .05 2 .15 2 .25
a V E H  +  1 0 .0  S A -5 7
L o g  F re q u e n c y
%
 M
C
R
1 .7 1 .8 1 .9 2 .0 2 .1 2 .2
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
V E H  +  1 0 .0  S A -5 7
B a s e lin e
1 .75 1 .85 1 .95 2 .05 2 .15 2 .25
* * * ** * * *
* * * *
* * * *
* * * *
* * * *
b
3 .0  R IM  +  V E H
L o g  F re q u e n c y
%
 M
C
R
1 .7 1 .8 1 .9 2 .0 2 .1 2 .2
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
3 .0  R IM  +  V E H
B a s e lin e
1 .75 1 .85 1 .95 2 .05 2 .15 2 .25
c 3 .0  R IM  +  1 0 .0  S A -5 7
L o g  F re q u e n c y
%
 M
C
R
1 .7 1 .8 1 .9 2 .0 2 .1 2 .2
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
3 .0  R IM  +  1 0 .0  S A -5 7
B a s e lin e
1 .75 1 .85 1 .95 2 .05 2 .15 2 .25
* * *
d
1 0 .0  R IM  +  V E H
L o g  F re q u e n c y
%
 M
C
R
1 .7 1 .8 1 .9 2 .0 2 .1 2 .2
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
1 0 .0  R IM  +  V E H
B a s e lin e
1 .75 1 .85 1 .95 2 .05 2 .15 2 .25
e 1 0 .0  R IM  +  1 0 .0  S A -5 7
L o g  F re q u e n c y
%
 M
C
R
1 .7 1 .8 1 .9 2 .0 2 .1 2 .2
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
1 0 .0  R IM  +  1 0 .0  S A -5 7
B a s e lin e
1 .75 1 .85 1 .95 2 .05 2 .15 2 .25
f
 
Figure Continues 
 
 
113 
 
Figure Continued 
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Figure 28. SA-57 CB1 antagonism assessment. Panels a – f shows rate-frequency data during 
RIM antagonism tests with 10.0 mg/kg SA-57. Panel g shows all baselines rate-frequency curves 
during CB1 testing. Percent maximum control rate is displayed on the y-axis, log-frequency 
values are shown on the x-axis. Panel h shows percent baseline stimulations (± SEM) for all 
treatments. Significant interactions were followed up by post-hoc analyses, and differences from 
baseline (a – g) or other conditions (h) are denoted by asterisks. ****p < 0.0001, ***p < 0.001, 
**p < 0.01. Raw overall response rates (stimulations/min; mean ± SEM) during baseline (B) and 
test (T) sessions were as follows: (a) VEH + VEH: B (34.83 ± 3.65) T (34.88 ± 3.64); (b) VEH + 
10.0 mg/kg SA-57: B (36.48 ± 3.76) T (10.97 ± 3.30); (c) 3.0 mg/kg RIM + VEH: B (33.64 ± 
4.43) T (35.88 ± 5.23); (d) 3.0 mg/kg RIM + 10.0 mg/kg SA-57: B (34.32 ± 3.50) T (28.11 ± 
5.18); (e) 10.0 mg/kg RIM + VEH: B (36.69 ± 5.45) T (38.65 ± 6.61); (f) 10.0 mg/kg RIM + 
10.0 mg/kg SA-57: B (35.07 ± 4.71) T (34.02 ± 6.63). 
 
SA-57: Evaluation of CB2 receptors. This study assessed the involvement of CB2 
receptors in the reduction of ICSS produced by SA-57 using the CB2 antagonist/inverse agonist 
SR2 (10.0 mg/kg). Six subjects completed tests, and data were analyzed using two-way repeated 
measures ANOVAs (treatment x frequency). VEH and VEH administration did not affect ICSS 
behavior; there was a main effect of frequency (F 9, 45 = 32.61, p < 0.0001), but no main effect of 
treatment (F 1, 5 = 0.004, p > 0.05) and no interaction (F 9, 45 = 1.06, p > 0.05) (Fig. 29a). 
Administration of VEH and 10.0 mg/kg SA-57 reduced self-stimulation rate; there was a main 
effect of frequency (F 9, 45 = 46.55, p < 0.0001), treatment (F 1, 5 = 73.80, p < 0.001) and an 
 
 
114 
 
interaction (F 9, 45 = 5.24, p < 0.0001) (Fig. 29b). Post-hoc analysis showed significant decreases 
at seven frequencies which are denoted on Fig. 29b. SR2 (10.0 mg/kg) co-administered with 
VEH did not affect ICSS; there was a main effect of frequency (F 9, 45 = 29.76, p < 0.0001), but 
no main effect of treatment (F 1, 5 = 0.05, p > 0.05) and no interaction (F 9, 45 = 0.85, p > 0.05) 
(Fig. 29c). SR2 (10.0 mg/kg) did not block the reduction of ICSS produced by 10.0 mg/kg SA-
57, as there was a main effect of frequency (F 9, 45 = 30.81, p < 0.0001), treatment (F 1, 5 = 84.46, 
p < 0.001) and an interaction (F 9, 45 = 4.84, p < 0.0001) (Fig. 29d). Post-hoc analysis revealed 
reductions at seven frequencies which are denoted on Fig. 29d. Baseline rate-frequency 
stimulations did not differ during any condition tested (Fig. 29e); there was a main effect of 
frequency (F 9, 45 = 41.88, p < 0.0001), but no main effect of baseline day (F 3, 15 = 1.14, p > 
0.05), and no interaction between baseline day and frequency (F 27, 135 = 0.98, p > 0.05). 
Percent baseline stimulations data were analyzed using a two-way, repeated-measures 
ANOVA (RIM vs. VEH x 10.0 mg/kg SA-57 vs. VEH). SR2 (10.0 mg/kg) did not block the 
attenuation of stimulations produced by 10.0 mg/kg SA-57 (Fig. 29f); there was no main effect 
of first treatment (VEH vs. SR2) (F 1, 5 = 1.07, p > 0.05), but there was a main effect of second 
treatment (VEH vs. SA-57) (F 1, 5 = 153.6, p < 0.0001), as SA-57 produced a reduction of ICSS. 
There was no interaction between first treatment and second treatment (F 1, 5 = 1.14, p > 0.05). 
SA-57 (10.0 mg/kg) reduced ICSS when co-administered with either 10.0 mg/kg SR2 or VEH, 
indicating that the reduction in stimulations is not mediated through CB2 receptors. Results are 
confirmed by rate-frequency analysis, where SR2 (10.0 mg/kg) was unable to block the 
reduction attenuation produced by SA-57. These findings are similar to those obtained with 
THC, PF-3845, and JZL184 as none of these drugs produce ICSS modulating effects that are 
CB2 receptor dependent.  
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Figure Continued 
Figure 29. SA-57 CB2 antagonism assessment. Panels a – d shows rate-frequency data during 
SR2 antagonism tests with 10.0 mg/kg SA-57. Panel e shows all baselines rate-frequency curves 
during CB2 testing. Percent maximum control rate is displayed on the y-axis, log-frequency 
values are shown on the x-axis. Panel f shows percent baseline stimulations (± SEM) for all 
treatments. Significant main effects were denoted on figure legends. Significant interactions with 
were investigated with post-hoc analyses, and differences from baseline (a – e) are denoted by 
asterisks. ***p < 0.001, **p < 0.01, *p < 0.05. Raw overall response rates (stimulations/min; 
mean ± SEM) during baseline (B) and test (T) sessions were as follows: (a) VEH + VEH: B 
(38.23 ± 3.87) T (38.37 ± 3.91); (b) VEH + 10.0 mg/kg SA-57: B (35.89 ± 3.45) T (16.99 ± 
3.57); (c) 10.0 mg/kg SR2 + VEH: B (34.09 ± 2.78) T (34.20 ± 2.46); (d) 10.0 mg/kg SR2 + 10.0 
mg/kg SA-57: B (34.45 ± 4.37) T (13.63 ± 4.09). 
 
SA-57 Spontaneous Locomotor Activity Assessment 
Spontaneous locomotor activity was assessed after VEH or SA-57 treatment (1.0, 3.0 and 
10.0 mg/kg). Distance travelled (m), mean speed (m/s) and time immobile (s) were analyzed 
using one-way ANOVAs (Fig. 30). SA-57 reduced distance travelled (F 3, 32 = 14.78, p < 
0.0001). Post-hoc analysis revealed that 10.0 mg/kg SA-57 significantly reduced (p < 0.0001) 
distance travelled, while 1.0 and 3.0 mg/kg SA-57 did not differ from VEH (Fig. 30a). Time-
immobile increased with SA-57 (F 3, 32 = 85.14, p < 0.0001). Post-hoc analysis showed that 10.0 
mg/kg SA-57 increased (p < 0.0001) time-immobile, while 1.0 and 3.0 mg/kg did not produce an 
effect (Fig. 30b). SA-57 did not affect adjusted speed of locomotion (F 3, 32 = 0.33, p > 0.05) 
(Fig. 30c). Similar to ICSS results, 10.0 mg/kg SA-57 reduced locomotor behavior, but in 
contrast, 3.0 mg/kg SA-57 did not disrupt spontaneous locomotor activity, but reduced ICSS.  
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Figure Continued 
Figure 30. SA-57 spontaneous locomotor activity. All panels show dose of SA-57 and VEH on 
the x-axis. Panel a shows distance travelled on the y-axis, panel b shows time-immobile, and 
panel c shows adjusted speed. Significant one-way ANOVAs were investigated with post-hoc 
analysis, and significant differences from VEH are denoted by asterisks. ****p < 0.0001 
 
SA-57 Endocannabinoid Quantification Experiment 
This experiment assessed the ability of SA-57 to alter endocannabinoid levels in specific 
brain regions. Concentrations of 2-AG, AEA, and AA were determined from samples of 
PFC,NAc, VMB, amygdala, and cerebellum after treatment with VEH, or SA-57 (1.0 or 10.0 
mg/kg). Separate one-way ANOVAs were conducted within each brain region to analyze 
concentration changes from VEH treatment.  
SA-57 increased 2-AG in the PFC (F 2, 12 = 161.4, p < 0.0001); post-hoc analysis showed 
that treatment with 10.0 mg/kg SA-57 increased (p < 0.0001) concentrations of 2-AG to over 16-
fold of VEH concentrations, while treatment 1.0 mg/kg did not differ from VEH (Fig. 31a). 
Administration of SA-57 increased AEA in the PFC (F 2, 12 = 7.07, p < 0.01); post-hoc analysis 
showed that both 1.0 and 10.0 mg/kg SA-57 increased (p < 0.01) AEA to almost 3-fold of VEH 
levels (Fig. 31b). SA-57 decreased AA concentrations in the PFC (F 2, 12 = 9.36, p < 0.01); post-
hoc analysis showed that 10.0 mg/kg SA-57 reduced AA concentrations to 66 % of VEH levels, 
while 1.0 mg/kg SA-57 did not affect AA levels (Fig. 31c). 
 Treatment with SA-57 increased 2-AG in the NAc (F 2, 12 = 708.0, p < 0.0001); post-hoc 
analysis showed that 1.0 mg/kg SA-57 did not differ from VEH, but 10.0 mg/kg SA-57 increased 
(p < 0.0001) 2-AG to over 12-fold VEH concentrations (Fig. 31a). SA-57 increased AEA in the 
NAc by (F 2, 12 = 7.55, p < 0.01); post-hoc analysis showed that 1.0 and 10.0 mg/kg SA-57 
increased (p < 0.01; p < 0.05) AEA to over 2-fold VEH concentrations (Fig. 31b). 
Administration of SA-57 reduced AA tissue concentration in the NAc; there was a main effect of 
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SA-57 treatment (F 2, 12 = 4.05, p < 0.05), but post-hoc analysis showed that 1.0 and 10.0 mg/kg 
SA-57 AA levels did not differ from VEH (Fig. 31c). 
SA-57 treatment increased 2-AG in the VMB (F 2, 12 = 33.41, p < 0.0001); post-hoc 
analysis showed that 10.0 mg/kg SA-57 increased 2-AG to over 6-fold of VEH concentrations, 
while 1.0 mg/kg SA-57 did not differ from VEH levels (Fig. 31a). SA-57 increased AEA in the 
VMB (F 2, 12 = 9.49, p < 0.01); both 1.0 and 10.0 mg/kg SA-57 increased (p < 0.05; p < 0.01) 
AEA concentrations to 5-fold and 8-fold VEH levels respectively (Fig. 31b). SA-57 did not 
modulate AA concentrations in the VMB (F 2, 12 = 0.01, p > 0.05) (Fig. 31c).  
SA-57 increased 2-AG in the amygdala (F 2, 12 = 112.00, p < 0.0001); post-hoc analysis 
showed that 10.0 mg/kg SA-57 increased (p < 0.0001) 2-AG to over 11-fold VEH 
concentrations, while 1.0 mg/kg SA-57 did not affect 2-AG levels (Fig. 31a). Treatment with 
SA-57 increased AEA in the amygdala (F 2, 12 = 3.69, p < 0.01); post-hoc analysis showed that 
low dose SA-57 (1.0 mg/kg) increased (p < 0.01) AEA to over 3-fold VEH levels, while the high 
dose SA-57 (10.0 mg/kg) did not affect AEA concentrations (Fig. 31b). SA-57 reduced AA 
tissue concentrations in the amygdala (F 2, 12 = 32.71, p < 0.0001); post-hoc analysis showed that 
low dose SA-57 (1.0 mg/kg) did not affect AA, while high dose SA-57 (10.0 mg/kg) reduced (p 
< 0.0001) AA concentrations to 46 % of VEH levels (Fig. 31c). 
Administration of SA-57 increased 2-AG in the cerebellum after treatment with SA-57 (F 
2, 12 = 165.4, p < 0.0001); post-hoc analysis showed that high dose SA-57 (10.0 mg/kg) increased 
2-AG increased (p < 0.0001) to over 4-fold VEH concentrations. In contrast, low dose SA-57 
(1.0 mg/kg) 2-AG levels did not differ from VEH (Fig. 31a). SA-57 produced an increase of 
AEA in the cerebellum (F 2, 12 = 27.30, p < 0.0001); post-hoc analysis showed that both 1.0 and 
10.0 mg/kg SA-57 increased (p < 0.001; p < 0.0001) AEA concentrations to over 5-fold and 6-
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fold VEH levels respectively (Fig. 31b). SA-57 treatment decreased AA in the cerebellum (F 2, 12 
= 32.15, p < 0.0001); post-hoc analysis showed that high dose SA-57 (10.0 mg/kg) significantly 
reduced (p < 0.0001) AA to 57 % of VEH levels, while low dose SA-57 (1.0 mg/kg) did not 
affect AA concentrations (Fig. 31c).  
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Figure Continued 
 
Figure 31. SA-57 endocannabinoid and AA concentrations. All panels show brain region on the 
x-axis (AMYG = amygdala, CEREB = cerebellum). Panel a shows 2-AG levels on the y-axis, 
panel b shows AEA, and panel c displays AA. One-way ANOVAs were calculated within each 
brain region and substrate measured. Significant one-way ANOVAs were investigated with post-
hoc analyses, and significant differences from corresponding VEH treatment are denoted by 
symbols. 
+
 p < 0.0001, 
#
p < 0.001, 
!
p < 0.01, *p < 0.05 
 
Discussion 
 These studies were conducted to evaluate the effects of the exogenous agonist THC, and 
catabolic enzyme inhibitors of the endocannabinoids AEA and 2-AG on ICSS and other 
behaviors. One of the goals of this study was to determine the impact of THC on operant 
responding for brain stimulation reward.  In general, pharmacological treatments that reduce the 
amount of electrical stimulation needed to maintain reinforcement are interpreted as reducing 
brain reward thresholds, or potentiating reinforcement produced by brain stimulation (R. A. 
Wise, 2005). Conversely, treatments that reduce ICSS, or increase the amount of stimulation 
needed to maintain reinforcement are interpreted as increasing reward thresholds or producing 
anhedonia, or general motor impairment (Cryan, et al., 2003; Markou & Koob, 1991). The goal 
of these studies is to test whether exogenous and endogenous cannabinoids alter reward 
motivated behaviors mediated through the mesolimbic system. In these studies, we utilized 
JZL184 to inhibit MAGL, PF-3845 to inhibit FAAH, and SA-57 the dual FAAH/MAGL 
inhibitor in order to discern the effects of 2-AG, AEA, and the combination, respectively. To our 
knowledge, none of these drugs have been tested with ICSS in mice, and PF-3845, JZL184, and 
SA-57 have not been tested in any species. 
 
 
 
 
123 
 
Cocaine 
Cocaine (5.0 and 10.0 mg/kg) produced a dose-related increase of ICSS, or leftward shift 
in the frequency response curve, indicating decreased reward thresholds, or increased brain-
reward function. These studies were conducted because cocaine reliably increases mouse ICSS 
behavior, indicative of enhanced brain-reward function. Thus, cocaine was employed as a 
positive control for this study (Fish, et al., 2012; Robinson, et al., 2012). These data show that 
psychomotor stimulants potentiate ICSS in the C57BL/6 mouse, as cocaine produced a robust 
facilitation of ICSS. 
 
 
 
Table. 2  
 
Summary of THC and Enzyme Inhibitor Results 
 
Results      ICSS      % Baseline                   ICSS   Receptor Mediation    Operant (food)           Spontaneous              
Drug              R-F     Stimulations   Time-course   CB1           CB2    Responding    locomotor Activity           
THC (s.c.)  ↓  ↓    ↓   YES  NO  ↓   N.T. 
Doses (mg/kg):  (3, 5.6 & 10)      (5.6 & 10)                  (10)   (10)          (10)           (10 & 20)          
Antagonist Doses:             R-F = 5 min – 8 h               (3.0 RIM)        (3.0 SR2)       
       % baseline = .5 – 8 h            
JZL184 (i.p.)  ↓  ↓   ↓   YES  NO  ↓   ↓  
Doses (mg/kg):     (16 & 40)        (16 & 40)                    (40)   (40)          (40)               (40)             (40) 
Antagonist Doses:             R-F = 1 – 24 h        (3.0 RIM)        (10.0 SR2)                 (16: immobility only) 
       % baseline = 1 – 24 h           
PF-3845 (i.p.)  ↓  ↓   ↓   NO  NO  N.T.   N.T. 
Doses (mg/kg):         (30)                  (30)                    (30)   (30)          (30)        
Antagonist Doses:            R-F = 1 – 24 h        (10.0 RIM)      (10.0 SR2)       
       % baseline = 2 – 24 h           
SA-57 (i.p.)  ↓  ↓   ↓   YES  NO  N.T.      ↓  
Doses (mg/kg): (3, 10 & 17.8)  (3, 10 & 17.8)                    (10)    (10)          (10)                        (10)    
Antagonist Doses:            R-F = 1 – 8 h         (10.0 RIM)      (10.0 SR2) 
       % baseline = 1 – 8 h            
JZL184  2-AG      AEA   AA    SA-57            2-AG          AEA   AA 
Brain Region:  PFC:     ↑(40)        ↓(40)  ↓(40)     PFC:   ↑(10)        ↑(1&10)  ↓(10)  
NAc:       ↑(4&40)        ↓(40)      NAc:  ↑(10)        ↑(1&10)  
VMB:     ↑(4&40)     ↓(40)                          VMB:  ↑(10)        ↑(1&10) 
     Amygdala:    ↑(4&40)     ↓(40)          Amygdala:  ↑(10)        ↑(1)   ↓(10) 
   Cerebellum:    ↑(4&40)     ↓(40)     Cerebellum:  ↑(10)        ↑(1&10)   ↓(10)  
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CB1 and CB2 Antagonists 
One intriguing finding of this study was that the CB1 antagonist, RIM (3.0 and 10.0 
mg/kg), did not produce a disruption of ICSS in C57BL/6 mice as shown on Table 2. This may 
be a species-specific effect, as all other studies that have reported disruption of ICSS with CB1 
antagonists assessed rats. Some rat studies have reported decreases in baseline ICSS after 
moderate doses of RIM including 1.0 and 3.0 mg/kg (De Vry, et al., 2004; Deroche-Gamonet, et 
al., 2001; Trujillo-Pisanty, et al., 2011) while others don’t report disruption of ICSS until higher 
doses of 10.0 mg/kg RIM (Xi, et al., 2008) or higher (Arnold, et al., 2001). Specifically, Arnold 
and colleagues observed that doses up to 10.0 mg/kg RIM did not disrupt ICSS in Lewis rats 
(Arnold, et al., 2001), so our findings in mice are not unprecedented. It is well-accepted that CB1 
antagonists disrupt ICSS behavior, and it has been cited as indirect evidence that cannabinoids 
can enhance dopamine levels in the mesolimbic system (Tanda & Goldberg, 2003). The 
inconsistency of RIM effects in this assay raises questions about how endocannabinoids function 
in the mesolimbic system. The present data indicate that C57BL/6 mice may not be sensitive to 
ICSS-facilitating effects of cannabinoids, since they were not affected by high doses of RIM. 
Interestingly though, the only other study that has shown no effect on ICSS with a dose of 10.0 
mg/kg RIM was conducted in Lewis rats, which is a strain that has produced facilitation of ICSS 
with THC (Arnold, et al., 2001; Gardner, et al., 1988; Lepore, et al., 1996). The lack of rate-
decreasing effects with CB1 antagonism does not necessarily mean that agonists would be 
precluded from producing the opposite effect. Thus, C57BL/6 mice may still show facilitating 
effects of ICSS with cannabinoid agonists. Similar to the CB1 antagonist RIM, the CB2 
antagonist SR2 (3.0 and 10.0 mg/kg) did not produce an effect on ICSS alone. We did not expect 
SR2 to reduce ICSS when administered alone, but given recent reports about the role of CB2 in 
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drug reward, it was interesting to confirm that it had no effect (Ignatowska-Jankowska, Muldoon, 
et al., 2013; Xi, et al., 2011). This is a novel finding, as CB2 antagonists have not been assessed 
in ICSS in any species to our knowledge.   
THC 
 As summarized on Table 2, THC produced a dose-related attenuation of ICSS behavior 
or a rightward shift in the frequency-response curve. Two potential interpretations of this finding 
are that THC reduced brain reward functioning, or simply reduced behavior through a non-
mesolimbic mediated, or non-specific motor effect. Although we hypothesized that THC would 
facilitate ICSS in the mouse, there is much evidence to the contrary reported in the rat (see table 
1). In fact, the majority of studies that reported low doses of THC facilitating ICSS used a 
specific strain of rat (Lewis), so it is likely a strain-specific effect (Gardner, et al., 1988; Lepore, 
et al., 1996). Similar to many studies discussed in the introduction, low doses of THC (0.3 and 
1.0 mg/kg) did not affect ICSS. The most recent study with THC and ICSS showed that only 
low-dose THC (0.1 mg/kg) produced facilitating effects, while 1.0 mg/kg THC reduced 
responding in Sprague-Dawley rats (Katsidoni, et al., 2013). We did not assess any doses lower 
than 0.3 mg/kg THC, as there was no effect with 1.0 or 0.3 mg/kg THC. Lower doses may have 
potentially facilitated ICSS in the C57BL/6J mouse, but we assessed a 10-fold range of 
ineffective doses, and there was no trend toward increasing ICSS with the lowest dose of THC 
(0.3 mg/kg) (p = 0.08). If anything there was a trend toward decreasing responding as shown on 
Fig. 4d. Additionally, time-course evaluations with low doses of THC may have unmasked 
facilitating effects. In the present study, we elected to focus on the ICSS decreasing effects of 
THC, as they were the prominent effects observed during initial dose-response tests. The 
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attenuation of ICSS produced by 10.0 mg/kg returned to baseline between 8 and 24 hours after 
administration. 
 It is important to note that the 3 studies that show ICSS is facilitated by THC analyzed 
changes in “threshold,” which typically uses linear regression to determine calculate the 
frequency which maintains a given level of responding (e.g. 0%, 50%, etc.). Threshold analysis 
is a common way to analyze ICSS data; the methods used to determine thresholds and changes in 
thresholds however, vary greatly between laboratories. ICSS rate-frequency response curves are 
typically curvilinear or sigmoidal shaped. Thus, by using linear regression to determine lines, 
some of the data is usually left out of analysis to create a straight slope. In addition to removing 
data from analysis, some investigators also “interpolate” data points, or add data when data 
doesn’t follow a linear trend. These practices make can make the data analysis process more 
subjective than traditional statistical measures such as ANOVA. Also, because of the wide range 
of response patterns shown between subjects and tests, exhaustive lists of “rules” for inclusion 
and exclusion of data must be created by experimenter. These rules are almost never reported in 
the methods section of papers, making it very difficult to infer how the experimental values were 
actually calculated. Because of all of these potential issues with analyzing ICSS thresholds, we 
chose to analyze data using standard repeated-measures, two-way (frequency x treatment) 
ANOVAs. By doing so, we were able to analyze all data without altering or removing any 
information, thereby limiting subjectivity. We also calculated percent baseline stimulations, 
which similar to threshold determinations is a summation measure, but more objective.  
 Although there is supporting biochemical evidence that exogenous cannabinoids increase 
both tonic and phasic dopamine in the nucleus accumbens, it is important to note that many of 
those reports used synthetic agonists such as WIN 55,212-2 (Cheer, et al., 2004; Cheer, Wassum, 
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et al., 2007), although some showed a similar effect with THC (J. Chen, et al., 1990; J. P. Chen, 
et al., 1991). It is important to note also that nearly all of those studies examined cannabinoid 
agonists that were administered i.v., as route of administration can have a considerable influence 
on drug effects. The i.v. route of administration may provide the most relevant data to human 
cannabinoid use, as humans typically inhale marijuana. Both inhalation and i.v. administration 
allow drugs reach the brain much more quickly, and with less early metabolism than other 
routes, which has been associated with higher abuse and dependence liability. It remains to be 
determined whether i.v. administration of THC could potentially produce a facilitation of ICSS 
in C57BL/6 mice. Additionally, although THC and other cannabinoid agonists produce increases 
in dopamine levels in the nucleus accumbens, the magnitude of the increase is not nearly as large 
as that produced by cocaine, or other psychomotor stimulants. THC can produce increases in 
extracellular dopamine in the nucleus accumbens up to about 150 % of baseline dopamine 
(Tanda, et al., 1997). In contrast, cocaine has been shown to increase dopamine levels to over 
400% of basal levels (Panos & Baker, 2010). Furthermore, stimuli other than drugs of abuse can 
also produce increases in dopamine in the nucleus accumbens. For example, studies have shown 
that an aversive tail-pinch can produce increases in dopamine measured by in vivo voltammetry 
(D'Angio, Serrano, Rivy, & Scatton, 1987). This suggests that dopamine release in the nucleus 
accumbens may be related to salient stimuli in general, rather than being specific to drugs of 
abuse. This is important to take into consideration when evaluating data on cannabinoid agonist-
induced increases in extracellular dopamine.     
 In the present study, THC-induced reduction of ICSS was found to be mediated through 
CB1 receptors, as it was blocked with RIM (3.0 mg/kg) pre-treatment. This effect has been 
established in rat studies using ICSS, as rightward shifts of rate-frequency response curves 
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produced by THC were blocked by pre-treatment with RIM (Kwilasz & Negus, 2012; Vlachou, 
et al., 2007). Even though we found that CB1 antagonism blocked THC-induced reduction of 
ICSS, we wanted to rule out the involvement of CB2 receptors. As expected, CB2 blockade did 
not prevent the attenuation of ICSS produced by THC. Although CB2 receptors have recently 
been implicated in cocaine reinforcement and nicotine reward (Ignatowska-Jankowska, 
Muldoon, et al., 2013; Xi, et al., 2011), they do not appear to be involved in the reduction of self-
stimulations produced by THC. 
The rate-reducing effects produced by THC were not specific to ICSS alone; we found 
that high dose THC (10.0 mg/kg) also reduced operant responding for food pellets, while 5.0 
mg/kg did not affect response rates. These results may seem incongruent with studies in the 
literature, as cannabinoid agonists have been shown to increase food intake (Wiley et al., 2005). 
But it is important to note that food intake is a different measure than performing an operant 
response for food pellets. The latter requires a trained behavior that has a large motor 
component, while the former requires a less complex, more naturalistic feeding behavior. The 
reduction of nose-poking to receive food-pellets may represent more of an overall motor effect 
than a feeding-specific effect. Similar to these effects seen on ICSS and food-maintained operant 
responding, THC also reduced spontaneous locomotor activity. A recent study in rats reported 
that 1.0 mg/kg THC reduced locomotor activity, while a lower dose (0.1 mg/kg) increased 
locomotor activity (Katsidoni, et al., 2013). Many other studies in mice have reported decreases 
in locomotor activity with 3.0 mg/kg or higher doses of THC (Kinsey, O'Neal, et al., 2011; L. E. 
Long et al., 2010; Varvel et al., 2006; Wiley et al., 2013). This decrease in overall activity 
produced by cannabinoids makes interpretation of the ICSS effects presented here difficult. 
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Cannabinoid Catabolic Enzyme Inhibitors 
JZL184. The MAGL inhibitor JZL184 (16.0 and 40.0 mg/kg) produced a decrease in 
ICSS responding, or a rightward shift of the rate-frequency curve, which might be interpreted as 
a decrease in brain-reward function in the mesolimbic system. These results are similar to what 
we and others have reported with THC and other cannabinoid agonists, but with a lesser 
magnitude of reduction. This finding is also concurrent with the one study in the ICSS literature 
that has assessed a 2-AG modulating drug. Vlachou and colleagues have shown the purported 
AEA transport inhibitor AM-404 reduces ICSS responding in rats through a CB1 dependent 
mechanism (Vlachou, et al., 2008). The relevance of this finding to the present study is related to 
findings by Wiskerke and colleagues, who have reported that AM-404 (1.0 mg/kg) causes 
increases of extracellular 2-AG in the nucleus accumbens shell of rats, while not affecting AEA 
levels (Wiskerke, et al., 2012). AM-404 may be attenuating ICSS via increased 2-AG in brain-
reward relevant regions (e.g. NAc) which converges with our JZL184 data in ICSS. The MAGL 
inhibitor JZL184 also affects ICSS through a similar mechanism. Similar to our data with THC, 
the attenuation of ICSS produced by JZL184 was a CB1 dependent effect, and it was not affected 
by CB2 antagonism (Vlachou, et al., 2006; Vlachou, et al., 2008). The time-course of JZL184-
induced suppression of ICSS behavior lasted up to 48 h after treatment, which was longer than 
THC-induced attenuation or ICSS, though the reduction of responding was not as drastic. This 
finding is consistent with the fact that JZL184 is an irreversible MAGL inhibitor that can 
produce increases in brain 2-AG that last up to 24 h (J. Z. Long, Li, et al., 2009). 
 In addition to attenuating ICSS, JZL184 (40.0 mg/kg) reduced operant responding for 
food and decreased spontaneous locomotor activity. As mentioned above, the reduction in nose-
poke behavior is probably not reflective of a decrease in motivation for feeding, but more of a 
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general motor effect. Studies that have shown increases in food-intake with cannabinoids have 
not assessed feeding via an operant response (Wiley, et al., 2005). The reduction in operant 
responding for food by JZL184 (40.0 mg/kg) was of a similar magnitude (≈ 50%) to that 
produced by THC (10.0 mg/kg).  
PF-3845. The FAAH inhibitor PF-3845 reduced ICSS responding, but only at a very high 
dose (30.0 mg/kg). It is important to note that no other studies in the literature have assessed a 
dose of 30.0 mg/kg PF-3845. The results were followed up with a time-course study, where we 
found it produced a moderate attenuation of ICSS that persisted until between 24 and 48 h after 
treatment. The effect was recapitulated during antagonism tests, where we found that PF-3845-
induced reduction of ICSS was not mediated through CB1 or CB2 receptors. It was interesting, as 
the magnitude of effect was near that produced by JZL184, though not mediated through 
cannabinoid receptors. There are a few possible explanations for the observed effects of PF-
3845. This high dose of PF-3845 could simply be producing a non-specific effect, given the fact 
that 30.0 mg/kg is a 3-fold higher dose than the highest reported in the literature (Ahn, et al., 
2009; Booker, et al., 2012; Ramesh et al., 2011; Wiskerke, et al., 2012). PF-3845 (30.0 mg/kg) 
could also be producing its effects through a substrate other than AEA. FAAH is implicated in 
the metabolism of fatty acid amides other than AEA, including PEA, and OEA. It has been 
shown that AEA, OEA, PEA, and other fatty acid amides have been shown to bind to 
peroxisome proliferator-activated alpha (PPARα) receptors, at TRPV1 receptors and other non-
cannabinoid receptors (Jhaveri, et al., 2008; Ross, 2003; Zygmunt, et al., 1999). These receptors 
are also found throughout brain regions in the mesolimbic system (Luchicchi et al., 2010; Melis 
et al., 2010; Melis, et al., 2006). We will be pursuing this line of research in the future by 
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assessing antagonism of these receptors known to interact with AEA and other substrates 
increased during FAAH inhibition.  
SA-57. The combined FAAH/MAGL inhibitor SA-57 (3.0, 10.0, and 17.8 mg/kg) also 
produced an attenuation, or rightward shift of ICSS, indicating it may be producing a reduction 
of brain-reward functioning in the mesolimbic pathway. The magnitude of ICSS reduction 
produced by SA-57 was more similar to that of THC than JZL84 or PF-3845. SA-57 produced its 
effects on brain-reward functioning within 1 h after administration and returned to normal 
stimulation rates within 24 h. Similar to THC and JZL184, but in contrast to PF-3845, SA-57-
induced attenuation of ICSS was mediated through CB1 receptors, and was also not affected by 
CB2 antagonism. Interestingly, a higher dose of the CB1 antagonist RIM (10.0 mg/kg) was 
required to block the effects produced by SA-57 than was used to block THC or JZL184 (3.0 
mg/kg). This may indicate the involvement of a greater number of CB1 receptors following 
administration of SA-57 (10.0 mg/kg) than with attenuation caused with THC and JZL184, since 
more antagonist was required to block the effect. SA-57 (10.0 mg/kg) reduced locomotor activity 
of naïve mice, similar to JZL184.  
Endocannabinoids in Brain  
High dose JZL184 (40.0 mg/kg) increased 2-AG in all brain regions ranging between 4-
fold and 13-fold of VEH levels, while low dose JZL184 (4.0 mg/kg) significantly increased 2-
AG in all regions except prefrontal cortex. JZL184 (40.0 mg/kg) also produced a decrease in 
AEA in the prefrontal cortex and nucleus accumbens and trended toward a reduction in the 
amygdala. Not surprisingly, JZL184 (40.0 mg/kg) also significantly reduced AA levels in almost 
all regions.  
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High-dose SA-57 (10.0 mg/kg) increased 2-AG in all brain regions, while low-dose SA-
57 (1.0 mg/kg) did not affect 2-AG levels as shown on Fig. 31. There was also a significant 
increase in AEA with 1.0 and 10.0 mg/kg SA-57 in nearly all brain regions, and reduced AA 
levels in the PFC, amygdala, and cerebellum only with high-dose SA-57 (10.0 mg/kg). 
It was notable that 2-AG levels were increased across all brain regions with JZL184 (4.0 
and 40.0 mg/kg); 4.0 mg/kg only failed to increase 2-AG in the prefrontal cortex, although there 
was a trend toward significance (p = 0.09). If the reduction ICSS via MAGL inhibition is a 2-
AG-mediated effect, which it seems to be since it is CB1 mediated, the biochemical data could 
mean that the effect was driven by 2-AG elevation in the PFC. This is conceivable, since the 
PFC is responsible for executive functioning and the control of goal-directed behavior, and it has 
been reported that cannabinoid receptors, as well as diacylglycerol lipase-alpha, a 2-AG 
biosynthetic enzyme, are localized on glutamatergic neurons in the PFC (Lafourcade et al., 
2007). Disrupting cannabinoid signaling in the PFC could interfere with motivated behavior by 
reducing dopamine output. 
When assessing the brain level endocannabinoid data after SA-57, it was apparent that 2-
AG elevation was necessary for disruption of ICSS through CB1 receptors. Low-dose SA-57 (1.0 
mg/kg) significantly increased AEA in all brain regions, but failed to alter ICSS behavior. 
However, the combined FAAH/MAGL inhibitor SA-57 produced a higher degree of attenuation 
than either FAAH or MAGL inhibition alone, so it seems that AEA played a role in this 
behavior. There are a few different reasons for why that might be. FAAH and MAGL inhibition 
combined may simply increase the amount of free endocannabinoids in the brain, producing an 
additive effect of AEA and 2-AG. AEA and 2-AG could also be producing their effects in 
distinct synapses within these brain regions. Although this study has shown increases in all brain 
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regions measured, we are not able to detect disparities between AEA and 2-AG at the synaptic 
level using these measures. That would be better assessed using in vivo microdialysis. As was 
noted in the introduction, AEA and 2-AG have distinct biosynthetic and metabolic pathways, 
which may underlie their differences in behavioral effects. For example, MAGL is located pre-
synaptically, while FAAH is located in the post-synaptic terminal. It appears that AEA and 2-AG 
are producing cooperative effects in this assay. Dual FAAH and MAGL inhibition has also been 
shown to produce more THC-like effects than inhibiting either independently, including memory 
deficits, and substituting for the discriminative stimulus of THC (J. Z. Long, Nomura, et al., 
2009; L. E. Wise, et al., 2012).     
 Additionally, we showed that the reduction in response rates produced by PF-3845 was 
CB1 receptor independent, suggesting that it is suppressing ICSS through a completely different 
mechanism than SA-57, JZL184, and THC. It may be producing its effects through increased 
levels of AEA, as demonstrated with the neurochemical data. If this is the case, these effects are 
mediated through non-cannabinoid receptors activated by AEA (e.g., PPARα, TrpV1), or via a 
non-specific mechanism. It would have been helpful for the interpretation of endocannabinoid 
level results to assess intermediate doses of JZL184 and SA-57. Moderate doses of JZL184 (16.0 
mg/kg) and SA-57 (3.0 mg/kg) both produced effects in ICSS, but not in distance travelled or 
operant responding for food in the case of JZL184. 
General Discussion  
Given the decreases in ICSS following treatment with direct and indirect cannabinoid 
agonists, it was important to test whether these compounds produced hypolocomotion, a well-
documented cannabinoid behavioral effect. These experiments were intended to help delineate 
potential reward-attenuating effects from non-selective decreases in motor function. Both 
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JZL184 and SA-57 reduced spontaneous locomotor activity, but only with the highest dose tested 
(40.0 and 10.0 mg/kg, respectively). They also both decreased responding for ICSS, but at 
slightly lower doses (16.0 and 3.0 mg/kg, respectively). This is evidence that ICSS is more 
sensitive to the behaviorally disruptive effects of cannabinoids than spontaneous locomotor 
activity. An alternative explanation could be that spontaneous locomotor behavior is less 
physically demanding than lever pressing, and is an innate behavior, and therefore higher doses 
of CB1 agonists are required to disrupt the behavior. Furthermore, spontaneous locomotor 
activity may be less goal-directed than operant responding for reinforcement, which could help 
differentiate motor suppression from effects on motivated behavior. 
Further evidence that ICSS is more sensitive to the disruptive effects of cannabinoids was 
that only high dose JZL184 (40.0 mg/kg) disrupted operant-responding for food pellets. 
However, it should be noted that there were a number of procedural differences between operant 
responding for food and brain stimulation. First, and most obvious, the reinforcer is different 
(food vs. electrical stimulation). Second, the operant response is different, as lever-pressing was 
required for ICSS experiments and nose-poking was the operant in the food-responding 
experiments. Third, the test session length varied between the two tasks, operant responding for 
food sessions were 15 min, while ICSS test sessions were 24 min. Finally, in the operant 
responding tasks, subjects were food-deprived, while ICSS subjects were maintained at free-
feeding weights. The differences in response topography between nose-poking and lever pressing 
have to be considered; nose-poking is a more innate response than lever pressing. It would be 
logical that the effort required for a given behavior would correlate with disruption of behavior. 
For example, as nose-poking is a more innate behavior than lever pressing, all other things being 
equal, lever-pressing should be disrupted before nose-poking. This has been demonstrated by 
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(Gerhardt & Liebman, 1981) who have shown that nose-poking is less susceptible to drug-
induced gross motor effects than lever pressing behavior. ICSS is known to produce robust 
reinforcement, so it is intriguing that it is disrupted before a more innate response like nose-
poking. Certainly it seems that ICSS is more sensitive to disruption by cannabinoids than 
spontaneous locomotor activity or operant responding for food. Food-deprivation could also play 
a role in the drug effects produced as some drug effects are enhanced, and some are reduced 
during food-deprivation (D'Cunha, Sedki, Macri, Casola, & Shalev, 2013; Shalev, 2012). Of 
course, the caveat with interpreting these results is that cannabinoids can have both stimulatory 
and suppressive effects on food intake and food-motivated behavior.      
 One potential explanation for the actions of endocannabinoids on reward-related 
measures is that these neurotransmitters/neuromodulators are involved in the environmental cue-
evoked dopamine release associated with drug use and other rewards. In other words, 
cannabinoids are involved more in the signaling of reward-relevant stimuli, rather than being a 
substrate for reward. Many studies show that cannabinoid antagonism disrupts behavior for drug 
rewards including nicotine (Cohen, Perrault, Voltz, Steinberg, & Soubrie, 2002; Le Foll & 
Goldberg, 2004), methamphetamine (Vinklerova, Novakova, & Sulcova, 2002), opioids (Caille 
& Parsons, 2003), alcohol (Arnone et al., 1997; Economidou et al., 2006), and cocaine (Xi, et al., 
2008). The evidence with cocaine may be the most revealing of cannabinoid effects on 
dopamine-evoked events. CB1 receptor blockade interferes with progressive ratio responding to 
receive cocaine, and prevents drug-induced and cue-induced reinstatement to drug-seeking 
behavior (De Vries et al., 2001; Xi, et al., 2008; Xi et al., 2007). However, CB1 antagonism is 
less efficacious in reducing ongoing self-administration (De Vries, et al., 2001; Filip et al., 2006; 
Tanda, et al., 2000). This is especially relevant to ICSS, as it directly stimulates the mesolimbic 
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system, which is thought to indirectly activate dopaminergic neurons in the VTA projecting to 
the NAc. However, there are cues present with ICSS as there are with almost all behaviors, so 
cannabinoids could be affecting cues associated with ICSS responding. Though this is not likely 
the case, as ICSS is a well-trained behavior with extremely salient reinforcement.  
This cue-evoking role of endocannabinoids fits with the data from these studies. If the 
role of endocannabinoids is to signal reward-relevant stimuli, then disruption of cannabinoid 
signaling through either blockade or over-activation of CB1 receptors could disrupt reward-
related behavior. This would help explain why both CB1 agonists (Arnold, et al., 2001; Vlachou, 
et al., 2005, 2006; Vlachou, et al., 2007) and antagonists (Arnold, et al., 2001; Deroche-
Gamonet, et al., 2001; Trujillo-Pisanty, et al., 2011; Xi, et al., 2008) have been shown to reduce 
ICSS behavior. This is particularly interesting given the fact that high doses of CB1 antagonists 
are typically required to disrupt ICSS, presumably by disrupting endocannabinoid tone, while 
relatively low doses of exogenous agonists typically disrupt ICSS, presumably by disrupting 
normal CB1 signaling. Although RIM (10.0 mg/kg) did not attenuate ICSS in the current study, 
this may be a species-specific effect in the mouse. Thus, even though endocannabinoid tone may 
be necessary for cue-evoked dopamine release that shapes behavior, enhancing endocannabinoid 
tone without the ability of metabolic clearance may cause endocannabinoids to affect receptors 
similar to exogenous agonists and disrupt reward-motivated behavior rather than facilitate it. 
 It is important to consider that with ICSS we are assessing drugs by how they affect the 
brain during activation of the mesolimbic dopamine system. There is much evidence that this 
system is part of a common reward pathway, but of course it is not the only reward-mediating 
area of the brain. Cannabinoids may be exerting their rewarding effects in humans through 
activation of cannabinoid receptors in other areas of the brain that interact with the mesolimbic 
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system, with areas completely independent of that system. For example, cannabinoids have 
effects on stress and anxiety (Hill, Hunter, & McEwen, 2009; Hill & McEwen, 2010; Hill et al., 
2009). Marijuana use has been reported to produce anxiolytic and mood-elevating effects that 
reduces stress and promotes relaxation, which likely contributes to its recreational use (Green, 
Kavanagh, & Young, 2003). The presence of endocannabinoids and cannabinoid receptors in 
stress-responsive areas of the brain including the amygdala and hypothalamus, and 
responsiveness of the endocannabinoid system to stress manipulations, suggests that they are 
involved in altering stress responses. Endocannabinoids have been shown to both activate and 
deactivate the hypothalamic-pituitary-adrenal (HPA) axis, which mediates stress responses (Hill 
et al., 2010). Stress causes and increase in glutamate release in the HPA axis, and specifically the 
basolateral amygdala. Endocannabinoids are located within this region, and can modulate 
glutamate release, which provides a mechanism for exogenous cannabinoids to be used for the 
management of stress responses.  
Clearly, more effort will need to be devoted to understanding the discrepancies 
underlying this and other preclinical models of reward (CPP) and reinforcement (self-
administration), as cannabinoid effects in these models may not accurately reflect the abuse-
liability seen with marijuana in humans. It is also important to note that we are modeling 
marijuana use with THC in animals. THC can produce different effects than marijuana in 
humans, specifically it has been shown to sometimes produce aversive effects (Calhoun, et al., 
1998) and produces only modes reinforcing effects in experienced marijuana users (Hart, et al., 
2005; Vandrey, et al., 2013). In light of these studies, perhaps we are accurately representing 
abuse-liability of THC in humans, as it is not typically used by humans for recreational purposes 
(Calhoun, et al., 1998). Thus, the failure of cannabinoids to produce effects in preclinical models 
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may be due to the fact that we are assessing THC rather than marijuana. Future studies assessing 
inhaled marijuana or synthetic cannabinoids in similar assays would provide an important 
contribution to this literature.  
 In conclusion, THC and endocannabinoid catabolic enzyme inhibitors do not produce 
facilitation of ICSS in C57BL/6 mice. In fact, at higher doses, they tend to produce the opposite 
effect, attenuation. This reduction of ICSS after cannabinoids is correlated with reduction of 
other behaviors including operant responding (nose-poking) for food and spontaneous locomotor 
activity. It does appear that ICSS is more sensitive to attenuation produced by cannabinoids than 
these other behaviors are. ICSS was consistently shown to be affected by lower doses of THC or 
cannabinoid enzyme inhibitors than other behaviors. With the exception of PF-3845, these 
effects were found to be mediated through CB1, but not CB2 receptors. Interestingly, PF-3845-
induced attenuation of ICSS was not reversed by either CB1 or CB2 antagonism. All time-course 
evaluations of the drugs tested were in line with previous determinations of their duration of 
action. 2-AG was shown to be important for the attenuation of ICSS with endocannabinoid 
inhibitors JZL184 and SA-57, as JZL184 produced an attenuation of ICSS, and principally 
elevated 2-AG levels. AEA does play a role also, though, as combined FAAH/MAGL inhibition 
produces a higher degree of ICSS attenuation than either enzyme inhibitor assessed alone and 
more similar to THC or other exogenous agonists. It seems that AEA and 2-AG produce a 
cooperative effect when elevated at the same time. Overall, it is unclear how exogenous and 
endocannabinoids modulate rewarding effects in the human brain. Based on the results from this 
and other studies, endocannabinoid modulation of reward may not result entirely from activity in 
the mesolimbic system.  
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